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English abstract 
During the drug development process, almost 35% of the compounds fail due to poor absorption, 
distribution, metabolism, excretion and toxicity (ADMET). An important role on these failures is 
played by improper interactions with antitarget proteins, such as cytocrome P450, P-glycoprotein 
and the hERG potassium channel. 
The hERG potassium channel is expressed in various cells and tissues, such as heart, neurons 
and smooth muscle. In the heart, the hERG channel plays an important role in the third phase of 
heart repolarization, due to the conduction of the rapid delayed rectifier K
+
 current (Ikr). A delay 
of this phase of repolarization leads to a syndrome called Long QT syndrome (LQTs) which 
might cause a potentially fatal arrhythmia called Torsade de Pointes (TdP). Many different 
classes of compounds were withdrawn from the market in the past decade due to their interaction 
with the hERG channel. Similar to other antitarget proteins, the hERG channel is polyspecific in 
the ligand recognition, hence it can interact with many classes of compounds, such as 
psychiatric, antihistaminic, antiarrhytmic and antimicrobial drugs. Several studies show that 
some molecules do not dissociate during the channel gating and are trapped in the closed state of 
the hERG channel. 
In this study, propafenone and derivatives were docked into homology models of the hERG 
channel in the closed and open states to shed more light on hERG inhibition and on drug 
trapping. 
With the aim to investigate the interactions between the hERG channel in the closed state and the 
compounds investigated, a series of trapped propafenone derivatives were docked into the 
homology model of the hERG channel in the closed conformation using Dock, the docking tool 
of MOE, and Glide, the docking tool of Schrödinger. A svl script called ROTALI was used to 
generate RMSD matrices with which the duplicate poses lying in different directions of the 
central cavity were detected and deleted, thus allowing to identify possible binding modes 
through agglomerative hierarchical clustering. This analysis led to the identification of two 
possible binding modes. 
The same process was applied to the poses obtained by docking the propafenones into a 
homology model of the hERG channel in the open state. Three possible binding modes were 
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selected through agglomerative cluster analysis of the RMSD matrix generated taking into 
account the propafenone derivatives’ common scaffold and the amino acids that might interact.  
Finally, in order to take into account protein flexibility, nine propafenone derivatives were 
docked into eight models of the hERG channel in the open state obtained from snapshots of 
molecular dynamics simulations. Clustering both according to the common scaffold RMSD and 
the RMSD matrix of the amino acids interacting with the poses, two binding modes were 
selected. Biological studies suggest that non-trapped propafenones hinder the hERG channel 
gating with a mechanism called “foot in the door”. In four out of the five selected clusters, it is 
possible to explain the “foot in the door” mechanism. 
Interestingly, ranking the poses of the five clusters above-mentioned according to the potential 
energy values of the R1 substituent, and according to this value divided by the number of heavy 
atoms, it is possible to distinguish between trapped and non-trapped propafenones. In the non-
trapped compounds, this value is always higher than in the trapped ones. The fact that it works 
also in cluster five, where the R1 substituents are placed under the ring formed by the four 
Phe656, might indicate that drug trapping phenomena depend more on intrinsic properties of the 
R1 susbstituent rather than on its conformation when it interacts with the hERG channel. Hence, 
this might indicate that the rigidity and the bulkyness of the substituent determines whether a 
propafenone derivatives is trapped or not independently of the binding mode in the hERG 
channel. 
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Abstract Deutsch 
Während des Arzneistoffentwicklungsprozesses scheitern fast 35% der Arzneistoffe wegen 
schlechter Absorption, Verteilung, Metabolismus, Ausscheidung und Toxizität (ADMET). Ein 
wichtiger Bestandteil dieses Scheiterns ist die Interaktion mit Anti-Target Proteinen wie 
Cytochrom P450, P-glycoprotein und dem hERG Kaliumkanal. 
Der hERG Kaliumkanal ist in vielen verschiedenen Zellen und Geweben wie dem Herz, Nerven 
und glatten Muskelzellen vorhanden. Im Herzen spielt der hERG Kanal während des 
Aktionspotentials in der dritten Phase der kardialen Repolarisierung wegen der Weiterleitung des 
schnellen Kalium Ausstroms (Ikr) eine wichtige Rolle. Ein Verzögern dieser Phase führt zum 
Long QT Syndrom (LQTs), das eine potenziell tödliche Arrhythmie verursachen kann. Viele 
Klassen von Medikamenten wurden wegen ihren Wechselwirkungen mit dem hERG Kanal in 
den letzten zehn Jahren vom Markt zurückgezogen. Wie auch andere Anti-Target Proteine, ist 
der hERG Kanal in der Ligandenerkennung unspezifisch, weshalb er mit vielen Klassen von 
Arzneistoffen wie Psychopharmaka, Antihistaminika, Antiarrhythmika und Antibiotika 
interagieren kann. Viele Studien zeigen, dass eine erhebliche Anzahl von Molekülen während 
der Schließung des Kanals nicht dissoziieren und im geschlossenen Zustand des hERG Kanals 
gefangen bleiben. 
In dieser Studie wurden Propafenon und dessen Derivate in ein Homologie-Modell des hERG 
Kanals im geschlossenen und geöffneten Zustand gedockt, um die hERG Hemmung und das 
„drug trapping“ besser verstehen zu können. 
Ziel war es, die Wechselwirkungen zwischen dem hERG Kanal im geschlossenen Zustand und 
den Liganden zu untersuchen. Aufgrund dessen wurde eine Serie von „trapped“ Propafenon-
Derivaten im hERG Kanal, welcher sich im geschlossenen Zustand befand, mit Dock, einem 
Docking Modul des Programms MOE, und GLIDE, dem Docking-Programm von Schrödinger,  
gedockt. Es wurde ein svl-Skript, genannt ROTALI, verwendet, um RMSD Matrizen zu 
erstellen, mit welchen die Duplikate unter den Posen, die in Bezug auf die Central Cavity 
unterschiedlich positioniert waren, zu erkennen und zu löschen. In weiterer Forlge wurden  die 
möglichen binding modes durch agglomeratives hierarchisches Clustering identifiziert. Die 
Analyse der Posen führte zur Identifizierung von zwei möglichen Binding Modes. 
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Derselbe Prozess wurde angewandt, um eine Serie von Propafenon-Derivaten in ein Homologie-
Modell des hERG Kanals im geöffneten Zustand zu docken. Drei mögliche Binding Modes 
wurden durch die agglomerative Cluster Analyse der RMSD Matrix identifiziert, welche durch 
das gemeinsame Gerüst der Propafenon Derivate und jenen Aminosäuren generiert wurde, die 
mit den Molekülen interagierten. Um die Flexibilität des Proteins zu berücksichtigen wurden die 
Propafenon Derivate zusätzlich in acht verschiedene Schnappschüsse einer Moleküldynamik des 
Homologie-Modelles des hERG Kanals im geöffneten Zustand gedockt. In diesem Fall wurden 
zwei Binding Modes selektiert. 
Interessanterweise war es durch das Einordnen der Posen der fünf oben genannten Cluster  nach  
der potenziellen Energie des R1 Substituenten, geteilt durch die Anzahl an Schweratomen, 
möglich, zwischen den „Trapped“ und „non-Trapped“ Propafenon-Derivaten zu unterscheiden. 
Dieser Wert war bei den „non-Trapped“ Substanzen immer höher als bei den „Trapped“ 
Molekülen. Der Umstand, dass dies auch bei den Vertretern des fünften Clusters möglich ist, bei   
denen der R1 Substituent unterhalb der vier Phe656 zum Liegen kommt, deutet darauf hin, dass 
das Phänomen des Drug-Trappings mehr auf die inhärenten Eigenschaften des R1 Substituenten 
als auf seine Konformation zurückzuführen ist, wenn er mit dem hERG Kanal interagiert. Dies 
könnte bedeuten, dass die Starrheit und die Sperrigkeit der Substituenten bestimmt ob 
Propafenon und dessen Derivate „Trapped“  sind oder 
nicht, unabhängig vom Bindemodus im hERG Kanal. 
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INTRODUCTION 
1
The ensemble of properties which describe absorption, distribution, metabolism, elimination 
and toxicity (ADMET) are of utmost importance for the drug discovery process. In light of the 
studies on antitarget proteins responsible for poor ADMET properties of drug candidates, many 
high-throughput methods have been developed for early identification of compounds with a bad 
ADMET profile. In the past decade many strategies were developed to screen libraries of 
compounds and to assess the risk of a bad ADMET profile. There is overwhelming evidence that 
                                               
1
The introduction is taken from: Schiesaro A, Ecker GF, "Prediction of hERG channel inhibition using in silico techniques", 
chapter of the book of Dr. Gupta SP “ Ion channels and their inhibitors” edited by Springer (submitted). 
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the inhibition of the hERG potassium channel is directly correlated with a lethal arrhythmia 
called Torsade de Points. Thus, the discovery of unwanted interactions between compounds 
under development and the hERG channel is a killing criteria. One of the main challenges of 
antitarget proteins such as hERG, cytochrome P-450, P-glycoprotein and serum albumin is their 
polyspecificity. Even though the binding sites of many hERG blockers were indentified through 
docking into homology models, the molecular basis of the hERG polispecificity is not clear yet. 
Due to the lack of crystal structures, ligand-based approaches were developed in order to predict 
the hERG activity of candidate compounds. Recent studies show that a combination of different 
methodologies, such as 2D- and 3D-QSAR with pharmacophore modeling and classification 
algorithms was quite successful and might be a powerful tool in the in silico screening of 
compound libraries. Within this chapter we will present selected in silico models developed to 
predict hERG channel blockers. 
1.1 Long QT syndrome 
The cardiac action potential is composed of five phases. Phase 0 is characterized by rapid 
depolarization due to an inward Na
+
 current. This phase is followed first by an initial short 
repolarization (phase 1) due to an outward K
+
 current and then by a plateau (phase 2), which is 
characterized by a slow repolarization rate. During the plateau phase an inward Ca
2+ 
current is 
balanced by an outward K
+
 current. In phase 3 of the cardiac action potential the rapid and the 
slow delayed rectifier K
+ 
(IKr and IKs, respectively) determine the repolarization of the myocyte 
with its membrane potential to the resting state (phase 4). A long cardiac action potential is a 
safeguard mechanism that prevents the onset of potentially dangerous arrhythmias. However, 
this mechanism is not perfect, as a delay of cardiac repolarization prolongs the QT time. 
Through the electrocardiogram is possible to register the electrical activity of the heart. The P 
wave registers the atrial depolarization, followed by the QRS complex, which registers the 
ventricular depolarization. The T wave finally corresponds to the ventricular repolarazion. 
During the interval between the Q and T waves (QT interval), which is a measure of 
repolarization duration, the heart is refractory to new excitations. A delay in ventricular 
repolarization is registered in the ECG as a prolonged QT interval. The Long QT syndrome 
(LQTs) is associated with increased risk of occurrence of potentially lethal arrhythmias called 
Torsade de Pointes (TdP). The LQTs is estimated to affect 1 person every 5000-10000 people.[1] 
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The LQTs is mostly due to mutations of the hERG channel, a potassium-selective voltage-gated 
channel that conducts the IKr current, and to the KCNQ1 channel, that encodes the Kv7.1 channel 
which is responsible for the IKs current. Up to now there are almost 300 mutations known to 
affect the hERG potassium channel. 
Many classes of compounds known to block the hERG potassium channel prolong the QT 
interval and thus also might be involved in potentially dangerous arrhythmias such as TdP.[2-21] 
1.2 Structure of the hERG channel 
The name of the hERG potassium channel origins from the human homologous gene ether-a-go-
go (eag) found in Drosophila melanogaster. The human related ether-a-go-go related gene is also 
called KCNH2 according to the new nomenclature, and the protein encoded is often referred as 
hERG, even if the official annotation according to the new nomenclature name is Kv11.1. 
The hERG potassium channel has a tetrameric architecture, where each subunit is formed by six 
transmembrane domains (S1-S6). Up to date two forms of hERG are known, hERG1a and 
hERG1b, which can form a homo- or hetero-tetrameric structure with different kinetic 
proprieties. Each subunit is formed by a voltage-sensing transmembrane domain (S1-S4), and the 
K
+
-selective pore (S5-S6), which is responsible for the K
+ 
conduction. 
The K
+
 channel can be divided into three regions: the K
+
-selectivity filter, the central cavity and 
the inner pore.[22] The K
+
-selectivity filter is a narrow cylinder built to mimic perfectly an 
aqueous environment and to conduct specifically K
+
 ions. The highly conserved signature 
sequence in the Kv channels (Thr/Ser-Val-Gly-Tyr/Phe-Gly) at the C-terminal end of the 
selectivity filter is responsible for the creation of the aqueous environment. The hydroxyl groups 
of Thr as well as the carbonyl groups of the other four amino acids form several octahedral 
binding sites which coordinate the K
+
 ions analogous to a water filled environment. The diameter 
of the cylinder is too large for the Na
+
 ions and thus they cannot be well coordinated, so they stay 
in the aqueous environment where the water molecules coordinate the ions.  
The central cavity is a wide water filled pore located below the selectivity filter, whose size 
changes in the open and in the closed conformation. 
The inner pore is located at the cytoplasmatic side of the membrane and connects the central 
cavity with the cytoplasm of the cell. It consists of two concentric rings made by four Tyr652 and 
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four Phe656. The four Phe656 form the first ring located at the cytoplasmatic side of the hERG 
channel. The four Tyr652 build the second ring which faces the central cavity. These two 
concentric rings are considered the main feature responsible for the polyspecificity of the hERG 
channel, mainly due to the possibility to make multiple and compound specific interactions. In 
the closed conformation the S6 domains intersect at the cytoplasmatic side of the channel, 
closing the inner pore and preventing the flow of K
+
 ions. During channel activation the S6 
domains rotate outwards, opening the inner pore and allowing ions to flow. 
The hERG channel and other K
+
-channels contain a PAS domain on the cytoplasmatic N-
terminus,[23] which is involved in protein-protein interactions. Although the function of the PAS 
domain in the hERG channel is not understood, mutagenesis studies show that disruption of this 
domain reduces the outward current and prolongs the QT interval.[24] 
Also the role of the C-terminus domain is not yet completely clarified, although a cAMP binding 
domain is located there. cAMP accelerates the deactivation kinetics of the hERG channel.[25] 
1.3 Ligand based approaches 
1.3.1 Pharmacophore models 
Several pharmacophore models have been published up to date. They provide a powerful tool for 
the identification of potential hERG blockers by virtual screening of compound databases. Some 
pharmacophore models were already reviewed elsewhere.[26, 27] 
Morgan and Sullivan[28] analyzed a set of class III antiarrhythmic drugs. In the pharmacophore 
model the charged nitrogen is linked by 1-3 atoms to two features which might be an aromatic 
ring or an alkyl moiety. A third feature, consisting of a para-substitued ring, is linked to the 
charged nitrogen through a chain of 1-4 atoms. 
The model derived by Ekins et al.[29] was generated from a training set of 15 compounds taken 
from the literature. The pharmacophore model contains one positive ionizable feature connected 
with four hydrophobic moieties. 
A “constructionist approach” was used by Cavalli et al.[30] to develop a pharmacophore model. 
The crystal structure of astemizole was used as template on which molecules with similar 
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geometry were aligned, leading to the addition of new pharmacophoric features which were not 
present in the previous pharmacophore. To the initial pharmacophore consisting of a basic 
nitrogen (N) and two aromatic features (C0 and C1), a fourth feature defined by the aromatic 
ring (C2) of an astemizole derivative was added.  Thus, the charged nitrogen group (N) is 
connected to three aromatic groups (C0-C2). The authors noted that all the hERG blockers tested 
have the C0 feature, while some molecules lack the C1 or C2 moieties. They also found that a 
polarizable function in C0, such as a carboxylic or a sulfonamidic group, may also influence the 
activity. 
Pearlstein et al.[21] developed a “drain plug” model through a combination of hERG homology 
modeling and the CoMSIA analysis of 22 sertindole derivatives and 10 structurally diverse 
hERG inhibitors. The analysis of the hERG homology model reveals a “drain plug” picture 
which is complementary to the shape of the cavity, where the amino acids responsible for the 
interactions are located. The “drain plug” pharmacophore model consists of two aromatic groups 
that can interact with Phe656, and a basic nitrogen that might interact with Tyr652. They also 
suggest that a hydrophobic or an aromatic substituent in this portion of the molecule might 
improve the potency of hERG blockers through the interaction with Tyr652. 
Aronov et al.[31] used a set of 85 hERG blockers to develop three hypotheses of three point 
pharmacophores. The first two hypotheses are in agreement with the C0-N-C2 and C0-N-C1 
pharmacophores published by Cavalli et al.[30] In the third pharmacophore model there is a 
hydrogen bond acceptor feature placed between the charged nitrogen and the aromatic ring, at a 
distance of 1.8-3.7 Å from the latter one. Similarly Testai et al.[32] found that an acceptor feature 
is normally placed within 4-6 Å from an ionizable center. 
Aronov et al.[33] also used the pharmacophore elucidation module implemented in MOE to 
analyze an in-house dataset of 194 uncharged compounds. At the beginning two point queries are 
generated and used to make more complex n-point queries through a “build up” method. Two 
five point pharmacophore models containing three hydrophobic/aromatic features and two 
hydrogen bond acceptors were selected from all generated pharmacophore models. This two five 
point pharmacophore models, which differ only in the position of one of the hydrogen bond 
acceptors, were merged into a six point pharmacophore. The two five point pharmacophores 
were able to correctly classify 78% and 69% of potent hERG blockers of the dataset. The six 
point pharmacophore matched 21% (IC50 < 10 µM) and 44% (IC50 < 30 µM) of hERG blockers 
Andrea Schiesaro Introduction 2011 
6 
    
and 4% of non-blockers. Applying a ClogP > 1 cutoff, the number of false positives was reduced 
in all three models. 
Crumb et al.[34] developed a qualitative pharmacophore model through the analysis of 11 
antipsychotic drugs. The model, which consists of one aromatic query surrounded by three 
hydrophobic moieties, is matched by the most potent hERG blockers present in the dataset. 
A collection of 1,075 hERG inhibitors was used by Johnson et al.[35] to develop a series of 
pharmacophore and QSAR models. As seen in previous studies, the basic nitrogen, which is 
placed 6-9 Å apart from a centroid of an aromatic ring, was found to be an important feature for 
hERG blockers. In the second pharmacophore model the effect on the activity of the basic 
nitrogen is attenuated by the presence of two hydrogen bond acceptors and a lipophilic group. 
This might be a useful hint for development of compounds with reduced hERG blocking activity. 
In the third pharmacophore the aromatic rings are placed at the opposite side of the molecule and 
are separated by 14 bonds. In the fourth model the aromatic ring feature is coupled with a 
hydrogen bond moiety. The fifth pharmacophore model consists of two aromatic rings placed 
within 6-13 Å from two hydrogen bond donors. 
With the aim to subdivide specific and nonspecific hERG blockers in a dataset of 113 
compounds, Kramer et al.[36] developed a method where pharmacophore and QSAR techniques 
are combined. SA15 (sertindole analogue), clemastine, tolterodine and haloperidol were used to 
build the first pharmacophore model. Similarly to other published models, it contains a positive 
ionizable nitrogen feature connected to two aromatic/hydrophobic features, one of which is in 
close proximity with a hydrophobic spot. The model was tested against the entire dataset and 51 
compounds matched the pharmacophore. The potent hERG blockers astemizole, cisapride, 
flunarizine and sertindole, which match the first pharmacophore model, were used to develop a 
more specific model. Differently from the first pharmacophore, in this model the hydrophobic 
queries are directly connected with the charged nitrogen. The second model is similar to the one 
obtained by Cavalli et al.[30] 
Through the analysis of 56 compounds using Catalyst Garg et al.[37] generated seven models. 
The most predictive pharmacophore model consists of one hydrophobic group (HP), one 
aromatic ring (RA) and one hydrogen bond acceptor lipid group (HBAl), which are three 
important features for potent hERG blockers. This model was able to find 22 of the 25 potent 
blockers in the dataset, showing to be capable to distinguish between potent and non-potent 
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blockers. 
With the aim to avoid the potentially lethal hERG blockage of cemokine receptor antagonists, 
Shamovsky et al.[38] analyzed the influence of four classes of fragments on the hERG 
inhibition. They obtained two pharmacophore models. The first pharmacophore model consists 
of one aromatic ring, one basic center, two hydrogen bond donors and one hydrogen bond 
acceptor. The fragments that match this pharmacophore increase the hERG blocking potency 
even if they decrease the lipophilicity of the compounds. In the second pharmacophore model 
there are two aromatic rings connected with a basic nitrogen. Here the fragments that match this 
pharmacophore increase the hERG potency by increasing the lipophilicity of the compounds. 
Coi et al.[39] generated a “toxicophore” using the docking poses of compounds docked in the 
hERG channel in the closed state. The analysis of the interactions of the lowest-energy poses 
with the hERG channel shows that there are several hot spots in the binding site: Ser624 (E), 
Gly657 (I), the region around Phe656 (H), and four cavities in the region around Tyr652 (C). 
The docking pose of the potent hERG blocker astemizole was used as “template” to generate the 
toxicophore. The analysis of the poses of astemizole, haloperidol, ritanserine, R59022, cisapride, 
spiperone, 8-hydroxy-DPAT, sotalol, quinidine, trifluperidol, and tetracaine, allowed the 
identification of the features needed to interact with the hERG channel: (a) the optimal distance 
between the protonated nitrogen and a hydrogen-bond acceptor is 4.5 Å; (b) aromatic rings 
located in I or in E. Moreover, the authors suggest that also hydrophobic interactions with the 
amino acids located in C and/or H should be avoided. To evaluate the toxicophore 18 known 
hERG blockers/non-blockers were docked into the homology model of the hERG channel in the 
closed state. The results confirmed that the toxicophore is able to distinguish between hERG 
inhibitors and non-inhibitors. 
In summary, the pharmacophore models suggest that the hERG blockers are characterized by the 
presence of a protonated nitrogen linked with two or three hydrophobic and/or aromatic 
moieties. The only exception is the pharmacophore model obtained by Aronov et al., which was 
generated solely by uncharged molecules. This indicates that the development of uncharged 
compounds is not a safe way to avoid unwanted inhibition of the hERG channel. The charged 
nitrogen atom, the hydrophobic and the aromatic features might interact with the amino acids 
Tyr652 and Phe656. Some pharmacophore models suggest also that hydrogen-bond donor and/or 
acceptor groups might play an important role for hERG inhibition, probably by interactions with 
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Thr623, Ser624, or Ser649. 
1.3.2 3D-QSAR 
The first 3D-QSAR model for prediction of hERG blockers was developed by Ekins et al.[29] 
through the analysis of 15 molecules with Catalyst. These compounds are characterized by the 
presence of one ionizable feature and four hydrophobic moieties. The pharmacophore shows the 
presence of one ionizable feature surrounded by four hydrophobic features. The 3D-QSAR 
model shows a high correlation with an r² of 0.90, and also a good performance in the prediction 
of the activity of the external test set, with an r² of 0.83. The ability of the model to correctly 
rank the hERG blockers according to their IC50 values achieved a Spearman's rank coefficient of 
0.76 and 0.77 for the training and the test set, respectively. The excellent performance of the 
model for both qualitative prediction and quantitative ranking of hERG inhibitors indicates that it 
is a suitable tool to discover potential hERG blockers. 
Cavalli et al.[30] developed a 3D-QSAR model through the analysis of 31 hERG blockers using 
the CoMFA technique. For most of the molecules the 3D structure was retrieved from the 
Cambridge Structural Database (CSD) or by adding substituents to the crystallographic structure. 
3D structures of additional molecules were generated with SYBYL. The alignment of the 
molecules was performed using the previously generated pharmacophore. The model shows a 
good predictive performance with r² = 0.95 and q² = 0.74. In a further validation using a test set 
of compounds not involved in the model generation, an r² of 0.74 was achieved. The comparison 
of the pharmacophore and the CoMFA models shows that the pharmacophoric features C1 and 
C2 are sterically favorable regions, while C0 is influenced by the steric and electrostatic 
properties of the compounds. In particular an increased volume in C0 will decrease the activity, 
while an opposite effect is predicted for charged groups. 
Through the application of the CoMSiA technique, 22 sertindole analogues and a set of 10 
structurally different hERG blockers were analyzed by Pearlstein et al.[21] The best model 
reached a q² of 0.571. Docking studies performed in a homology model of the hERG channel in 
the open state could explain the pharmacophore and the CoMSiA models.  
In total 882 compounds were used by Cianchetta et al.[40] to develop a GRIND-based model. 
Four probes representing hydrophobic interactions (DRY), hydrogen bond acceptor (sp² carbonyl 
oxygen), hydrogen bond donor (neutral flat amide NH) and the molecular shape (TIP) were used 
Andrea Schiesaro Introduction 2011 
9 
    
to calculate the GRIND descriptors. The correlation between the GRIND descriptors and the 
pIC50 values of the hERG blockers was analyzed through multivariate techniques such as 
principal component analysis (PCA) and partial least squares (PLS). The dataset was subdivided 
into two subsets characterized by the presence or absence of a basic nitrogen atom. The 338 
hERG blockers which form the subset of compounds without a charged nitrogen, were 
subdivided into a training set of 322 compounds and a test set of 16 molecules. The model 
obtained resulted in four latent variables and showed an r² of 0.76 and a q² of 0.72. The 544 
compounds that constitute the charged nitrogen database were split into a training set of 518 
molecules and in a test set of 26 compounds. The model obtained from the PLS regression 
analysis had three latent variables yielding an r² of 0.77 and a q² of 0.74. The descriptors 
involved in the two models were practically identical. The authors suggest that this might 
indicate that the charged and noncharged compounds share the same binding mode. The two 
models differ in terms of distance between the edge of the molecule and the space between a 
hydrophobic MIF and a hydrogen bond donor group. In the first case the distance for the 
optimum space between the two fields generated is 25 Å for the noncharged molecules and 29 Å 
for the charged compounds. In the second case the DRY/hydrogen bond distance for the 
noncharged compounds is 14 Å, while for the charged molecules it is 21 Å. Statistical analysis 
shows that in both models a hydrogen bond moiety close to the edge of the molecules plays an 
important role. 
Johnson et al.[35] analyzed 1,075 compounds through a combination of physicochemical and 
pharmacophoric descriptors. Least median squares (LMS) regression was used to analyze the 
925 compounds of the training set and the resulting model shows an r² of 0.65 and a q² of 0.66. 
In a further test using 1,679 compounds the model showed an r² of 0.54. These compounds were 
then clustered based on Daylight Fingerprint Tanimoto using the average linkage method and a 
similarity cut off of 0.7. In the largest cluster the model achieved an r² of 0.32. However, when 
only the compounds in the training set with a Tanimoto similarity greater than 0.65 were 
considered, the r² for the validation set increased to 0.72. 
With the aim to develop a model able to discriminate between hERG inhibitors and non 
inhibitors, Li et al.[41] combined pharmacophore-based GRIND descriptors and support vector 
machine techniques. Four GRIND probes representing hydrophobic interactions (DRY), 
hydrogen bond acceptors (sp² carbonyl oxygen), hydrogen bond donors (NH neutral flat amide) 
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and molecular shape descriptors (TIP) were used. From a library of 495 compounds, only the 
192 molecules with IC50 values lower than 40 μM were considered. The model generated from 
the PLS analysis consists of three latent variables and shows a rather poor r² of 0.34 and a q² of 
0.07. The analysis of the predicted versus the experimental pIC50 shows that the IC50 of 
sertindole derivatives is overestimated. A better model with  r²= 0.57 and q²= 0.41 was obtained 
considering only the hERG blockers with an IC50 value lower than 32 nM and by removing the 
sertindole derivatives. The analysis of the influence of the descriptors highlights that the 
descriptor related to two hydrogen donor atoms placed at a distance of 9 Å has the highest 
principal component coefficient. This descriptor is encoded by the charged nitrogen atom. Also 
the descriptors related to the presence of a hydrogen bond acceptor and a hydrogen bond donor 
(6 Å or 9.5 Å apart), to the presence of the hydrophobic moiety and a hydrogen bond donor (9 Å 
or 16 Å apart) and to the hydrogen bond donor and one of the edges of the molecule (10 Å or 
17.5 Å apart), show a high correlation with biological activity. These data are in agreement with 
the model published by Cianchetta et al.[40] 
In a recent study Kramer et al.[36] reported a predictive QSAR model able to distinguish 
between specific and non specific binding. 113 compounds from the literature were split into six 
groups of equal activity range. From the 113 compounds 15 molecules were randomly selected 
as validation set. The remaining 98 compounds were divided into a training set of 75 molecules 
and a test set of 23 molecules. The uncharged forms of the compounds was used to calculated 
1D-, 2D- and 3D-descriptors such as the molecular electrostatic potential (MEP), the local 
ionization energy (IEL), the local electron affinity (EAL), the local polarizability (POL), and the 
Shannon entropies (SHANI and SHANE). The first model was obtained using a combination of 
ε-SVR and multiple linear regression descriptor selection. An r² of 0.81 for the training set was 
obtained by using EALmax, EALmin, POLmin, SHANIbar, Naryl, shapeQ2 and shapeQ4 
descriptors. The model shows a good performance also for the validation set with an r² of 0.70, 
while the q² is 0.50. In the second model the Naryl, shape and EALmin descriptors were 
selected. The statistical analysis of this model resulted in an r² for the training, test and validation 
set of 0.64, 0.61 and 0.62, respectively. The Naryl descriptor encodes for the number of aromatic 
rings in the molecule, and its selection highlights that the potency of the blockers is correlated 
with the number of aromatic rings. The shape descriptors are a measure of the shape similarity 
with astemizole, cisapride and sertindole. They have a positive sign, indicating that the more the 
shape of the molecule is similar to those of one of the three compounds cited above, the higher is 
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the probability of the compound to be a potent blocker. The EALmin descriptor has a positive 
value, which might suggest that the potency of the hERG blockers is decreased if the minimum 
electron affinity decreases. Additional six models were generated, all of them showing quite 
satisfactory performance. These six models describe a specific or an unspecific binding type. In 
general, the models suggest that the affinity of the blockers is correlated to the similarity of the 
compounds with the three hERG inhibitors cited above, and with the number of aromatic rings 
present. To decrease the hERG potency it is necessary to introduce electronegative moieties, 
such as carbonyl groups, as indicating by the EALmin descriptor. The positive coefficient of the 
ClogP indicates that decreasing the lipophilicity of the compounds might also lead to a hERG 
affinity decrease. In addition, the number of hydrogen-bond donors is negatively correlated with 
the potency, probably due to the desolvation penalty that cannot be compensated by the 
hydrogen-bond interactions with the amino acids facing the central cavity of the hERG channel. 
Ermondi et al.[42] reported a GRIND-based 3D-QSAR model generated by the ALMOND 
software. They used the 31 hERG blockers that Cavalli et al.[30] used to the develop the 
CoMFA model, and six compounds as a test set. The descriptors were calculated using probes 
that represent the hydrophobic interaction (DRY), hydrogen bond acceptor properties (sp² 
carbonyl oxygen), hydrogen bond donor properties (neutral flat amide NH) and molecular shape 
(TIP probe). The PLS analysis resulted in a model with three latent variables, which shows an r² 
of 0.93 and a q² of 0.69. The analysis of the model suggests that the presence of aromatic rings 
on the edges of the molecule, hydrogen bond donor moieties not related to the basic nitrogen, 
hydrogen bond acceptors far from the aromatic rings and placed at the same distance of the 
hydrogen bond donors from the aromatic group, increase the potency of the hERG blockers. The 
37 molecules were also analyzed using the DRY-DRY GRIND descriptors. Interestingly, the 
PC1 discriminates between the potent blockers and the weak blockers. In particular, it 
highlighted that the potent blockers have two or more hydrophobic regions far away from each 
other. The ALMOND model was compared with the CoMFA model obtained by Cavalli et 
al.[30] Both models show a comparable predictivity and have problems to predict the activity of 
lipophilic hERG blockers. In the ALMOND model there is a second hydrophobic feature which 
is missing in the CoMFA model, probably due to the different calculation methods for 
hydrophobic interactions. 
The 3D-QSAR techniques, such as Catalyst, CoMFA, CoMSiA and ALMOND have proven to 
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be a powerful tool for hERG potency prediction. Together with the pharmacophore models, 3D-
QSAR shed light on the molecular determinants that characterize hERG inhibitors, and provided 
insights for the potential binding mode of blockers. The 3D-QSAR models further underline the 
importance of a basic nitrogen, of a hydophobic/aromatic moieties and of a hydrogen bond donor 
and acceptor groups. 
1.3.3 2D-QSAR 
Although 3D-QSAR techniques are a powerful resource in the drug discovery process and 3D-
models can be very useful to discover compounds which potentially block the hERG channel, 
they suffer from limitations due to the requirement of conformational sampling alignment 
(CoMFA, CoMSiA). 
Aptula et al.[43] developed a 2D-QSAR model based on the stepwise regression analysis using 
the hydrophobicity corrected for ionization (logD) and the maximum diameter for the molecules 
(Dmax) as descriptors. The model, based on 19 molecules, shows a good internal and external 
validation with an r² of 0.87 and a q² of 0.73. The analysis of 81 hERG blockers highlights that 
the most active compounds have a Dmax > 18 Å, indicating that the cavity of the hERG channel 
is big enough to accommodate large compounds. 
Keserü et al.[44] developed a QSAR model for a series of 55 hERG inhibitors. The model 
consists of five descriptors, such as ClogP, molar refractivity, partial negative surface area, 
polarizability (Volsurf W2) and hydrophobicity (Volsurf D3). It shows a good performance with 
an r of 0.97. The five descriptors indicate that lipophilic, polarizable compounds with a basic 
moiety and a large size might interact with the hERG channel. The model was evaluated with a 
test set of 13 compounds, and gained an r value of 0.75. In a second test the model was evaluated 
in the ability to classify 82 active and nonactive compounds selected from the World Drug Index. 
The molecules of the dataset with an IC50 < 1μ were considered as actives. The model showed a 
good performance classifying correctly 83% of the blockers and 82% of the non-blockers. Also a 
hologram QSAR model was generated using the same data set. The model shows an excellent 
performance with an r value of 0.98. The test set achieved an r value of 0.90, indicating that the 
model has also a high predictive power. For the active compounds of the World Drug Index, the 
model was able to correctly classify 81% of the molecules. The HQSAR model was further 
tested against 743 compounds approved in the World Drug Index, where it achieved a low rate of 
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false positive (18%). 
Five QSAR models with a q² ranging from 0.65 to 0.90 were developed by Fioravanzo et al.,[45] 
where 29 compounds from a training set and 30 compounds from a test set were analyzed 
through PLS and PCA techniques with EVA and DRAGON descriptors.  
Song et al.[46] used a combination of fragment based descriptors, support vector regression 
(SVR), partial least squares (PLS) and random forest (RF) to develop a QSAR model to predict 
the activity of hERG blockers. 71 compounds were initially used to calculate and identify 
fragment descriptors correlated with hERG inhibition. Subsequently, they were used to build 
SVR, PLS and RF models. 19 compounds served as test set. The best performance was achieved 
by the SVR model with an r² of 0.91 and a q² of 0.64. The model showed also a good 
performance for the test set with an r² of 0.85. The analysis of the fragment descriptors highlights 
that lipophilic fragments have a positive impact on the hERG activity, while hydrophilic moieties 
generally decrease the binding affinity. Fluorine and methane sulfonamide are two exceptions on 
this general rule. The two moieties, despite their hydrophilic nature, are positively related with 
the hERG activity. The model also reveals that tertiary amines are important for drug binding.  
The role of the nitrogen atom on the hERG activity of compounds was studied by Zolotoy et 
al.[47] They found that a tertiary amino group is present in 84% of the hERG channel blockers 
with IC50 < 1 μM. In 73% of the inhibitors with 1 μM < IC50 < 10 μM the charged nitrogen is 
located at the periphery of the compounds. In 84% of the weak blockers the amine is primary, 
secondary or neutral. 
The CODESSA program was used by Coi et al.[48] to study a series of hERG blockers. Two 
experiments were performed. In the first experiment the compounds of the dataset were divided 
into 55 and 27 molecules for the training and test set, respectively. The first model showed an r² 
of 0.77 using 12 descriptors. The training and the test set used to generate the second model 
contained 64 and 18 compounds, respectively. The best model selected for this sets showed an r² 
of 0.74 using 9 descriptors. The analysis of the descriptors selected in the two models 
highlighted that the relative number of double bonds (RNDB), the factorized molecular volume 
(MV/XYZB), the relative number of carbon atoms (RNCA) and the relative negative charge 
(RNCG) are the most important descriptors. The first two descriptors are negatively correlated 
with the pIC50, highlighting that the hydrophobicity and the proprieties related to the volume of 
the molecules increase the potency of the hERG blockers. These two descriptors might explain 
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why the ideal hERG blocker candidates are hydrophobic molecules with a large size, as in the 
case of some potent hERG blockers such as MK-499 and astemizole. On the opposite, small 
molecules with high globularity lacking hydrophobic moieties normally show a lower ability to 
block the hERG channel. 
Yoshida et al.[49] analyzed 104 compounds collected from the literature. The model included the 
topological polar surface area (TPSA), the octanol/water partition coefficient (ClogP), the largest 
value in the distance matrix (diameter) and the summed surface area of atoms with partial 
charges from -0.25 to 0.20 (PEOE_VSA-4). They also introduced an indicator variable (Cell) 
indicating if the drugs were tested  in the hERG channels expressed in Human Embrionic Kidney 
(HEK) cells (value of 0), or in Chinese Hamster Ovary (CHO) cells (value of 1). In the most 
significant model the statistical analysis showed an r² of 0.70 and a q² of 0.67. The interactions 
between the hERG channel and the blockers occur in the inner cavity. Many studies show that 
the size of the cavity is big enough to accommodate large compounds, and this is fully in 
agreement with the positive coefficient of the diameter descriptor. The positive coefficient for the 
PEOE_VSA-4 descriptor might be explained by the interactions with amino acids such as 
Thr623, Ser624, Ser649, and Tyr652, which are capable to form hydrogen bond interactions. The 
pore region has a hydrophobic nature due to the high number of hydrophobic amino acids, thus 
the potency of the drugs increase with the ClogP of the molecules. In contrast, increasing the 
hydrophilicity of the compounds, represented by the TPSA descriptor, decrease hERG potency. 
Seierstad et al.[50] reported a combination of models based on neural network ensembles with 
different representations of the structural properties. For 439 compounds six sets of descriptors 
were calculated using DirectedDiversity, comprising 117 Kier-Hall (KH) topological indices, 
142 Ghose-Crippen atom types, 166 Isis keys, 150 atom pair descriptors, 49 electrotopologic 
state descriptors, six common medicinal chemistry descriptors, and 146 2D descriptors 
calculated with the Molecular Operating Environment (MOE) package. To select the descriptors 
different feature selection algorithms were employed comprising four filter-based ones such as 
PCA, correlation with response variable, difference in distribution between actives and inactives, 
training error of single-feature models, and two wrapper-based such as Forward stepwise 
selection and Simulated annealing. The neural network and neural network ensemble models 
were obtained from 10 fold cross-validation procedures. The authors found that the “neural 
network ensembles have greater generalization ability and are less susceptible to the particular 
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choice of training and test sets” showing that this methodology is a powerful tool for hERG 
prediction. In the filter type technique the PCA showed the best performance, although the 
simulated annealing reached the highest r² value. The 2D model, which is based on 20 
descriptors selected through the simulated annealing technique, shows an r² of 0.76. The model, 
tested with an external validation set of 40 compounds, achieves an r² of 0.52. Each of the 20 
descriptors was used alone to build a model and the cross-validation r² values were calculated. 
As in many other models the top scoring descriptors, such as AlogP and L-10-L (which describe 
2 hydrophobic moieties separated by a chain of the atoms), show that hydrophobic interactions 
and π-stacking are important for hERG blocking. The highest r² value was obtained with the 
model generated using only the descriptor F-C1sp
2
 (fluorines connected to sp² carbons). The 
importance of this group might depend to its ability to form strong π-stacking interactions. The 
Goose-Crippen atom type O in phenol, enol and carboxyl OH shows a negative correlation with 
the hERG inhibition. It is noteworthy that two of the three compounds which show the largest 
error contain a carboxylic moiety, thus the model seems to underestimate its contribution to the 
decrease of hERG inhibition. 
Ekins et al.[51] showed that also recursive partitioning models can be applied for early discovery 
of potential hERG blockers. 99 compounds from literature sources were used to develop two 
models using the ChemTree software package. In the first model 99 compounds were used to 
generate 100 random models using 564 path length molecular descriptors. The model showed a 
good IC50 correlation with an r² of 0.90, but the prediction of the 35 compounds of the validation 
test set resulted in an r² of 0.33. In the second model 134 compounds were used to generate 694 
path length descriptors, which were employed in the generation of 100 random models. The 
second model showed a lower r² value (0.85). 
Leong et al.[52] used a combination of pharmacophore modeling and support vector machines to 
predict the potency of hERG blockers. The model obtained from the 26 compounds of the 
training set had an r² of 0.97, while for the 13 compounds of the validation test set the q² value 
was 0.94. 
Recently, Gavaghan et al.[53] studied 1,312 compounds through the combination of D-optimal 
onion design, partial least squares and principal component analysis techniques. The molecular 
descriptors calculated with the software packages Selma, DRONE and VolSurf were integrated 
with fragment based descriptors, which were used to calculate base level PLS models from each 
Andrea Schiesaro Introduction 2011 
16 
    
descriptor set. The scores generated from the base level PLS models were combined and used as 
descriptors in the upper level hierarchical PLS models. The best hierarchical PLS model 
generated from 13 descriptors and a training set of 436 compounds showed a q² of 0.59. The 
model was tested with an additional external test set of 7,520 compounds, composed of 4,813 
actives and 2,707 inactives. Unfortunately the model was unable to distinguish between potent, 
moderate and nonactive blockers. 
Recently a dataset of 68 compounds collected from the literature was used by Garg et al.[37] to 
perform a 2D-QSTR analysis based on S_sNH2 (primary amines), JX (Balaban index), Kappa-3 
(third order of Kier shape index), ADMET_PPB (tendency to bind to plasma protein), 
Atype_O_57 (atom type Oin phenol, enol, carboxyl OH), Atype_O_59 (atom type O in Al-O-Al) 
and Atype_H_46 (atom type H attached to Csp3
0
) descriptors. The model shows a good 
prediction ability achieving an r² of 0.84 and a q² of 0.78. In a validation with an external test set 
of 12 molecules, the QSTR model shows an r² value of 0.70. The importance of the Kappa-3 
descriptor might indicate that the molecular shape can play a role in the hERG interaction. The 
S_sNH2 descriptor highlights that the presence of a primary amine group increases hERG 
inhibition. The Balaban index is inversely correlated with hERG potency, indicating that it might 
be possible to decrease the activity of hERG blockers by increasing the branching of the 
molecule. All the A-type descriptors are negatively correlated with the inhibition of the hERG 
channel. This suggests that hERG potency decreases by adding electronegative groups. 
Shamovsky et al.[38] studied hERG selectivity of 4 classes of chemokine receptor (CCR) 
ligands. In this study, the baseline lipophilicity relationship (BLR) approach was used to increase 
the hERG selectivity of compounds. Mathematically the BLR is: 
pIC50= a × logD – k × ΔGintr + const 1 
pIC50= potency of the compound. 
a= hydrophobicity factor of the binding site. 
D= n-octanol/water partition coefficient. 
ΔGintr= intrinsic binding energy nonrelated with the desolvation. 
k= coefficient equal to (2.303 × RT)
-1
. 
The term a × logD is the lipophilicity driven component of potency caused by desolvation. The 
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second term – k × ΔGintr is the intrinsic potency, which depends on the molecular interactions of 
the ligand with the target. When the hERG selectivity of the compound (C) is taken into 
consideration, the equation becomes: 
pIC50
C
 – pIC50
hERG 
= (pIC50
C
 – ahERG × logD) + k ×  ΔGintr
hERG
 + const 2  
The term k × ΔGintr
hERG
 does not depend on the interactions with the primary target. The term 
(pIC50
C
 – ahERG × logD) (lipophilicity-adjusted primary potency) is independent on the hERG 
binding affinity. The lipophilicity-adjusted hERG potency (pIC50
hERG
 – ahERG × logD) was used 
in a fragment-based QSAR analysis to identify moieties that form important non-hydrophobic 
interactions with the hERG channel. The fragment-based QSAR analysis in a given chemical 
series ranks the fragments according to their contribution to the hERG potency. The regression 
analysis using eq. 1 shows that a
hERG
 is close to one for all 4 classes of compounds. This means 
that if the lipophilicity increases by one unit, also the hERG potency increases. Further analysis 
of eq. 1 indicates that the lipophilicity has a stronger influence on hERG potency than on hERG 
selectivity. This renders it quite difficult to enhance the hERG selectivity by decreasing the 
lipophilicity, suggesting that it is easier to improve the hERG selectivity by increasing the 
lipophilicity-adjusted primary potency value. 
In a follow up study Shamovsky et al.[54] used 464 CCR8 antagonists and 8 hERG mutants to 
increase the selectivity of the compounds towards the hERG channel. A 2D fragment-based 
QSAR analysis performed on a subset of 25 spirocyclic CCR8 antagonists revealed that bulky 
and rigid substituents decrease the hERG affinity due to van der Waals clashes with Phe656. 
Based on a dataset of 67 compounds, 50 in the training set and 17 in the test set, Roy et al.[55] 
combined the extended topochemical atom (ETA) indices for diverse hERG blockers and non-
ETA-descriptors with factor analysis followed by multiple linear regression, stepwise regression, 
and PLS, to develop QSTR models. The best model was obtained combining ETA and non-ETA 
descriptors (r² of 0.619 and a q² of 0.546). The model indicates that the hERG affinity is 
increased by enlarging the size of the molecule and increasing the electron richness, while the 
presence of a carboxylic group and an aliphatic tertiary nitrogen are detrimental for the hERG 
activity, which, under the light of all models discussed so far, seems quite unlikely. 
Due to their simplicity, the 2D-QSAR were extensively applied to develop models able to predict 
hERG potency. Interestingly, some 2D-descriptors provided structural information of the central 
cavity of the hERG channel, suggesting that it can accommodate large molecules. The 2D-
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descriptors also provided some interesting insight into the characteristics of hERG blockers, 
indicating that the nature and the charge of the nitrogen atom might have a strong influence on 
the potency. 
1.3.4 1D-QSAR 
A new QSAR technique was proposed by Diller et al.[56, 57] to analyze 230 compounds 
collected from the literature. In order to minimize the variation on the IC50 values due to the use 
of different cell lines, the data were corrected by introducing a correction factor for each cell 
type to obtain a match of the data measured in HEK cells. Through the projection of the atoms of 
the molecules onto one dimension using multi dimensional scaling, the structures were described 
as a 1D string of atoms. 6 descriptors were employed to generate the model: Size (number of 
heavy atoms), C-Aliph-Estate (the electro-topological state of the atom if the atom is a carbon 
not in an aromatic ring), C-Arom-Estate (the electro-topological state of the atom if the atom is a 
carbon in an aromatic ring ), N-Acc-Estate (10 minus the Estate of the atom if the atom is a 
nitrogen with a free lone pair), N-Don-Estate (the electro-topological state of a nitrogen with an 
attached hydrogen), and O-Estate (the electro-topological state of the atom if the atom is an 
oxygen). The statistical analysis of the model showed a correlation coefficient of 0.68 for the 
training (189 compounds) and of 0.76 for the test (41 compounds) set, respectively. The 
descriptors that mainly contribute to hERG inhibition were the N-Acc E-state and the C-Arom-
Estate, revealing the importance of the basic nitrogen and the aromatic ring. 
The same QSAR technique based on 1D-descriptors was used by Diller et al.[58] The one 
dimensional representation of the molecules was achieved by multidimensional scaling from 2D 
topological descriptors. To generate the model 6 descriptors were used: the number of heavy 
atoms, E-state key for aliphatic carbons, E-state key for aromatic carbons, E-state key for 
nitrogen atoms with a free lone pair, E-state key for nitrogen atom with an attached hydrogen and 
E-state key for oxygen atoms. The IC50 values of 230 compounds collected from the literature 
were corrected as previously described. The analysis of the contribution of the descriptors 
revealed the positive contribution of the E-state key of the aromatic carbon and of the nitrogen 
atom with a free lone pair. In particular, the model indicates that a separation of 9-10 bonds 
between two phenyl rings increases hERG affinity. This is consistent with previously published 
pharmacophore models, which indicates the importance of the presence of a tertiary amine 
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linked to two aromatic rings. The final model achieved the mean absolute errors of 0.62 and 0.62 
for the training set (189 compounds) and test set (41 compounds). Differently from other 
publications, the authors used the mean absolute errors as performance measure, which makes it 
complicated to compare their model with the results already published.  
The 1D-, 2D- and 3D- QSAR models discussed highlight the importance of the basic nitrogen 
and of the hydrophobic and aromatic groups for strong hERG blockers. To reduce hERG 
affinity, the QSAR models suggest to reduce the number of aromatic rings, to modulate the pKa 
of the basic nitrogen, and to reduce the lipophilicity of the molecule. It is noteworthy that the 
compounds with a carboxylic group are unlikely to be hERG blockers. 
1.4 Classification models 
To discover potential hERG blockers classification techniques became an important and 
powerful tool. Although they do not need accurate IC50 values, it is necessary to set up a 
threshold which defines if the compounds are considered as active or as inactive. 
Bains et al.[59] chose an IC50 of 1 μM as threshold to define hERG blockers and non-blockers. 
Tobita et al.[60] used thresholds of 1 μM and 40 μM to classify active and inactive compounds. 
Roche et al.,[61] Dubus et al.,[62] Ekins et al.,[51] Thai et al.[63-65] and Chekmarev et al.[66] 
classified the hERG blockers into three different classes: low IC50 (lower than < 1 μM, blockers), 
medium IC50 (between 1 μM and 10 μM), and high IC50 (higher than > 10 μM, non-blockers). 
Doddareddy et al.[67] used the cut off values of IC50 < 3 μM, 6 μM and 10 μM to define hERG 
inhibitors, and of > 30 μM for the hERG inactives. O´Brien et al.[68] selected the value of 20 
μM to define hERG inhibitors. Sun et al.[69] and Jia et al.[70] defined a compound as hERG 
blocker if it has an IC50 value lower than 30 μM. Buyck et al.[71] used the threshold of 130 nM 
to define if the compounds are hERG blockers or not. Catana et al.[72] used an IC50 of 40 μM as 
a cut off to define the separation between hERG blockers and non-blockers. Li et al.[41] used the 
threshold values of 1 μM, 5 μM, 10 μM, 20 μM, 30 μM and 40 μM. Some approved drugs have 
an IC50 value between 1 μM and 10 μM. Typically a drug is considered safe if the IC50 value is 
higher than 10 μM.[53] To assess the safety of compounds also the ration between the free 
therapeutic plasma concentration and the hERG IC50 has to be considered. Generally, a molecule 
with a margin greater than 30-fold between the free therapeutic plasma concentration and the 
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hERG IC50 is regarded as safe.[73] 
Roche et al.[61] employed different techniques such as self-organizing maps (SOM), PCA, PLS 
and supervised neural networks to develop predictive models based on 1,258 descriptors in order 
to classify 472 compounds. The substructure analysis performed with LeadScope did not 
highlight any moieties exclusive for blockers or for non-blockers, although some weak trends 
could be noted. In 57% of the non-blockers and in 30% of the blockers 2 hydrogen-bond donors 
separated by six bonds were present. In 20% of the non-blockers and in 2% of the blockers a 
benzenesulfonyl groups was found. In 49% of hERG inhibitors the 1-R-4-alkyl-benzene moiety 
was found. The best prediction performance was achieved with the neural network model, which 
was able to correctly classify 93% of the non-blockers and 71% of the blockers (95 compounds 
validation test set). The prediction method was additionally used to analyze virtual combinatorial 
libraries to demonstrate its applicability for shaping compounds libraries towards low probability 
to contain potential hERG blockers. The structures based on scaffold one (fig. 1) have a 
structural moiety common to many hERG inhibitors, while the molecules based on scaffold two 
are designed to be non-blockers. The prediction highlights that in the library of compounds based 
on scaffold one there are 58% of potential hERG blockers, while in the second library the 
possibility to have hERG blockers decreases to 0.1%. 
N
R1 R2 N
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O
Scaffold 1 Scaffold 2  
Fig. 1 Chemical scaffolds of the combinatorial libraries. 
Bains et al.[59] applied evolutionary programming with fragment-based descriptors to predict 
hERG inhibition. The resulting model shows an accuracy of 85-90% for the classification of 
blockers and non-blockers. The model was generated calculating 618 fragment- and non-
fragment-based descriptors on 124 compounds randomly partitioned in 70:30:24 for training, 
generalization and validation data sets. Ten different partitions and subsequently 10 runs for each 
partition were performed to generate a “consensus model” based on the average of the prediction 
of the 10 best generalizing models. The partition with the best performance over the data sets 
was selected. Through a meta-SAR analysis 30 descriptors related to hERG inhibition were 
identified. Inspection of the selected descriptors revealed that the presence of a secondary or 
tertiary amino group, of one or more aromatic rings and of a five-membered nitrogen heterocycle 
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increases the potency of hERG blockers. The model also shows that the presence of negatively 
ionizable groups such as COOH and of oxygens as H-bond acceptors is detrimental for hERG 
inhibition. Analysis of the 60 most correlated descriptors with hERG blockade provided a 
pharmacophore model similar to the already published ones. It consists of a nitrogen atom in the 
center to which an aromatic and a hydrophobic feature are attached, separated by a linker of 4-5 
and 1-2 carbon atoms, respectively. This pharmacophore model highlights again the importance 
of the presence of a secondary or tertiary amino group linked to two hydrophobic or aromatic 
features, which might interact with the aromatic amino acids Phe656 and Tyr652. The model 
also suggests that the amino group should be located asymmetrically between the hydrophobic or 
aromatic features, in order to interact optimally with the hERG channel. 
A set of linear solvation energy relationship (LSER) descriptors were used by Yap et al.[74] to 
develop an SVM-based classification using a training set of 271 compounds collected from the 
ArizonaCERT, Micromedex, Drug Information Handbook, Meyler´s side Effect of Drugs, and 
from the work of De Ponti and the American Hospital Formulary Service. The model obtained 
was validated using leave-one-out and Y-randomization methods and model was further tested 
with an independent validation set of 78 compounds. Furthermore, the prediction accuracy was 
compared with those obtained from other classification methods such as k nearest neighbor 
(KNN), probabilistic neural network (PNN) and C4.5 decision tree. The SVM classification 
model shows a higher performance than the other three classification methods, reaching a 
prediction accuracy of 97.4% and 84.6% for the blockers and non-blockers and an overall 
accuracy of 91%. 
Tobita et al.[60] also generated an SVM model which achieved a prediction accuracy of 90% 
and 95% with two different test sets. To build the discriminant models they used 73 compounds 
from the literature for which 57 2D descriptors from the MOE software package, and 51 
molecular fragment-count descriptors taken from the MACCS key set were calculated. The 
support vector machine implemented in the WEKA software package was used to develop two 
different discriminant models using IC50 values of 1 μM and 40 μM to define blockers and non-
blockers. The accuracy of the two models to correctly classify the inhibitors and the non-
inhibitors was evaluated through 10-fold cross validation. The model shows an accuracy of 
prediction of 70% when it was tested with an external dataset of 827 compounds using a 
threshold 1 μM. In both models the most accurate classification was achieved selecting 8 
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descriptors. For the model with a threshold of 40 μM the descriptors selected were five 2D 
descriptors (SlogP, PEOE_VSA6, PEOE_VSA + 1, SMR_VSA5, DIAMETER), and three 
fragment-count descriptors (number of NH2 fragments which is correlated to the possible 
number of hydrogen bond sites, ACH2CH2A and A$A!A$A related to flexibility/hydrophobicity 
of the molecule and the presence of two rings connected by a bond respectively). The fragment 
ACH2CH2A also suggests that the presence of a long chain might play an important role for 
potent hERG blockers. In the models with a threshold of 1 μM the descriptors indentified as 
important were three 2D descriptors (VSA_BASE, PEOE_Vsa0, SMR_VSA0), and five 
molecular fragment-count descriptors (OAAAO, ACH2AAACH2A, Nnot%A%A, 
ACH2AACH2A and 8-membered or larger rings). The descriptors selected by the two models are 
basically different. In the model with the IC50 value of 40 μM the 2D descriptors selected are 
measures of global properties of the compounds, while in the model with the IC50 value of 1 μM 
they are related to a particular structure of the hERG blockers. This highlights that non-potent 
hERG blockers need to satisfy some general properties such as the DIAMETER and the SlogP, 
while for potent blockers the presence of certain structural fragments is important. The analysis 
of molecular fragments shows that the descriptors selected for the threshold at 1 μM are specific 
cases of the descriptors selected for the threshold at 40 μM. The fragments ACH2AACH2A and 
ACH2AAACH2A are related to the global descriptor SlogP. The fragment Nnot%A%A is a 
specific case of the A$A!A$A fragment. Two fragment patterns (pattern1 and pattern2) (fig. 2), 
common to many potent blockers, were discovered through the mapping of the descriptors 
selected with the threshold at 1 μM. The fragments of pattern1 are related to the ACH2AACH2A 
and ACH2AAACH2A fragments, while the fragments of pattern2 are characterized by a nitrogen 
atom bound to an aromatic ring. 
N
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Fig. 2 Fragments related to strong hERG inhibition. 
A series of 246 descriptors and the naïve Bayes classification technique were used by Sun et 
al.[69] A training set of 1,979 compounds from Roche and generic molecular descriptors and 
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fingerprint-based descriptors were used to generate a classification model. The model achieved a 
ROC accuracy of 0.87. The model, tested with an external dataset, predicted correctly 58 out of 
66 molecules. The fingerprint-based naïve Bayes model was built using FCFP_6 (functional 
class fingerprints), a 2D-descriptor where each heavy atom of the molecule is described by a 
string of extended connectivity values, together with physicochemical descriptors such as AlogP, 
molecular weight, number of hydrogen bond donors and acceptors, and number of rotatable 
bonds. The model achieved a ROC accuracy of 0.93, indicating that the classification accuracy 
of the fingerprint-based model is higher than the one of the atom-typing model. The predictive 
accuracy of both models is similar, as shown by the predictions of the 66 compounds of the test 
set. Analysis of the most important atom-types indicates that some particular fragments might 
play an important role for hERG inhibition. The presence of acidic groups abolishes hERG 
blocking, while basic groups such as piperidines and piperazines are important for hERG 
blockage. They also observed that compounds which branch immediately after an aromatic 
moiety have the tendency to be hERG blockers. 
Support Vector Machines (SVM) combined with the pharmacophore-based GRIND descriptors 
were used by Li et al.[41] to design a classification model. To generate the GRIND descriptors 
495 compounds were docked into a homology model of the hERG channel in the open state. For 
every molecule the best scoring pose was selected to calculate the pharmacophoric GRIND 
descriptors, which were combined with the SVM to generate classification models using cut off 
values of 1 μM, 5 μM, 10 μM, 20 μM, 30 μM and 40 μM. Four probes were selected to calculate 
the pharmacophore-based GRIND descriptors: DRY (representing the hydrophobic interactions), 
O sp
2
 carbonyl oxygen (representing H-bond acceptor), NH neutral flat amide (representing H-
bond donor) and TIP probe (representing molecular shape descriptors). The model obtained 
using a threshold of 40 μM showed the best performance. It classified correctly 283 out of 343 
non-blockers and 83 out of 152 blockers, with an overall accuracy of 74%. For the external test 
set comprised of 66 compounds from the WOMBAT-PK database, the model achieved an 
overall accuracy of 72%, with a correct prediction of 85% and 36% of blockers and non-
blockers, respectively. In an additional test using 1,877 compounds from the PubChem database, 
the model correctly classified 107 out of 187 inhibitors and 1,271 out of 1,690 inactives. 
Thai et al.[65] developed two binary QSAR models for the prediction of hERG blockers using 
two sets of descriptors, 32 P_VSA descriptors, and 11 relevant 2D descriptors such as 
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hydrophobic descriptors (SlogP, a_hyd, SlogP_VSA7, Q_VSA_HYD, PEOE_VSA_HYD), 
diameter, atom counts (a_heavy), bond counts (opr_nrot), subdivided surface areas 
(SMR_VSA5), as well as Kier and Hall connectivity indices (chi1v_C, chi0_C). A dataset of 313 
compounds collected from the literature was divided into three classes based on the IC50 value: 
class 1 with IC50 < 1 μM (low IC50), class 2 with IC50 ≥ 10 μM (high IC50) and class 3 with IC50 
in the range 1-10 μM. In order to generate the training and test sets, 184 2D descriptors were 
calculated on the 313 molecules of the dataset and combined with the pIC50 to perform a diverse 
subset selection, which resulted in 240 compounds for the training set and 73 structures for the 
test set. A second dataset was generated removing the compounds containing carboxylic 
moieties. The best binary QSAR model with a cut off at 1 μM (MODEL I) was obtained using 11 
relevant 2D descriptors and removing the compounds with carboxylic groups from the training 
and test sets. The model showed a total accuracy of 0.85 for the training set and 0.94 for the test 
set. The best binary QSAR model with a threshold at 10 μM (MODEL II) was also based on the 
dataset without compounds containing carboxylic groups. The model achieved a total accuracy 
of 0.83 for the training set and of 0.75 for the test set, respectively. Due to the difficulty to 
correctly classify compounds with IC50 values in the range of 1-10 μM, new training and test sets 
were generated omitting the molecules that belong to this class. The binary QSAR based on 11 
relevant 2D descriptors (MODEL III) showed a total accuracy of 0.87 for the training set and of 
0.93 for the test set. All three models were further tested with an external test set of 58 
compounds taken from the literature and showed a good performance, with a total accuracy of 
0.84, 0.78 and 0.86 for MODEL I, MODEL II and MODEL III, respectively. 
Counter-propagation neural network (CPG-NN) were used by Thai et al.[64] to develop 
classification models using 285 compounds collected from the literature and 2 sets of 2D 
descriptors, one based on 32 P_VSA descriptors and the other one on 11 relevant descriptors. 
Based on the IC50 values the compounds were divided into three classes: class 1 (IC50 ≥ 10 μM), 
class 2 (10 μM ≤ IC50 < 1 μM) and class 3 (IC50 < 1 μM). The dataset was split into training and 
test sets by random division (80:20 and 50:50), or by diverse subset selection (80:20 and 50:50). 
The best CPG-NN classification performance, obtained with a 3D output layer combined with 11 
selected 2D descriptors, reached a total accuracy of 0.93-0.95 for the training set and 0.83-0.85 
for the test set, respectively. In particular, this model was able to correctly classify high, 
moderate and weak hERG inhibitors with an accuracy of 0.93 for class 1, 0.97 for class 2, and 
0.96 for class 3. Using only one output layer, the CPG-NN was also used to predict hERG 
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affinity. The model based on 11 relevant descriptors showed highest performance with an r² of 
0.87 for the training and the test set. 
A new series of fragment/pharmacophore descriptors combined with Support Vector Machine 
(SVM) and Random Forest (RF) was applied by Catana et al.[72] to develop classification 
models for a dataset of 561 compounds. An external test set of 1,895 molecules from the 
PubChem was used to validate the model. Each molecule was hashed into different fragments. 
Subsequently, each fragment was mapped back onto the dataset compounds, numbered, and a C-
fragment descriptor was calculated. The value of the “comprehensive fragment” descriptor (CF) 
is calculated by summing the contribution of each atoms of the fragment. This implies that the 
values of each CF descriptor differ for each molecule. The followign descriptors were calculated: 
E-state (CF_E-state_*), AlogP (CF_AlogP_*), MR (CF_MR_*), positive Gasteiger partial 
charges (CF_GC_P_*), negative Gasteiger partial charges (CF_GC_N-*), the van der Waals 
surface area positively charged (CF_VSA_P_*), the van der Waals surface area negatively 
charged (CF_VSA_N_*), the van der Waals surface area (CF__VSA_*), the van der Waals 
surface area with a positive AlogP (CF_VSA_AlogP_P_*), the van der Waals surface are with a 
negative AlogP (CF_VSA_AlogP_N_*). In addition, pharmacophore fingerprints implemented 
in MOE were used to generate a new set of descriptors, called C-pharmacophore descriptors 
(CP_ *) using the approach described above. The model generated by RF using the CF_Estate_*, 
CF_VSA_P_*, CF_VSA_N_* and CF_GA_N_* and some 2D MOE descriptors showed an 
overall accuracy of 0.79 with a precision of 62.2% and 92.3% for true active and inactive 
compounds, respectively. For the external test set the model correctly predicted 105 of 193 
inhibitors and 1,408 of 1,702 inactives. The model created using the SVM based on the C-
pharmacophore descriptors showed a poor performance for the classification of hERG blockers 
(78 out of 193 compounds were correctly predicted). Conversely, the good result achieved in the 
prediction of hERG inactives indicates that this model might be used to select non-blockers. 
In a recent study in silico binary QSAR and counter-propagation neural network were used by 
Thai et al.[63] to classify hERG blockers and non-blockers. The models were built using a 
dataset of 243 compounds with similarity-based (SIBAR) descriptors calculated on basis of four 
reference sets: 24 diverse drugs obtained from Sköld et al.,[75] 20 hERG blockers, 20 hERG 
non-blockers and 20 compounds divided in 10 blockers and 10 non-blockers. The SIBAR 
descriptors were calculated from 11 selected descriptors from a total number of 184 2D 
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descriptors, 86 VolSurf descriptors, 50 3D “inductive” QSAR descriptors (related to atomic 
electronegativity, covalent radii and intramolecular distances) and 32 P_VSA descriptors. The 
binary QSAR models were generated using 16 SIBAR descriptors and threshold values of 1 μM 
and 10 μM. The best classification model was obtained with the 11 hERG relevant descriptors 
using the 20 most diverse hERG blockers as reference set (total accuracy of 0.85-0.88 for the 
training set and 0.73-0.92 for the test set). The CPG-NN models were built using the dataset 
divided into class 1 (low hERG activity), class 2 (high hERG activity) and class 3 (medium 
hERG activity). The dataset compounds were divided into the training set by random selection 
(80:20) or by diverse subset selection (80:20). The architecture of the CPG-NNs was designed 
with 3 output layers representing the classes 1-3. The CPG-NN models were trained with 16 
different sets of descriptors. The CPG-NN model obtained using the set of 11 hERG relevant 
descriptors and the reference set of 20 diverse inhibitors showed the best performance, reaching 
a total accuracy of 0.73-0.74 for the test set and 0.92-0.93 for the training set. The best binary 
QSAR and CPG-NN models were validated using 1,806 compounds published in the PubChem 
compound library and 58 compounds collected from the literature. With the threshold value of 1 
μM the binary QSAR model achieved the total accuracy of 0.93. The CPG-NN model correctly 
classified 68% of the compounds in class 1, 100% of the compounds in class2 and 75% of class 
3. 
Jia et al.[70] designed a classification model using an SVM and the atom type as molecular 
descriptors. The model yielded an overall accuracy of 99.59% for the 977 compounds of the 
training set and of 94% for the 66 compounds of the test set. The use of the atomic molecular 
descriptors makes the classification model easy to interpret. The most important atom-type 
descriptors were the N16 (nitrogen atom in an aliphatic ring), C17 (unsubstituted carbon atom 
next to the N16 in a ring), H4 (acidic hydrogen) and M12 (number of aromatic rings). The 
nitrogen of the N16 descriptor was usually protonated, and it was found in hERG blockers 308 
times out of 322 times of the total occurrence of the descriptor. The C17 descriptor was found 
1,635 times of which 1,318 times it was associated with hERG inhibitors. The H4 descriptor was 
found in 60 structures of which only 5 were hERG positives, in agreement with the fact that 
negatively charged compounds are normally non-blockers. The M12 descriptor occurred 2,581 
times. Only 94 out of 535 molecules containing 3 aromatic rings were hERG inactive, while 14 
out 19 compounds containing one aromatic ring were non-blockers. 
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New descriptors generated from the Shape Signature method were used by Chekmarev et al.[66] 
in combination with k nearest neighbors (k-NN), support vector machines (SVM) and Kohonen 
self-organizing maps (SOM) to create classification models. The models were built based on a 
dataset of 83 compounds divided in strong binders (IC50 < 1 μM) and weak binders (IC50 > 10 
μM). Two different sets of molecular descriptors were calculated, one based only on molecular 
shape and the other one based on molecular shape and polarity. The SVM models showed a 
better performance than the k-NN with an overall accuracy of 69-74% and of 66-67%, 
respectively. 
1.4.1 Decision trees 
The decision tree approach was chosen by several groups in order to classify hERG blockers and 
non-blockers. The ClogP, MR and pKa were used by Buyck et al.[71] Compounds were 
classified as hERG inhibitors when the following three conditions are satisfied: clogP ≥ 3.7, -110 
≤ MR < 176 and pKa ≥ 7.3. 
 A Neural Network model based on the E-state keys and Barnard 4096-bit fingerprints, and a 
Bayesian model based on FCFP_6, AlogP, Molecular Weight, and the counts of hydrogen bond 
acceptors and donors descriptors were used by O´Brien et al.[68] to generate a consensus model. 
The models were built using a dataset of 58,963 compounds randomly divided (80:20) to obtain 
a training and a test set of 46,967 and 11,996 compounds, respectively. The Neural Network 
model shows slightly better results than the Bayesian model with 85% vs 82% of compounds 
correctly classified. To improve the ability to correctly classify the compounds the Neural 
Network and the Bayesian models were combined. The “recover +ve” classifies the compound 
as hERG blockers if one of the models predicts it to be positive. The “recover -ve” classifies a 
compound as negative if one of the models predicts it to be negative. With this classification 
model the number of false positives increases. The “consensus model” classifies a compound as 
positive or negative if both models agree. The model correctly classifies 91% of hERG blockers 
and 87% of hERG non-blockers. With the “consensus model” the rates of false positive and false 
negative are reduced compared to the Neural Network and Bayesian models. 
A total of 155 descriptors such as physicochemical, topological, SMARTS strings and SIMAST 
descriptors were computed on a dataset of 264 compounds by Gepp et al.[76] in order to 
generate two decision trees composed by a maximum of 8 branches. The first descriptor used in 
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the two partitioning models is the pharmacophoric string PHARM$, which correctly classifies 
71% of the compounds in both models and only 13 compounds were misclassified as false 
positives. The two models are identical in the two subsequent layers, which contain the 
descriptors HACSUR (ratio of surface of hydrogen-bond acceptor atoms to total surface), T1E 
(topological electronic index using the number of non-hydrogen atoms), HY (number of 
hydrogen atoms), DIPDENS (dipolar density) and T2E (topological electronic index using the 
number of bonds between non-hydrogen atoms). The differences between the two models start 
from the fourth layer. The first model contains 7 branches and the last fourth layers contain the 
descriptors HLSURF (ratio of surface on halogen atoms to total surface), MDE23 (molecular 
distance-edge vector λ23), MR, CHBBA (covalent hydrogen-bond basicity), logP, QSUMN (sum 
of atomic charges on nitrogen atoms) and MGHBD (minimal geometric distance between two 
hydrogen-bond donor atoms). In the second partitioning model the SIMAST descriptor 
(fingerprint similarity compared to astemizole) is used in many branches instead of the MR and 
logP, and the QSUM- (sum of negative ESP charges) replaces the MR in the fifth layer. The first 
and the second partitioning models achieve overall accuracies for the training set of 91.7% and 
93.2%, and of 76% and 80% for the test set. 
Recursive partitioning models were developed by Dubus et al.[62] They used 203 molecules 
from the Aureus Pharma database, 32 P_VSA descriptors and 23 uncorrelated relevant 
descriptors selected from 184 2D-descriptors calculated with the Molecular Operating 
Environment (MOE) software. Model1 used an active/inactive boundary of 1 μM. Classification 
accuracy for the training set of 96% and 97.5%, and of 74% and 81% for the test set was 
achieved by the model using the relevant and P_VSA descriptors, respectively. In detail the 
models correctly classified 94% of the strong blockers, while the precision for classification of 
the weak blockers decreased to 63% for the relevant descriptors model and to 74% for the 
P_VSA model. Noteworthy, the misclassified molecules mainly showed an IC50 between 1 and 
10 μM. 
In a study performed by Ekins et al.[51] recursive partitioning, Sammon nonlinear mapping and 
Kohonen self-organizing maps were investigated with the aim to analyze the performance of 
these techniques individually or in a consensus approach. The recursive partitioning model was 
built using a training set of 99 compounds providing an r
2
 of 0.90. Interestingly, the performance 
of the test set of 35 compounds was improved (from an r
2
 value of 0.33 to 0.83) when the 
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Tanimoto index was introduced to filter the molecules according to their similarity to those used 
in the training set. The Sammon nonlinear mapping and Kohonen self-organizing maps models 
were generated using a dataset of 93 compounds and 8 descriptors selected with the PCA 
technique from more than 150 descriptors. The 8 descriptors selected are the Wiener index (a 
measure of molecular branching), the topological Balaban index (provides information on the 
connectivity and branching of the molecule and is related to the hydrophobic interaction of the 
molecule), number of H-bond donors, hydrophilicity index and electrotopological state indices 
(CH2, CH and > N, which provide information on the topology, polarity and hydrogen bonding 
capabilities of the compound). These descriptors suggest that the topology of the molecule plays 
an important role for hERG inhibition. The 93 molecules of the training set were divided in three 
classes based on their activity: class0 (IC50 < 1 μM), class1 (1 < IC50 < 10 μM) and class2 (IC50 > 
10 μM). The analysis of the non linear map generated with the Sammon non linear mapping 
technique revealed that the compounds of the classes 0 and 2 were mapped in two different 
areas. The compounds of class 1 were mapped in a wide area of the map overlapping the areas 
occupied by class 0 and 2, resulting in a poor prediction ability. The model predicts correctly 
86% and 100% of the compounds in the classes 0 and 2, giving an overall classification accuracy 
of 95%. As happened for the Sammon non linear mapping, also in the map generated with the 
Kohonen self-organizing map the molecules belonging to class 0 and 2 were mapped in distinct 
areas, while the area occupied by compounds belonging to class 1 overlapped the sites of the 
other two classes. The method correctly classified 86% and 79% of the compounds belonging to 
class 0 and 2, respectively. A consensus analysis performed using the three methods resulted in 
86% of the compounds correctly classified in the classes 0 and 2. The consensus approach did 
not improve the results obtained with the individual methods. 
Doddareddy et al.[67] designed 24 binary models by using Linear Discriminant Analysis (LDA) 
and Support Vector Machines (SVM) to classify 2,644 compounds. 4 molecular fingerprint 
descriptors belonging to the extended connectivity fingerprints (ECFPs) and to the functional 
class fingerprints (FCFPs) were chosen. Four representative models out of 24 were selected for 
further validation. The 4 classification models yielded overall accuracies of 82-86% for the 
training set and 83-85% for the test set. The selected models were further tested by using the 
PubChem database. The models showed a poor predictivity in the classification of the test set 
compounds, with only 78 out of 193 compounds correctly classified. In addition, 50 compounds 
from the Cambridge database that were predicted as hERG blockers and 10 compounds that were 
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predicted as non-blockers by two or more models were selected for experimental validation. 18 
of the 50 predicted hERG inhibitors showed more than 50% displacement of astemizole, while 
all the predicted non-blockers were found to be inactive. 
The SOM was used by Hidaka et al.[77] to classify the compounds using structural information. 
First, 37 compounds were divided into three classes depending on whether the activity (pIC50) 
was below 5, between 5 and 7, or higher than 7. The analysis of the map obtained reveals that the 
potent blockers and the inactive compounds occupy two different areas, while the compounds 
with the intermediate activity overlap the two areas. The same method was then applied to the 
public available dataset. They divided this database into active (“Hit”) and inactive compounds. 
The “Hit” molecules were subdivided into compounds that cause hERG blockade between 20-
30%, between 30-50%, and more than 50%. Considering only the “Hit” compounds they 
established a line which divides the map into two parts: hERG positive and hERG negative 
areas. All compounds that block the hERG channel by more than 50% are mapped in the area of 
the hERG positive potential, with the exception of one false negative. 
1.5 Matched molecular pairs 
In a recent and interesting study Papadatos et al.[78] applied the matched molecular pairs 
technique to three large data sets: hERG (76,266 compounds), solubility (94,053 compounds) 
and lipophilicity (180,440 compounds) to find the most frequent modifications of the molecules. 
The matched molecular pair analysis of the hERG database identified 15 frequent 
transformations. These modifications are related to only one or two heavy atoms, except for the 
substitution of a hydrogen atom with a phenyl ring. In 9 transformations out of 15 the 
modifications have only a small or no effect for the hERG affinity of the compounds. According 
to previous results, they found that replacing a hydrogen atom with a hydroxy group is 
detrimental for the hERG affinity in 45% of the cases, while replacing a hydrogen atom with a 
phenyl ring increases the hERG inhibition in 65% of the cases. The use of context descriptors, 
such as reduced graphs, Murcko frameworks and Daylight fingerprints, as well as more local 
descriptors such as localized RG nodes and atom environments, highlights significant trends that 
are not evident when only the matched molecular pairs technique is used. For example, 
considering the substitution of a hydrogen atom with a methoxy group the global distribution 
indicates that the possibilities to reduce or to improve the hERG affinity are more or less 
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identical. However, if one takes into account the reduced graph node the scenario appears to be 
more complex. The possibility to reduce the hERG affinity increases if the transformation is 
adjacent to an aliphatic chain. The opposite effect is obtained if the transformation is next to a 
hydrogen-bond acceptor in an aromatic ring. On the countrary, if the transformation is adjacent 
to an aromatic ring the hERG inhibition is not affected. These results are related to the possibility 
to form hydrogen-bonds by the oxygen atom of the methoxy group. In the case of the 
substitution of a methyl group with a fluorine atom, the global distribution indicates that this 
might result in an increase or a decrease of the hERG affinity. The presence of the fragment A 
(fig. 3) is correlated with the increase of hERG potency. The analysis of the global distribution 
shows that replacing the cyclohexyl with the phenyl group can reduce or improve hERG 
potency. The cyclohexyl >> phenyl transformation in the fragment B (fig. 3) increases the 
probability to obtain a more potent hERG blocker. This result is due to the increased lipophilicity 
and hydrophobicity of the molecule, and to the reduced ability to form hydrogen-bonds of the 
adjacent amidic carbonyl. These three examples show the importance to include contextual 
information in the drug discovery process to develop compounds with a good toxicological 
profile. 
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Fig. 3 Fragments found in hERG blockers. The asterisk indicates the attachment point. 
1.6 Structure based approaches 
1.6.1 Homology models of the hERG channel 
Up to date there is no crystal structure of the hERG channel and most of our knowledge comes 
from studies on the Shaker channel (Kv1.1) and on mammalian channels (Kv1.2), KcsA, MthK 
and KvAP. Since the eukaryotic and prokaryotic pores are closely related, it appears reasonable 
to use the crystal structures of KcsA (pdb codes 1BL8,[79] 1K4C[80] and 1R3J[81]) and of 
KirBac1.1 (1P7B[82]) to build homology models of the hERG channel in the closed state, or 
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MthK (1LNQ[83]) and KvaP (1ORQ[84]) for the open state. It has to be noted that the degree of 
the pore opening varies in the crystal structures, from the closed state (KcsA) to the open state 
(KvaP), up to an even more open state in MthK. These different degrees in pore opening might 
represent different gating properties of the K
+
 channel, or different snapshots in the gating 
trajectory. The first homology models of hERG channel were discussed also in several 
reviews.[26, 27, 85-87] 
Many groups modeled the hERG channel in the closed state using as template the crystal 
structures of KcsA (1BL8 or 1K4C),[4-6, 11, 12, 88-94] as well as of MthK (1LNQ),[11, 21, 49, 
88, 89, 94] KvaP (1ORQ, or 1R3J)[91, 94-99] and Kv1.2 (2A79)[100] were used as template  to 
construct the homology model of hERG channel in the open state (table 1).  
1.6.2 hERG inhibition and drug trapping 
In 1969 Armstrong[101] demonstrated that the channel opening is a necessary condition to 
obtain the inhibition of the voltage gated K
+
 channel by a small quaternary ammonium (QA) ion. 
Normally, the QA interferes with the channel gating upon repolarization causing a slow 
deactivation due to the impossibility to close the activation gate in a mechanism called “foot-in-
the-door”. In a few words, the activation gate cannot close until the inhibitor dissociates from the 
hERG channel. Armstrong noted that the channel block due to small QA compounds, such as 
tetraethylammonium, did not show interference with the deactivation rate, suggesting that these 
compounds might be trapped in the hERG channel in the closed state. A molecule can only be 
trapped only if it is small enough to fit into the central cavity. If the molecule is charged, it 
cannot leave the central cavity through the hydrophobic environment of the inner pore or through 
the membrane, hence the block is irreversible until the channel reopens. Mitcheson et al.[3] used 
the potent hERG blocker MK-499 and the hERG mutant D540K to test the trapping hypothesis. 
This mutant of the hERG channel has the particular characteristic to open in response to 
hyperpolarization. They observed that the channel reopening during the hyperpolarization 
allowed the recovery from the block of MK499, as postulated by the trapping hypothesis. 
Moreover, the observation that molecules with large size such as MK499 (7×20 Å) can be 
trapped, suggests that the hERG channel has a central cavity bigger than the one of the Shaker 
K
+
 channel. The Shaker K
+
 channel is blocked by tetraethylammonium (6.9 Å of diameter), but it 
cannot trap MK499. 
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1.6.3 Case studies: propafenone derivatives trapping 
Docking studies combined with alanine scanning of the amino acids facing the central cavity 
were performed to investigate the molecular determinants of hERG inhibition by propafenone, as 
well as the amino acids involved in the drug trapping.[11] The mutagenesis data showed that 
propafenone´s inhibition of hERG was strongly dependent on the interactions between the 
compound and the amino acid Phe656, while it was not affected by mutations of Tyr652, Thr623, 
Ser624, Val625, Gly648 or Val659. The analysis of recovery from the propafenone block showed 
that the compound was not released faster from the mutant channels T652A, V625A and S624A 
than from the wild-type channel. Only in the case of F656A the recovery from the block is 
slightly faster. These results suggest that only the mutation F656A slightly reduces the 
interaction of propafenone with the hERG channel in the closed state. Their results also indicate 
that the mutagenesis data are better rationalized with the docking poses obtained with the hERG 
channel in the open state. Almost all of the top ranked poses form π-stacking interactions with 
two Phe656 of adjacent subunits. The model of the hERG channel in the open state suggests that 
the four Phe656 are highly accessible to the compound, whereas in the closed state model the 
space between the Phe656 units is reduced, making it impossible for propafenone to form π-
stacking interactions with Phe656. This indicates that there are gating-induced changes in the 
position of Phe656 side chains. 
In a recent study, Thai et al.[102] used 5 propafenone derivatives to perform a systematic 
analysis of use-dependency and recovery from the block of the hERG channel. The pose of 
propafenone docked into the hERG channel in the closed state predicts that the phenyl ring forms 
π-stacking interactions with Tyr652, that the Thr623 makes hydrogen-bonds with the hydroxy 
group and the protonated nitrogen atom, and that Ser624 forms hydrogen-bonds with the 
hydroxy moiety. The pose of propafenone docked into the homology model of the hERG channel 
in the open state shows π-stacking interactions between the phenyl ring and Phe656, and that the 
hydroxyl and the carbonyl groups as well as the ether oxygen form hydrogen-bonds with Thr623 
and two Ser624 of adjacent subunits, respectively. The docking pose of propafenone into the 
hERG channel in the open state shows that the protonated nitrogen moves in the direction of the 
cytoplasm. This indicates that the propafenone moves upward when the hERG channel closes. 
The other trapped compound, the piperidine analogue, shows similar poses. The poses of non-
trapped propafenone derivatives bearing a 2,3-dimethylphenyl-1-piperazinyl ring docked into the 
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hERG open state, predict that the carbonyl group and the ether oxygen form two hydrogen-bonds 
with Ser624 of different subunits. The conformation of the non-trapped compounds is similar to 
the pose of propafenone, with the substituent located into the inner pore. The non-trapped 1-[4-
{3-[4-(2,3-dimethylphenyl)piperazin-1-yl]-2-hydroxypropoxy}-phenyl)ethanone makes a π-
cation interactions with Phe656, and a hydrogen-bond with Ser624. Like the other non-trapped 
molecule, the 2,3-dimethylphenyl ring is placed in the inner pore. Even if the compound has a 
smaller volume than propafenone due to the lack of the second phenyl ring, the molecule is not 
trapped. These poses indicate that electrostatic interactions are important for drug trapping, 
because the protonated nitrogen is pushed up during the channel gating. Witchel et al.[11] 
indicated that the amino acid Phe656 plays an important role in the interaction with propafenone, 
while the mutations of other amino acids to alanine do not affect the hERG block. In this study, 
the results suggest that also the amino acids Thr623 and Ser624 might interact with propafenone. 
The main structural difference between trapped and non-trapped compounds is the bulkiness of 
the substituent attached to the protonated nitrogen atom, which is larger in the non-trapped ones. 
In light of this consideration, the authors suggest that the size of the substituent might be one of 
the contributing factors playing a role in the drug trapping/non-trapping. In detail, all these 
results indicate that the compounds that are small enough and that can alter the conformation can 
be trapped, in contrast to compounds with a bulky substituent that can prevent the closure of the 
activation gate with a “foot-in-the-door” like mechanism. 
1.6.4 Amino acids involved in hERG inhibition 
At the base of the hERG channel, two concentric rings formed by four Tyr652 and four Phe656 
are located. The ring formed by the four Phe656 is placed near the cytoplasm, whereas the ring 
made by four Tyr652 faces the central cavity. These two rings can make hydrophobic, π-stacking 
and π-cation interactions, explaining the polyspecificity of the hERG channel. 
Several authors studied the physicochemical properties responsible for interactions with Tyr652 
and Phe656 with the ligands. Fernandez et al.[103] studied the nature of the interactions of MK-
499, terfenadine and cisapride with the amino acids Tyr652 and Phe656. They observed that the 
mutation of Phe656 to Trp, Tyr, Met, Leu or Ile altered the block of MK-499, cisapride and 
terfenadine only slightly. In contrast, the mutation of Phe656 to the polar amino acids Arg, Glu, 
Ser and Thr, or to small amino acids such as Ala and Gly increased the IC50. All together these 
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results indicate that the most important physicochemical feature of Phe656 is the hydrophobic 
volume and not the aromaticity. Mutation of Tyr652 to Phe or Trp did not influence significantly 
the sensitivity of hERG to MK-499, terfenadine and cisapride, indicating that the hydroxyl group 
of Tyr652 is not essential for the interaction with hERG blockers. The IC50 of MK-499, 
terfenadine and cisapride dramatically increased when Tyr652 was mutated to Ile, Val, Ala, Thr, 
Gln and Glu. All together these results highlight that the aromaticity at position Tyr652 is an 
important feature for hERG inhibition by these three potent blockers. 
Mitcheson et al.[6] found that the hERG block mediated by MK-499 was affected by mutations 
of Thr623, Ser624, Val625, Gly648, Tyr652, Phe656 and Val659. The experiments performed on 
terfenadine and cisapride supported the interactions with Tyr652 and Phe656, but not the 
interaction with Val625. Same results were obtained by Karczewski et al.[104] for MK-499, its 
enantiomers, and its analogs obtained replacing the hydroxyl group with a hydrogen or an amine 
group. In contrast, the carbonyl analog was insensitive to the Phe656Ala mutation. This result 
indicates that the carbonyl oxygen interacts with the hERG channel. 
The reduction of sensitivity due to the mutation of Thr623, Ser624 and Val625 to alanine was 
observed also for clofilium and ibutilide. Sanchez-Chapula et al.[5] determined that the binding 
site for the weak blocker chloroquine is formed by Tyr652 and Phe656. In contrast to previous 
results,[103] they found that the mutation Tyr652Phe was detrimental for the affinity, indicating 
that the hydroxyl group is essential for the inhibition of the hERG channel mediated by 
chloroquine. 
Mutation of the Phe656 and Tyr652 to alanine reduce the binding affinity of the potent blockers 
MK-499, terfenadine, cisapride,[6, 9] clofilium, ibutilide,[12, 105] thioridazine,[106] and of the 
weak blockers chloroquine,[5] nifekalant, bepridil,[8] maprotiline[107] and mianserin[108] 
indicating the importance of the presence of aromatic amino acids in this position. 
In contrast to these results, hERG channel block mediated by some blockers was almost 
insensitive to the mutations of Tyr652 and/or Phe656 to alanine. The inhibition of hERG 
channels by fluvoxamine was only partially attenuated by the Phe656Ala mutation.[109] 
Mutation of Phe656 to alanine did not affect the hERG block by dronedarone and 
amiodarone.[110] Tyr652Ala mutation showed a modest effect on the block mediated by 
dronedarone, while it had a more marked effect on the amiodarone binding. All these data 
suggest that neither Tyr652 nor Phe656 interact with dronedarone, while Tyr652 might be part of 
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the amiodarone binding site. Mutation of Tyr652 to alanine did not affect the hERG block by 
erythromycin, and mutation of Phe656 to alanine had only a weak effect on the inhibition.[88] 
An interesting study of Shamovsky et al.[54] analyzed the contribution of the desolvation 
component of hERG potency and the nondesolvation-related interactions with the hERG 
channel. They used 25 3,9-diazaspiro-[5.5]undecane analogs and 8 hERG mutants. The PLS 
discriminant analysis (PLS-DA) revealed that the desolvation component of hERG potency 
increases the block of the mutants Tyr652Ala and Tyr652Phe, while the Thr623Ser and 
Ser624Thr mutants are less sensitive to inhibitors. These results suggest that the desolvation 
component of hERG potency is related to the lipophilicity of the compounds. Within the 
nondesolvation-related interactions with the hERG channel the Thr623Ser, Ser624Thr, 
Tyr652Ala, Phe656Met, Phe656Thr and Phe656Trp mutants increase hERG potency. This 
indicates that the lipophilic substituents cannot fit into the inner pore due to clashes with Phe656. 
This hypothesis is confirmed by docking studies on the homology model of hERG in the closed 
state, which predicts that the molecules cannot fit well at the level of the four Phe656. All 
together these results suggest that bulky and rigid substituents are detrimental for the hERG 
affinity. 
1.6.5 Hydrogen bonds with Ser624, Thr623 or Val625? 
The amino acids Thr623, Ser624 and Val625 lie at the top of the inner cavity. Dougherty et 
al.[111] mutated the amino acids facing the hERG pore to determine the binding efficacy of 
astemizol, dofetilide, haloperidol, risperidone, droperidol, pimozide, loxapine, amoxapine, 
imipramine, fluphenazine, triflupromazine, cis-flupenthixol, and amperozide. Astemizole 
showed an increased IC50 value with the double flourinated Phe relative to the single flourinated 
Phe and the Tyr652Phe mutants, indicating that Tyr652 interacts with astemizole through π-
stacking and/or π-cation interactions. The mutation of Phe656 into the two flourinated 
phenylalanines did not affect hERG channel block. This suggests that Phe656 may not be 
involved in the binding of astemizole, or that it forms hydrophobic interactions. Mutation of 
Thr623 to the non-natural amino acid Thr623-(OH) led only to slight increase of the binding 
affinity, while the Thr623Val mutant is less sensitive to astemizole. The Ser624Thr mutation 
slightly decreased the astemizole hERG block, while the affinity for the hERG channel was lost 
in the Ser624Ala mutation. These results show the importance of the hydroxy group of Ser624. 
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Perry et al.[12] used site-direct mutagenesis to investigate the interactions of clofilium and 
ibutilide with hERG channel. The authors performed an alanine scanning of the amino acids of 
the S6 domain facing the pore of the hERG channel. The results show that both blockers were 
affected by mutation of the amino acids Thr623, Ser624, Val625, Gly648, Tyr652, Phe656 and 
Val659 to alanine. 
Using the same method, Kamiya et al.[8] determined that the binding site of the hERG blockers 
E-4031 and dofetilide consists of the amino acids Thr623, Ser624, Val625, Tyr652, Phe656 and 
Val659. The same effect was obtained for the hERG blocker nifekalant, except for the Val659Ala 
mutation that did not affect the hERG inhibition and for the Ile655Ala that reduced channel 
block. The Thr623, Ser624, Val625 and Phe656 mutations reduced the block of the hERG 
channel by bepridil. 
Using alanine scanning, Kamiya et al.[9] showed that amino acids Thr623, Ser624, Tyr652 and 
Phe656 play an important role in hERG inhibition by terfenadine and cisapride. 
Finally, Hosaka et al.[95] applied a site-direct mutagenesis to analyze the interactions between 
nifekalant and amino acids in the pore region of hERG. The mutation of Thr623, Val625, Gly648, 
Tyr652 and Phe656 to alanine abolished the block of the hERG channel. The mutant Val625Ala 
disrupted the K
+
 selectivity. This indicates that the side chain of Val625 might be essential for the 
stability of the selectivity filter structure, hence the mutant Val625Ala might perturb the surface 
of the inner cavity reducing indirectly the affinity for nifekalant. The homology model of the 
hERG channel in the open state showed that Gly648 was not part of the pore channel, so the 
reduction of the hERG block was due to an indirect action. 
1.6.6 Role of Gly648 
Siebrands et al.[112] created the hERG mutants T623A, S624A, V625A, G648A, Y652A, 
Y652T, F656A and F656T by site-direct mutagenesis to analyze the interactions between 
bupivacaine and the hERG channel. All the mutants abolished the channel block by bupivacaine. 
The mutation of Gly648 to alanine might lead to a reorientation of the amino acids in the S6 
domain, thus indirectly reducing the affinity for the blocker. 
1.6.7 Which subunits are involved in drug binding? 
Recently it was investigated which subunits of the hERG channel are involved in the interaction 
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with the blockers.[113, 114] Myokai et al.[113] constructed seven tandem dimers with single or 
double mutations (Y652A and/or P656A) to test which mutations affect the binding of cisapride. 
The results brought to light that the binding site of cisapride consists of several subunits. 
Combining the voltage dependence of the cisapride block, the steady-state block, mutagenesis 
and kinetic data, it was suggested that cisapride binds at first to the low-affinity binding site 
formed by the two Phe656 of opposite subunits. Only when the voltage-dependent 
conformational changes reorient the residues in the pore, cisapride binds to the high-affinity 
binding site constituted by the two Tyr652 of adjacent subunits and Phe656. 
Imai et al.[114] constructed the tandem dimers mutating the amino acids Ser624, Tyr652, and 
Phe656 of opposite subunits to investigate the binding site of cisapride, E-4031 and terfenadine. 
The inhibition curves of the mutant channels revealed that cisapride and E-4031 interact with 
Tyr652 and Phe656 of adjacent subunits and with Ser624, while terfenadine interacts with 
Tyr652 and Phe656 of opposite subunits but not with Ser624. Based on the results of the 
inhibition curves, the three compounds were docked into homology models of the hERG channel 
in the open state. The docking pose of cisapride shows π-π interaction between one aromatic ring 
of the molecule and Tyr652, and CH-π interaction between the Tyr652 of adjacent subunits and 
the methylene group near the protonated nitrogen in the piperidine ring. The second aromatic 
ring of the molecule forms π-stacking interactions with Phe656, and the carbonyl oxygen 
interacts via hydrogen bond with Ser624. The docking pose of E-4031 indicates that the aromatic 
rings form π-π interactions with herringbone geometry with two Tyr652 of adjacent subunits, that 
the pyridine ring makes a hydrogen-bond with Ser624, and that the methyl group in the 
methansulfonamide moiety forms a CH-π interaction with the amino acid Phe656. The pose of 
terfenadine shows that the two terminal aromatic rings and the second benzene ring of the 
benzhydryl moiety interact with Tyr652 and Phe656 through π-π interaction with herringbone 
geometry. Based on these interactions, the introduction of an electron withdrawing group, or the 
introduction of a bulky substituent, which disrupts the interactions with Tyr652 and Phe656, can 
lead to a terfenadine derivative with an attenuated hERG binding affinity. The docking poses of 
cisapride, E-4031 and terfenadine proposed in this study, in contrast to a previous study,[103] 
highlighted that π-cation interactions might not always play a dominant role, and that π-π 
interactions with herringbone geometry and CH-π interactions could be important in the hERG-
blocker complex formation. 
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1.6.8 Influence of para-substituents on the phenyl ring 
Mutagenesis data and docking studies suggest that the para-substituent of phenyl rings in 
inhibitors forms polar interactions with Thr623 and Ser624.[12] To test this hypothesis, a 
structure activity relationship of ibutilide derivatives was performed to analyze the influence on 
the IC50 of different para-substituents.[105] The IC50 of ibutilide analogs measured on wild-type 
hERG channels showed a rank order of nitro > chlorine > amine > amide. Similar results were 
obtained also with dofetilide derivatives. These results are in agreement with the 3D-CoMSiA 
and the 3D-pharmacophore models developed by Cavalli et al.,[30] which indicated the 
importance of a polar or a polarizable region close to an aromatic ring. All these information 
suggest that it is possible to reduce the hERG potency by modifying the nature of the substituent 
in the para position of phenyl rings and thereby develop compounds with a better toxicological 
profile. 
The docking poses of clofilium and the nitro analog show that the para-substituent interacts with 
Thr623 and Ser624 and that the phenyl ring forms π-stacking interaction with Tyr652. The ethyl 
group attached to the protonated nitrogen, which is placed in the center of the central cavity, 
forms hydrophobic interactions with Tyr652. The second ethyl group present in some docked 
inhibitors may form hydrophobic interactions with a second Tyr652. The docking poses indicate 
that bulky substituents in para position prevent to adopt the conformations of clofilium and its 
nitro analog. The pose of clofilium predicts that the chlorine atom forms hydrogen-bond 
interactions with Ser624. In the proposed binding conformation of ibutilide, the para-substituent 
interacts with Thr623, Ser624, and the phenyl ring forms π-stacking interaction with Tyr652. The 
amide analog cannot adopt the binding mode of ibutilide and interacts with Thr623 and Ser624, 
probably due to the lack of the sulfonyl and of the hydroxyl groups. The interactions with Tyr652 
are weak, and this explains the low affinity of the amide analog for the hERG channel. In all four 
compounds, the tail makes hydrophobic interactions with Phe656. 
1.6.9 Two or three binding interactions? 
Mutagenesis studies of the S6 domain identified Tyr652 and Phe656 as important sites of 
interaction. These results led to propose that the charged nitrogen atom may form π-cation 
interactions with Tyr652 or Phe656, and that the aromatic moieties of the blockers can make π-
stacking interactions with the amino acids cited above. Choe et al.[97] suggested a model with 
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three key interactions: hydrogen-bond interaction between the protonated nitrogen atom and the 
carbonyl oxygen of Thr623; π-stacking interactions between an aromatic ring and Tyr652; 
hydrophobic interaction between an hydrophobic moiety of the blocker and Phe656. To test the 
three key interactions model, 69 known hERG blockers were divided into eight binding types 
and further subdivided into two groups based on the number of interactions with the hERG 
channel (two or three) predicted by the model. Consistent with the three key interactions model, 
the different distribution of pIC50 values between the two groups reveals that the blockers can 
form three interactions, and that the compounds, which are predicted to form more interactions, 
show a higher mean pIC50 value. 
1.6.10 Docking studies and prediction of hERG binding affinity 
Rajamani et al.[89] developed a two-state binding affinity model to predict the IC50 values of 
potential hERG blockers. Homology models of the hERG channel in the closed and open states 
were constructed using as template the crystal structures of KcsA and MthK, respectively. 
Initially, the S6 helix of the reference closed state model was rotated to match MthK S6 helix, 
and subsequently the channel was closed rotating the S6 helix by 1°. The partial open state 
model (10° translation away from the reference model) and the fully open state (19° translation 
away from the reference model) were used to dock 32 hERG inhibitors. The best pose for each 
ligand was then minimized within the channel, and finally the minimized pose (bound state) was 
extracted and minimized in water (free state) to obtain the reference electrostatic and van der 
Waals energies. The difference in the computed energy values (Δele and Δvdw) between the 
bound and the free states were used to derive linear regression fits to the experimental pIC50. The 
estimated interaction energy was used to establish the preference of each ligand for one of the 
two states. The computed pIC50 values of the 21 ligands that prefer to bind the open state model 
were predicted with an RMSD of 1.2 [pIC50Open= -0.166(Δvdw) +0.002(Δele)]. For the 11 
compounds that preferentially interact with the partially open state model, the pIC50 values were 
calculated with an RMSD of 0.85 [pIC50Closed= -0.155(Δvdw) +0.0004(Δele)]. Given the fact that 
both models had essentially the same coefficients for the (Δvdw) term, a single model was 
generated combining the energies for each ligand docked into its best fit state. Plotting the 
experimental versus computed pIC50 values five outliers were identified. The model obtained 
[pIC50Combined= -0.163(Δvdw) +0.0009(Δele)] omitting those 5 outliers showed an RMSD of 0.56 
and an r² of 0.82. The equation reveals that the most important contribution to the hERG affinity 
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arises from Δvdw, in agreement with the previous observations, which indicated that 
hydrophobicity and aromaticity were the most important physicochemical features of Phe656 
and of Tyr652, respectively.[103] 
Österberg et al.[98] used molecular dynamics (MD) simulations and the linear interaction energy 
(LIE) method to calculate the binding affinity of six sertindole analogues docked into the 
homology model of the hERG channel in the open state. For each ligand, the pose with the 
lowest energy was selected from the two or three best clusters, and was submitted to MD 
simulations. The K
+
 ions can occupy the selectivity filter with the 1010 (K
+
-H2O-K
+
-H2O) or 
with the 0101 (H2O-K
+
-H2O-K
+
) configurations. The binding free energies for hERG indicated 
that the 1010 is the most favorable conformation. The higher value of binding free energies 
obtained with the 0101 configuration is due to the electrostatic repulsion between the basic 
nitrogen of the blocker and the K
+
 ion facing the central cavity. The plot of the calculated LIE 
free energies versus the experimental values shows a good correlation between these two terms. 
Also, Farid et al.[99] obtained a good correlation between the predicted and the experimental 
ligand binding free energy of four sertindole analogs. The compounds were docked into the 
homology model of the hERG channel in the open state using the induce-fit protocol. The 
correlation between the Extra Precision (XP) scoring in Glide and the experimental binding 
affinity shows an r² of 0.95. The analysis of the terms of the Extra Precision (XP) scoring 
indicates that the Glide-XP lipophilic contact and the Glide-XP van der Waals energy terms are 
favorable for hERG inhibitors, while the Glide-XP penalty for buried polar groups term is 
unfavorable. 
The GOLD docking software was used to dock 56 known blockers into a closed state model.[92] 
For each ligand, the best pose was selected and the docking GOLDScore fitness was used to 
derive a linear regression fit to the experimental pIC50. The model achieved an r² of 0.60 and a q² 
of 0.56, demonstrating that it can be used to predict the binding affinity of hERG inhibitors. 
1.6.11 Case studies: docking studies and improvement of the selectivity 
A structure-activity relationship combined with docking studies was used by Price et al.[115] to 
reduce the hERG affinity in a series of CCR5 antagonists. Docking of the lead compound into a 
homology model of the hERG channel in the closed state revealed that the benzimidazole group 
fits perfectly to the lipophilc region described by the four Tyr652. This result suggested that it 
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was possible to reduce the affinity of the compounds for the hERG channel by replacing the 
benzimidazole moiety with other moieties. This led to the discovery of maraviroc, a potent 
CCR5 antagonist, which does not interact with the hERG channel. 
Micheli et al.[100] performed an interesting study on the combination of docking experiments 
with structure-activity relationship (SAR) to improve the affinity of a series of 1,2,4-Triazol-3-
yl-thiopropyl-tetrahydrobenzazepines with the dopaminergic receptor D3 and to avoid the 
interaction with the hERG channel. The compounds were docked manually into homology 
models of the hERG channel in the closed and the open state. The docking experiments predict 
that the lead compound assumes a U-conformation, probably due to interactions with Tyr652, 
Phe656 and intramolecular π-stacking interaction. The pose shows that the charged nitrogen 
atom and the quinoxaline ring form hydrogen-bonds with serines in the pore of the hERG 
channel. Based on the docking results, two strategies were used to tackle hERG liability. In the 
first one the hydrophilicity of the compounds was increased. This strategy led to a compound 
highly selective for the D3 receptor and with a reduced affinity for the hERG channel. The 
second strategy was to reduce the π interactions between the isoxazolyl group and the hERG 
channel breaking the coplanarity between the isoxazolyl and the benzazepine moieties. This 
strategy led to a reduction of hERG activity, without affecting the D3 potency. 
Also, Dinges et al.[116] used a combination of SAR and docking results to develop KDR kinase 
inhibitors with an optimized hERG profile. One kinase inhibitor was manually docked into a 
model of the hERG channel in the closed state. The best fit was obtained by orienting the 
compound parallel to the pore of the channel, with the acetylenic ether group oriented towards 
the cytoplasmatic side of the hERG channel. The pose predicts that the 1,4-dihydroindeno[1,2-
c]pyrazole forms π-stacking interactions with Phe656, that the charged nitrogen atom on the N-
methylpiperazine moiety can make π-cation interactions with Tyr652, and that the external 
nitrogen forms a hydrogen-bond with Ser624. Based on this pose three strategies were 
developed. The first strategy consisted on the modification of the basic side chain. This approach 
led to compounds with a reduced hERG affinity, but the antitumoral efficacy was compromised. 
In the second strategy the polarity of the acetylenic chain was increased. This led to molecules 
with an attenuated hERG activity, but also the KDR affinity was reduced, except for the 
compound bearing the glycol ether moiety that inhibited 76% tumor growth in the MX-1 tumor 
xenograft model. The third approach used the introduction of groups that disrupt electronically 
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or sterically the π-stacking interaction between the 1,4-dihydroindeno[1,2-c]pyrazole and 
Phe656. The substitution of the methylene bridge with a carbonyl group reduced the hERG 
affinity, without affecting the KDR inhibition. 
In a recent study, Levoin et al.[117] combined homology modeling and docking to refine a 
homology model of the H3 receptor. The model of the H3 receptor was optimized in three 
different ways: ten independent molecular dynamics simulations of the proteins embedded in the 
membrane; ten independent simulated annealing (SA) runs with the most active compound of ten 
clusters obtained from the training set of inhibitors of each protein; iterative simulated annealing 
(ISA) with a rigid potent compound. The ligands were docked in the refined models and 
subsequently the first ranked pose of each ligand was selected, and the affinity with the protein 
was assessed using the DOCK_SCORE, Ligscore1-2, PLP1-2, Jain, PMF, and Ludi_1-3 scoring 
functions. The performance of the prediction was then evaluated using the ROC curve and the 
area under the curve (AUC). The best performing model in the screening of the training set 
compounds was the one refined via the ISA method, which achieved an AUC value of 0.73. 
Similar results were obtained with the test set, where the model showed an AUC of 0.71. To 
predict also the interactions with antitarget proteins, the same procedure was applied to refine the 
homology models of hERG and CYP2D6. Also in these cases, the refinement process leads to a 
better performance of the homology models by producing an AUC > 0.69 for both antitarget 
proteins. 
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Fig. 4 2D structure of the two compounds docked into the hERG channel. 
Recently, Shamovsky et al.[38] used a combination of pharmacophore modeling, QSAR and 
docking to develop a successful lead optimization strategy that overcomes the undesirable 
interactions with hERG. The aim of the docking experiments performed on a homology model of 
the hERG channel in the closed state was to explain the intrinsic hERG binding. To achieve this 
aim two compounds, which represent extreme cases of intrinsic hERG binding were docked into 
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the homology model of hERG. The compound A (fig. 4) makes cooperative hydrogen-bond 
interactions with Ser624, whereas the compound B forms cooperative π-stacking interactions 
with Tyr652. The docking poses suggest that also the amino acids Leu622, Ser649, and Phe656 
are involved in the intrinsic interactions between the hERG channel and the blockers. 
1.6.12 Orthogonal binding site? 
In contrast to the accepted idea that the blockers bind the hERG channel longitudinally to the z 
axis, Zachariae et al.[118] proposed an orthogonal binding site. During MD simulations of a 
homology model of the hERG channel in the closed state the four Tyr652 adopted a “down 
conformation” with the aromatic ring plane pointing into the central cavity. The “down 
conformation”, which is stabilized by the interactions with Phe656, opens a way to the 
membrane. This can explain why the cavity size of hERG in the closed state is larger than the 
vestibule of KcsA and can accommodate bulky compounds, such as MK-499.[3] Docking 
studies performed on several compounds such as dofetilide, terfenadine, and cisapride, and 
previously published pharmacophore models[28-30, 33] corroborate this model. The pose of 
dofetilide suggests that the charged nitrogen atom is close to the K
+
 binding site, and that the two 
aromatic rings form π-stacking interactions with two Tyr652 of opposite subunits. The binding 
position of terfenadine shows that the two neighboring aromatic rings of the molecule interact 
with two Tyr652 of adjacent subunits. In the case of cisapride, the two phenyl rings interact with 
two opposite Tyr652. 
1.6.13 Docking results 
The main goal of the docking technique is to model the molecules in the binding site and to find 
the bound conformation of the compounds as close as possible to the crystal poses, allowing the 
analysis of the interactions between the ligand and the target protein. 
Mitcheson et al.[6] docked MK-499 into a closed state homology model of the hERG channel. 
The analysis of the poses shows that the p-CN phenyl ring and the benzopyran form π-stacking 
interactions with Phe656 and Tyr652, while the methanesulfonanilide moiety is placed into the 
pocket delimited by Gly648, Thr623 and Ser624. 
Karczewski et al.[104] docked MK-499 into a homology model of the hERG channel in the 
closed state. The docking poses of MK-499 predict that the hydroxyl group forms a hydrogen-
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bond with Ser624, but the contribution of this interaction to the complex stabilization is modest 
due to the distance between the two hydroxy oxygens (3.4 Å). In the docking pose of the 
carbonyl analog the distance between the oxygen of the side chain of Ser624 and the one of the 
substituent is 3.0 Å. This indicates that the hydrogen-bond between the carbonyl analog and 
Ser624 is stronger than the previously discussed one, which might explain the insensitivity to the 
Phe656Ala mutation. 
Two possible binding modes of chloroquine were proposed by Sanchez-Chapula et al.[5] In the 
first binding mode, the molecule forms π-stacking interactions with Phe656 on three subunits, as 
well as a hydrogen-bond with Ser649, while the diethyl groups of the tail of the molecule form 
hydrophobic interactions with Tyr652. In the second binding pose, the quinoline group makes π-
stacking interactions with Tyr652 and Phe656. The nitrogen atom attached to the quinoline forms 
a hydrogen-bond with Ser649 and the ethyl group attached to the charged nitrogen interacts with 
Tyr652 through hydrophobic interactions. 
The aligned inhibitors used to generate the CoMSiA model of Pearlstein et al.[21] were docked 
into a homology model of the hERG channel in the open state. The proposed binding mode 
suggests that the Phe656 forms π-stacking interactions with an aromatic ring, that a second 
hydrophobic group can interact with another Phe656, and that the charged nitrogen atom makes 
π-cation interactions with Tyr652. The tail region of the blockers reaches into the pore region 
that extends from Tyr652 to the selectivity filter. 
Moreno et al.[4] studied the effect of irbesartan on hERG, KvLQT1+minK, hKv1.5 and Kv4.3 
channels using the patch clamp technique. The homology models of hERG and hKv1.5 channels 
in the closed state were generated using the KcsA crystal structure as template. The pose 
obtained from manual docking of ibersartan shows that the blocker forms a hydrogen-bond and 
π-stacking interactions with Tyr652, π-stacking interactions with Phe656 and van der Waals 
interactions with Thr623. 
The pose of clofilium proposed by Perry et al.[12] shows π-stacking interactions between the 
Tyr652 and the phenyl ring of the molecule, in addition to the hydrophobic interactions of the 
aliphatic tail of clofilium with Phe656 and the interactions of the chlorine with Thr623, Ser624, 
and Val625. 
Duncan et al.[88] docked erythromycin into a model of the hERG channel in the open state. All 
the poses with low energy interact with Phe656, while the interaction with Tyr652 is prevented 
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by the large size of the molecule that restricts the ability of erythromycin to move up into the 
inner cavity. The docking poses obtained with a model of the closed state shows high energy 
values due to steric clashes, indicating that the molecule cannot fit into the closed state channel. 
Visual inspection reveals that the molecule is too large for the central cavity of the hERG 
channel in the closed state. 
Yoshida et al.[49] docked the hERG blocker pimozide into an open state model to examine the 
correspondence between the molecular determinants derived from the 2D-QSAR model with the 
3D structure of the channel. The docking pose suggests that the fluorine atoms and the carbonyl 
group of pimozide form hydrogen bond interactions with Ser649 and Ser624, respectively. 
Hosaka et al.[95] performed a flexible docking of nifekalant into an open state model. Consistent 
with the mutagenesis data, docking simulations suggest that the entire molecule is placed in the 
central cavity surrounded by Thr623, Ser624, Tyr652, and Phe656 of different subunits and 
located in close vicinity to Ser649. 
Österberg et al.[98] docked a series of sertindole analogs into a homology model of the hERG 
channel in the open state. The docking pose of sertindole suggests that the carbonyl oxygen 
forms a hydrogen bond with the water molecule located in the selectivity filter. The 
imidazolidinone group makes good interactions with Thr623 and Ser624. Interestingly, the 
charged nitrogen is almost superposed to the crystallographic position of the K
+
 ion in KvaP. 
Farid et al.[99] used the induce-fit docking protocol to dock 12 known hERG blockers into 
hERG channel models in the open and closed state. S-terfenadine interacts with four Tyr652 and 
two Phe656. It forms T-shaped interactions with four of the six aromatic amino acids. The 
docking results show that the poses of R- and S-terfenadine are similar. S-terfenadine interacts 
simultaneously with four Tyr652 and two Phe656. The replacement of a T-shape interaction with 
a parallel one is the only important difference between the S- and R-terfenadine. S-terfenadine 
forms hydrogen-bonds with the backbone oxygen of the amino acid Leu622, and with the side 
chains of Ser624 and Ser649. R-terfenadine makes four hydrogen-bonds, three of them are with 
Ser624 of different subunits and the fourth one is with Tyr652. Also, the poses of (+)-cisapride 
and (-)-cisapride are similar. (+)-cisapride interacts with three Tyr652 and two Phe656, making 
two T-shaped interactions with the Tyr652 on opposite subunits, and a parallel interaction with 
one Phe656. The pose predicts also that the piperidine NH forms a hydrogen-bond with Ser624. 
The only difference between (+)-cisapride and (-)-cisapride is that the interaction with Phe656 is 
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replaced by an interaction with Tyr652. MK-499 interacts simultaneously with four aromatic 
amino acids (two Tyr652 and two Phe656). The molecule is predicted to be near Thr623, Ser624, 
Ser649, and Ala653, with which it can interact. The aliphatic chain of S-ibutilide interacts with 
three Tyr652 and one Phe656. The phenyl ring forms a T-shaped interaction with Tyr652. The 
methanesulfonanilide group and the basic nitrogen are predicted to make hydrogen-bonds with 
two Ser624 of adjacent subunits. The pose of R-ibutilide is a mirror image of the one of S-
ibutilide. Clofilium makes simultaneous interactions with four Tyr652 and three Phe656. The 
pose predicts one T-shaped interaction with Tyr652 and two with Phe656. Sertindole interacts 
with three Tyr652, two of which make T-shaped interactions. The docking pose shows also 
interactions with one Phe656. The pose of sertindole A5 predicts the interactions with two 
Tyr652 and one Phe656. It makes T-shaped interactions with one Tyr652 and one Phe656. The 
pose predicts also a hydrogen-bond between the backbone oxygen of Thr623 and the 
dimethylamine NH group. Sertindole A1-A4 interact with Tyr652 and Phe 656. Moreover, it 
makes hydrogen-bonds with Ser649 and with the backbone oxygen of Leu622. 
Masetti et al.[91] constructed a homology model of the hERG channel in the open and in the 
closed state. Subsequently, the two models were embedded in a membrane bilayer, solvated, and 
the system was neutralized. Both models were subjected to molecular dynamics simulations of 
5ns. The docking of astemizole into the hERG channel in the closed state could not provide any 
reasonable pose. Reliable binding poses were identified only when astemizole was docked into 
snapshots of MD simulations of the hERG channel in the open state. The top ranked pose shows 
that the benzimidazole ring forms π-stacking interactions with Tyr652 and parallel displaced π-π 
interactions with Phe656 of the same subunit. The p-fluorophenyl interacts with Tyr652 through 
parallel displaced π-π interactions. The pose predicts also a possible hydrogen-bond between the 
fluorine atom and Ser624, and the charged nitrogen atom of the piperidine ring forms a π-cation 
interaction with Phe656. The p-methoxybenzene ring is shown to be exposed to the cytoplasm. 
The pose of terfenadine reported by Du et al.[92] shows that the t-butylphenyl moiety forms 
hydrophobic interactions with the amino acids Ser649, Tyr652, Ala653, and Phe656, whereas the 
diphenylmethanol group makes hydrophobic interactions with Ser624, Ser649 and Tyr652. The 
phenyl ring of the hERG blocker ibutilide is predicted to form hydrophobic interactions with 
Thr623, whereas the alkyl chain makes hydrophobic interactions with Thr623, Ser649, Tyr652, 
Ala653 and Phe656. Furthermore, the nitrogen atom of the methylsulfonamide moiety can form 
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a hydrogen-bond with Thr623. 
Singleton et al.[93] docked a series of dofetilide derivatives bearing a fluorescent group into a 
hERG channel homology model of the closed state. The poses highlight that the compounds lie 
in the inner pore, where they interact with Tyr652 and Phe656. The polycyclic conjugated dyes 
occupy the central cavity. 
Models of hERG channel in the open and closed state were generated by Stansfeld et al.[94] 
using as template the structure of MthK, KvaP, and KcsA. As the models showed only partial 
agreement with mutagenesis data, a series of KcsA-based intermediate models were generated 
rotating the four S6 domains. To obtain homology models where the Phe656 can interact with the 
blockers also a series of intermediate models, which simulate the channel opening, were created. 
The docking poses of compounds E-4031, dofetilide, ibutilide, and dronedarone show that the 
methansulphonamide makes hydrogen-bonds with Thr623 and Ser624. A phenyl ring is predicted 
to form π-stacking interactions with Tyr652. The methanesulphonamide MK-499 does not 
interact with the amino acids Thr623 and Ser624. The pose of dronedarone predicts that the 
charged nitrogen atom is placed in the same position of the K
+
 identified in the inner pore in the 
KvaP crystal structure. The docking pose of fluvoxamine suggests that the protonated nitrogen is 
placed below Phe656, whereas the trifluoromethyl group lies in the central cavity and shows 
hydrogen-bond interactions with Thr623 and Ser624. The poses of propafenone and vesnarione 
make π-stacking interactions with Tyr652. For propafenone, it is also predicted that the charged 
nitrogen atom is placed between the Phe656 residues, with which it can form π-cation 
interactions. The pose of terfenadine indicates that this compound interacts with Tyr652 and 
Phe656. In the case of clofilium and cisapride the molecules make π-stacking interactions with 
Tyr652, whereas the polar groups interact with the amino acids Thr623 and Ser624. In the 
docking poses of quinidine and chloroquine, the basic nitrogen is placed above Phe656 and the 
ring system forms π-stacking interactions with Tyr652. 
In summary, numerous docking studies have been conducted and they support findings from 
QSAR and mutation studies. However, with respect to prediction of strong hERG binders, 
docking definitely suffers from the still unsolved issue of proper binding free energy 
calculations. In addition, the channel is quite flexible and compounds might bind to the closed, 
semiopen and/or open states. This renders hERG binding prediction solely based on docking 
quite risky. 
Andrea Schiesaro Introduction 2011 
49 
    
1.7 Conclusions 
In this chapter several methods to discover potential hERG blockers have been reviewed. The 
hERG channel opening and gating are multistep mechanisms and the blockers might inhibit the 
channel at any step of the processes. Even if the ligand-based methods presented highlight some 
structural trends for hERG blockers, and the docking results show that the interactions with some 
amino acids are crucial, the general limitations of in silico techniques render it difficult to 
perform virtual screening for discovery of potential hERG blockers. Thus, biological tests during 
the lead optimization process are still the first choice to develop compounds that don´t interact 
with the hERG channel. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Andrea Schiesaro Introduction 2011 
50 
    
Table 1. Published homology models of the hERG potassium channel in the closed and open state. 
Ref. Template Homology model / Docking  
[6] KcsA (1BL8) Insight II / FLOG 
[5] KcsA (1BL8) MOE / FLOG 
[21] MthK (1LNQ) Modeller 
[4] KcsA (1BL8) QUANTA/CHARMm / Manual docking 
[119] KcsA (1BL8) SWISS-MODEL / Chimera 
[12] KcsA (1BL8) Modeller v6.0 / GOLD 
[11] KcsA (1BL8), MthK (1LNQ) Insight II / FlexiDock 
[89] KcsA (1K4C), MthK (1LNQ) PRIME / Glide 
[105] KcsA (1BL8) Modeller v6.0 / GOLD 
[98] KvaP (1ORQ) SWISS-MODEL / AutoDock 3.0 
[88] KcsA (1BL8), MthK (1LNQ) Insight II / FlexiDock 
[97] KvaP (1R3J) Modeller v.8.0 / GOLD v.2.2 
[49] MthK (1LNQ) MOE / Glide 
[99] KvaP (1ORQ) PRIME / Glide 3.0 
[120] Kv1.2 (2A79) SWISS-MODEL / AutoDock 3.0 
[90] KcsA (1BL8) SWISS-MODEL / ZDOCK 
[95] KvaP (1ORQ) Modeller v6.0 / Sievgene 
[96] KvaP (1ORQ) Modeller 
[100] KcsA (1BL8), Kv1.2 (2A79) QUANTA / Manual docking 
[39] KcsA (1BL8) Insight II / DOCK v.5.2 
[121] KcsA (1BL8) Moloc / Manual docking 
[91] KcsA (1K4C), KvaP (1ORQ) Modeller v.7.7 / GOLD v.3.0.1 
[92] KcsA (1BL8) Modeller v.7.7/Insight II / GOLD v.3.1 
[116] KcsA (1BL8) Insight II / Manual docking 
[93] KcsA (1BL8) Modeler v6.0 / GOLD 
[94] MthK (1LNQ), KvaP (1ORQ), KcsA (1BL8) Modeler v.6.2 and Modeler v.7.7 / GOLD v.3.0 
[117] MthK (1LNQ) Modeler v.8.2 
[38] Kcsa (1R3J) Insight II / Glide 
[104] KcsA (1BL8) Insight II / FLOG 
[102] KcsA (1K4C) Modeller / FlexX 
[118] KcsA (2BOB, 2HjF and 2HVK) Modeller / GOLD 
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THE TRAPPING PHENOMENA 
Several studies demonstrate that drugs block the hERG channel when it is in the open or inactive 
state. During the closure of the activation gate some drugs dissociate from the hERG channel 
with a mechanism called “foot in the door”, or through rapid unbinding upon repolarization, 
while some drugs are trapped into the hERG channel in the closed state. In the “foot in the door” 
type mechanism the blocker do not allow the channel to close completely, leaving open a 
passage in the inner pore which is used by the drug to dissociated from the channel in the closed 
conformation. 
The first evidence of the drug trapping phenomenon was provided by Armstrong et al.[101, 122, 
123] Performing experiments on voltage-gated K
+
 channels, they demonstrated that the QAs 
inhibit the channel only if they are present in the cytoplasm, and that the inhibitors can gain 
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access to the central cavity only if the channel is in the open state. They observed that several 
QAs prevented channel gating, with a mechanism which was then called “foot in the door”, 
while small QAs slowed the recovery, hypothesizing that the compounds were trapped into the 
closed channel conformation. Other studies demonstrated that when the Na
+
 and K
+
 ion channels 
are inhibited they can close without affection on the deactivation rate, and that after the drug 
washout the block persists. These results indicate that the drug can be trapped into ion channels 
in the closed state. Consistently with the trapping hypothesis, Carmeliet showed that the recovery 
from the almokalant block is negligible at -75 mV, when the channels are closed, and slow at -50  
mV, when the channels can open, even if the drug is not present in the bathing medium.[124] 
These results indicate that the opening of the activation gate is necessary for the drug-ion 
channel dissociation. The confirmation of the drug trapping hypothesis’s correctness came from 
Mitcheson et al.[3] through the mutant D540K. The hERG mutant D540K has the peculiarity to 
open at hyperpolarized potential. Hence, after the membrane hyperpolarization the mutant 
channel reopen facilitating the hERG mutant-drug dissociation and the recovery from the block. 
Noteworthy, the size of the ligand used (MK-499; 7×20 Å) indicates that the pore of the hERG 
cavity is bigger than other K
+
 channels. 
Stork et al.[10] analyzed the use-dependent block and the recovery of eight hERG blockers 
divided into two groups: group 1 (amiodarone, cisapride, droperidol and haloperidol), and group 
2 (bepridil, domperidone, E-4031 and terfenadine). The drugs of the first group show a complete 
recovery from the block in contrast to the compounds of the second group, which are trapped 
into the closed state of the hERG channel. Interestingly they found that the molecules in the 
group 1 can dissociate from the closed hERG channel conformation. A possible explanation is 
that these drugs might not allow the channel to close completely through the “foot in the door” 
mechanism. They found that the drug trapping phenomenon was not correlated with the 
lipophilicity, volume, accessible surface area and molecular size of the ligands. 
In summary, the drug trapping phenomenon is characterized by ultra-slow recovery/lack of 
recovery from the block, as demonstrated also by other groups such as Kikuchi et al.[125] and 
Kamiya et al.[8] 
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2.1 The trapping phenomenon in the propafenone and derivatives 
As other hERG blockers, propafenone has to cross the cellular membrane and to be present in the 
cytoplasm to inhibit the hERG channel.[16] Witchel et al.[11] investigated the molecular 
determinants involved in the hERG inhibition and in the drug trapping phenomenon. In contrast 
to the results obtained by Arias et al.,[13] which suggest that  propafenone blocks the open and 
inactive conformations of the hERG channel, they demonstrated that it binds to the hERG 
channel in the open state and that the inactivation is not mandatory for the channel block. As 
already found by Carmeliet et al.,[124] they demonstrated that  propafenone can exit from the 
central cavity only if the hERG channel is in the open state. Alanine scanning showed that only 
Phe656 is important in the propafenone inhibition, while it was weakly or not affected by 
mutations of Thr623, Ser624, Val625, Gly648, Tyr652 and Val659. Mutagenesis data 
highlighted also that in the drug trapping only the amino acid Phe656 has a small influence. The 
four Phe656, which form an aromatic ring at the cytoplasmic side of the channel, have different 
accessibility when the channel is in the open or closed state. In the open hERG conformation the 
opening of the activation gate improves the distances between the four amino acids above-
mentioned, making possible their interactions with the compounds, while in the closed state this 
space is too narrow, the molecules cannot interact with them and the trapped compounds cannot 
dissociate from the channel. The docking poses of propafenone docked into an open hERG 
model show multiple π-stacking interactions between the ligand and Phe656 of adjacent or 
opposite subunits. In contrast to the results obtained with the hERG model in the open state, in 
the closed conformation the low energy poses cannot completely rationalize the mutagenesis 
data, suggesting that the interactions between the molecule and the hERG channel are stronger 
when it is in the open state rather than in the closed one. The authors suggest also that in the 
closed hERG channel conformation the distance between the Cα of Phe656 of opposite subunits 
might be bigger than the 10 Å suggested by their model. They also observed a direct influence 
on the propafenone binding from the electric field, forcing the molecule to dissociate from the 
central cavity when the membrane is hyperpolarized and the channel is in the open state. 
In recent studies Thai et al.[102] and Windisch et al.[126] investigated the drug trapping 
phenomenon through the voltage clamp and docking techniques applied on a series of 
propafenone derivatives, characterized by a common scaffold and different substituents attached 
to the protonated nitrogen. In agreement with previous studies,[11] Thai et al.[102] observed that 
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from the closed and open state of the hERG channel there is a small movement of the amino 
acids at the base of the selectivity filter, while the amino acids located in the inner cavity show a 
significant movement during the channel gating, indicating that this portion is responsible of the 
channel closure. The volume of the channel pore decrease from 1642.2 Å
3
 (open state) to 1048.2 
Å
3
 (closed state), with a reduction of more than 30%. Their data demonstrate that the non-
trapped compounds can dissociate from the hERG channel in the closed state with the “foot in 
the door” mechanism. The docking studies performed into the homology models of hERG 
channel in the open and closed state, show that propafenone forms hydrogen bonds with Thr623 
and with two Ser624 of adjacent subunits, and π-stacking interaction with Phe656.[102] During 
the channel gating the protonated nitrogen moves up into the central cavity where it makes 
hydrogen bonds with Thr623 and two Ser624, the hydroxyl group of the ligand conserves the 
hydrogen bond with the amino acid Thr623, and the phenyl ring forms π-stacking interaction 
with Tyr652. These poses suggest that during the channel closure the charged nitrogen of trapped 
compounds moves upward into the central cavity, probably due to the negative field in the 
channel pore. The docking poses show that the non-trapped propafenone derivatives place the 
bulky tail attached to the protonated nitrogen into the ring formed by the four Phe656 when the 
hERG channel is in the open state, with which the basic nitrogen can form π-cation interactions. 
The bulky and rigid moiety located at the center of this ring hinders the channel gating through 
the “foot in the door” mechanism. Taken together these results suggest that small and flexible 
molecules can be trapped into the closed state of hERG channel, while bulky and rigid 
compounds are forced to dissociate from the channel during the gating process. Windisch et 
al.[126] observed a correlation between the presence of a hydrogen bond acceptor in the tail 
attached to the protonated nitrogen, the pKa, the rigidity of the molecule, and the recovery from 
propafenone derivatives block, while the trapping phenomenon was not correlated with the 
molecular weight. The non-correlation between drug trapping and the molecular weight indicates 
that the size of the molecule is not sufficient to determine whether a molecule can be trapped or 
not. Their results suggest that the pKa of the compounds is an important feature in the drug 
trapping. In a few words, the trapped molecules have pKa values higher than the non-trapped 
propafenones, indicating that the protonation state of the molecule might hinder the drug 
dissociation during the channel closure. On the opposite, a bulky tail attached to the charged 
nitrogen of propafenone derivatives might hinder the channel gating. The experiments suggest 
that the molecules enter rapidly into the central cavity and block the hERG channel when it is in 
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the open conformation. The mutagenesis data indicate that Phe656 is essential in the hERG 
inhibition, while the Tyr652Ala mutant shows only a reduced sensitivity to the block mediated 
by propafenone and derivatives, as already found by Witchel et al.[11] In agreement with 
Carmeliet et al.[124] and with Witchel et al.[11] they found that the trapped compounds 
dissociate from the channel when it is in the open conformation, hence the propafenones enter 
and dissociate from the hERG channel in the open state. 
Summarizing, almost all compounds which block the hERG have to be present in the cytoplasm, 
and they inhibit the channel efficently when it is in the open or inactive conformation. During the 
channel gating many compounds dissociate through the “foot in the door” mechanism, or 
unbinding upon repolarization. Some compounds do not dissociate from it during the channel 
closure and are thus trapped into the closed channel state. The biological studies show that these 
trapped molecules can dissociate from the complex only when the channel reopens. 
2.2 How is possible to investigate in silico the trapping phenomena? 
Several techniques, such as classification methods, pharmacophore modeling, docking and 
molecular dynamics simulations can be applied to investigate the drug trapping phenomena. 
Through the classification methods it is possible to discriminate between trapped and non-
trapped compounds, and investigate the chemical-physical properties of hERG blockers, but it 
does not provide information regarding the binding modes. Also, the 3D-pharmacophore 
modeling technique can be used to investigate the trapping/non-trapping phenomena creating 
two pharmacophore models, one for the hERG channel in the closed state, and one for the open 
state. The models provide important information, such as the spatial distribution of molecular 
properties when the ligands bind the hERG channel in the open or closed conformation, but it is 
not possible, as for the classification methods, to hypothesize a possible mechanism explaining 
the drug trapping phenomenon. The docking technique can be applied to investigate the binding 
modes of trapped compounds when they interact with the hERG channel in the closed state, and 
of blockers when they bind to the channel in the open conformation, and hypothesize possible 
mechanisms to explain drug trapping phenomena and drug dissociation. Finally, molecular 
dynamics is a powerful method that can be used to investigate drug trapping phenomena. With 
this technique it is possible to determine the stability of binding modes, investigate the protein 
plasticity, simulate the drug trapping mechanism and the channel gating, identify intermediate 
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states occurring during the channel closure, and study the drug-hERG dissociation. 
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COMPUTATIONAL BACKGROUND 
The advent of computers deeply revolutionized every scientific field. The continuous increases 
of computing power allow scientists to study in detail complex systems, such as protein-ligand 
interactions, chemical reactions, etc…, and to develop complex models able to explain the 
observed phenomena. In particular, in drug discovery the computational techniques are used to 
classify compounds into active and inactive (classification techniques), to predict the activity 
(QSAR), to predict the protein structure (homology modeling), to study the ligand-protein 
interactions (docking), to study the protein dynamics (molecular dynamics), and to investigate 
the characteristics of a compound necessary to interact with the target (pharmacophore 
modeling). 
In this thesis, the docking technique was used to investigate the interactions between 
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propafenone derivatives and homology models of the hERG channel in the open and in the 
closed state. In the following chapter I will illustrate the method in more detail. 
3.1 Docking 
The docking technique is a computational method used to predict ligand-protein or protein-
protein interactions. In drug discovery, this method is used to predict the orientation of a 
molecule in the binding site of a target protein, with the aim to study the interactions, to predict 
the activity, and to investigate how we can increase or decrease the potency of the investigated 
drug. 
A ligand-protein interaction is a system with a high number of degrees of freedom, which is 
difficult to simulate without introducing approximations. To solve the problem in reasonable 
calculation time it is necessary to decrease the degrees of freedom of the system by e.g. 
specifying the binding site, fixing bond lengths and allowing rotations only around single bonds. 
Docking techniques can be classified into three classes, which treat the ligand and the protein 
with different degrees of freedom: 
1. Rigid docking: the ligand and the protein are rigid bodies and rotation around bonds is not 
allowed; 
2. Semiflexible docking: the ligand is considered as a flexible body and rotation around 
bonds is allowed, while the protein is considered as a rigid body; 
3. Flexible docking: ligand and protein are flexible. 
Of course, the calculation time and the accuracy of results increase with the number of degrees 
of freedom considered. Nowadays almost all docking programs perform a semiflexible docking. 
3.1.1 Search algorithms 
The methods used to search the conformational space of the ligand can be deterministic or 
stochastic. A deterministic method gives always the same results. A stochastic method most 
often returns different solutions due to the random factors used in this approach. 
The principal approaches are: 
1. Simulated annealing: it takes the name from a metallurgical process to increase the size 
Andrea Schiesaro Computational background 2011 
59 
    
of the crystals in which the temperature of the material is increased above the melting 
point and subsequently cooled until the crystallization temperature is reached. In this 
method, the cost function measure the internal energy of the molecule and a controlled 
parameter simulates the temperature. At every step, a Monte Carlo simulation is used to 
reach a thermal equilibrium dependent to the temperature of the system. At high 
temperatures, the energy barriers between conformations are overcome and the system 
can escape from a local minimum. As the system is cooled, only the low energy 
conformations are explored until the system is trapped in a local minimum. 
2. Tabù search: a list of tabù conformations already explored is created. The new solutions 
cannot adopt one of the conformations on the list. This force the molecule to examine 
part of the conformational space not previously explored. 
3. Incremental search: the ligand is divided into rigid fragments cutting all acyclic single 
bonds. Subsequently one or more base fragments are docked into the binding site and 
used as anchors to which the other fragments are attached. 
4. Genetic algorithms: this method mimics the process of biological evolution. At the 
beginning, a population of conformations is randomly generated and a fitness function 
calculates the ligand-protein interactions to measure the quality of possible solutions. 
Each member of the population (chromosome) encodes for a linear string of bits 
describing the properties of the conformation. Subsequently a new generation of possible 
solutions is generated. The parents of the new generation are randomly selected with a 
bias for the best individuals to ensure that the population evolves towards the best 
solution. The reproduction of the population is subjected to crossover and mutation. With 
crossover two chromosomes are cut in a random point and exchanged to create two new 
conformations. With the operator mutation one random bit is changed (i.e. 1 to 0) to 
create a new chromosome. 
5. Glide: it uses a series of hierarchical filters to find possible orientations of the ligand in 
the binding site. The shape and the properties of the binding site are represented on a grid 
precomputed upfront to perform the docking. The grid has different sets of fields that 
lead to an accurate scoring of the pose. A set of initial ligand conformations are generated 
performing an exhaustive conformational search, and the conformers generated are 
presented in a compact combinatorial form. Each cluster, which contains one 
conformation of the core and all possible conformations of the rotamer groups, is docked 
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as a single object. The search of the ligand orientation begins with an approximate 
positioning of the conformations in the binding site and a scoring phase, which reduce the 
number of poses considered in the further steps. The conformations selected are 
minimized on precomputed OPLS-AA Van der Waals and electrostatic grids. In the final 
step, the three-six lowest energy poses are subjected to a Monte Carlo simulation to 
examine the near torsional minima, and to correctly orient the peripheral groups. The 
final poses are then rescored. 
6. Triangle Matcher: an ensemble of hydrophilic and hydrophobic alpha spheres defines the 
binding site. The compound is placed in the binding site aligning triplets of ligand atoms 
with triplets of alpha spheres. 
7. Alpha PMI: the molecule is placed in the binding site aligning the principal moment of 
inertia of the conformations to alpha spheres randomly generated. 
3.2 Scoring functions 
Docking programs can generate a large amount of poses that need to be ranked to find the pose 
most similar to the crystallographic conformation. This operation is done by scoring functions, 
which attempt to estimate the binding free energy of the ligand-protein complex. The binding 
free energy is defined by the Gibbs-Helmholtz equation: 
STHG   -     3 
where ΔG is the binding free energy, ΔH is the enthalpy, T is the temperature, and ΔS is the 
entropy. The binding constant Ki can be calculated from the Gibbs-Helmholtz equation: 
KiRTG ln-     4 
where R is the gas constant. 
There are three principle types of scoring functions: 
1. Empirical scoring functions: several weighted terms are used to calculate the binding 
affinity: 
 
i
GiWiG      5 
      where ΔGi is determined by the contribution of different terms (hydrogen bonds, 
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hydrophobic interactions, entropy, Van der Waals, electrostatic, desolvation, etc…). The 
weighting terms Wi are optimized using a dataset of affinity data of ligand-protein 
complexes of known 3D-structure through a multilinear regression analysis. 
2. Force field scoring functions: are based on the non-bonded energy terms of molecular 
mechanics force field. 
3. Knowledge-based scoring functions: are based on the statistical analysis of preferred 
ligand-protein interactions. They are based on the assumption that the more often a ligand 
atom x and a protein atom y are found at a certain distance d the more favorable is the 
interaction. To the interaction between the ligand atom x and the protein atom y at the 
distance d is assigned a free energy interaction depending on the frequency of the 
interaction. The sum of all interatomic interactions is the ligand-protein interaction free 
energy. 
3.3 Compounds investigated 
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Table 2. Propafenone derivatives [a]Values are mean of at least three experiments and measured in heterologous hERG expressed 
in X. laevis oocytes.[126] 
 
 
 
 
 
 
Compound Scaffold R1 R2 R3 
IC50 
μM[a] 
Tapped 
Propafenone 
 
1 
 
*
 
 
3.79 ± 
0.24 
Yes 
GPV0005 1 
 
N*
 
*
 
 
1.34 ± 
0.04 
Yes 
GPV0009 1 N
*  
*
 
 
0.84 ± 
0.08 
Yes 
GPV0180 1 N*
 
*
 
 
1.78 ± 
0.15 
Yes 
GPV0929 2 N*
 
 O
*
 
1.27 ± 
0.05 
Yes 
GPV0031 1 NN* F
 
*
 
 
1.46 ± 
0.19 
No 
GPV0576 1 
NN*
 
*
 
 
1.84 ± 
0.24 
No 
GPV0019 1 NN*
 
*
 
 
1.42 ± 
0.18 
No 
GPV0062 1 N*
OH
 
*
 
 
1.05 ± 
0.05 
Yes 
SCT-AS03 1 N*
 
*
 
 
0.77 ± 
0.11 
Yes 
N
*
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AIM OF THE STUDY 
To predict correctly the adverse ADMET effects during the drug discovery process is a really 
important step, in which many different proteins play an important role. One of them definitely is 
the hERG potassium channel, which has been extensively studied due to its role in Torsade de 
Points, a lethal arrhythmia caused by drugs blocking the hERG channel. Although wealth of 
information has been obtained, there are still many open questions: are there other factors 
influencing the polispecificity? What is the conformation of the S5-P linker? What is the correct 
alignment of the S5? What are the molecular reasons of drug trapping? 
To investigate the drug trapping phenomenon is important to understand the molecular 
mechanisms involved in the hERG channel gating and drug-hERG complex dissociation. 
The aim of this thesis was to investigate trapping phenomenon using the docking technique. This 
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method was applied to analyze the interactions between propafenone and derivatives with the 
hERG channel in the open and the closed state, in order to explain the different trapping behavior 
of these compounds. 
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RESULTS 
5.1 Docking into the homology model of hERG channel in the closed state  
5.1.1 Material and methods 
5.1.1.1 Docking protocol 
The closed state of hERG channel homology model has been previously described by Thai et 
al.[102]  
The trapped compounds propafenone, GPV0005, GPV0009, GPV0180 and GPV0929 were 
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docked into the homology model of the hERG channel in the closed state using the Dock 
docking tool of MOE.[127] Due to the fact that it was not possible to select one of the possible 
binding modes through consensus scoring and mutagenesis data, the Glide docking tool of 
Schrödinger, LLC, New York, NY, 2008[128] was used with the aim to prioritize one of the 
selected clusters. 
MOE: to the pdb file of a homology model of the hERG channel in the closed state the hydrogen 
atoms were added and then minimized in the Amber99 force field using the MOE2007.09 tool 
Energy Minimize. During the minimization the partial charges of the model were recalculated. 
The ligands were drawn in the R configuration using the Molecule Builder tool of  
MOE2007.09,[127] and subsequently minimized, the partial charges calculated and the lone 
pairs atoms adjusted according to the default parameters with the program Energy Minimize 
using the MMFF94x force field. The nitrogen was maintained in the protonated state.[102] For 
every ligand a systematic conformational search was performed. The 100 most different 
conformations concerning the potential energy and the RMSD values were selected with Diverse 
Subset tool of MOE2007.09 and the partial charges recalculated according to the 
MMFF94(modified) force field. Subsequently, the 100 most diverse conformations were docked 
into the homology model of the hERG channel in the closed state. All atoms of the amino acids 
with an atom within 6.5 Å from a pose obtained in a previous study[102] were considered as part 
of the binding site and selected during the docking runs. For every run, only 20 poses per 
conformation were retained and minimized by the MMFF94x force field. Other parameters were 
kept as the default setting. 
Glide: The ligands were prepared in the R configuration with the Maestro tool LigPrep, version 
2.2, Schrödinger, LLC, New York, NY, 2005.[128] The nitrogen was maintained in the 
protonated state. The protein was prepared with the Protein Preparation Wizard included in 
Maestro, version 8.5, Schrödinger, LLC, New York, NY, 2008. Glide version 5.0, Schrödinger, 
LLC, New York, NY, 2008 was used to dock the compounds. We chose to carry out 100 poses 
for each ligand. Other parameters were kept as the default setting. The binding site was defined 
by the amino acids Ser624, Ser649, Tyr652 and Phe656 of each subunit. 
A second docking run using Glide was performed to investigate the distributions of similar poses 
in the four possible directions that they can have in the central cavity. With the aim to limit the 
number of duplicate poses deleted by the docking program, the compounds were docked using 
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the value of RMSD of 0.5 Å and the maximum atomic displacement lower than 0.001 Å. 
5.1.1.2 The symmetry problem in the hERG channel 
The hERG channel has homotetrameric architecture. The four monomers contain six 
transmembrane domains (S1-S6). Generally only the S5-P-S6 segment of one subunit is modeled 
while the other three subunits are just copies,[129] hence only the parts that define the binding 
site, the selectivity filter, the central cavity and the inner pore, are included in the model. This 
operation leads to a perfect symmetry, so when a docking is run in a symmetric binding site, it is 
possible to have the same pose in four different directions. The docking programs cannot detect 
these poses as duplicates, because, due to the placement with different directions, they have a 
high RMSD values even if they have the same interactions pattern. Hence, poses that would be 
detected as duplicates whether they have the same directions are classified as non-duplicates due 
to their different orientation. Thus we had to develop a method which takes this into account and 
harmonises equivalent poses. 
The symmetry problem can be faced in two ways. The first possible solution, as proposed by 
Farid et al.,[99] consists on a rigid body rotation of the complexes around to the identified 
symmetry axis. It is possible to apply this strategy also in non symmetric hERG channels, for 
example after molecular dynamics simulations, once the rotational axis is identified. We 
developed a new method in which only the ligand is rotated and the coordinates of the channel 
are kept fixed. This method can be used only if the protein, in this case the hERG channel, is 
symmetric. Our approach is computationally less expensive than the firs method mentioned, 
because in our case only the ligand is rotated and not the entire complex. These operations are 
useful to facilitate the visual inspection of the pose and the identification of possible binding 
modes. 
5.1.1.3 Alignment 
When a docking study is performed in symmetrical binding sites, such as in the hERG channel, 
the alignment of the poses facilitates the visual comparison of the conformations and, through 
the generation of an RMSD matrix and the agglomerative hierarchical clustering, makes it 
possible to identify possible binding modes without considering the original direction of the 
poses. In this subchapter, I will explain how the symmetry problem can be faced. 
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In order to align the poses it is necessary to define a rotational axis in the center of the channel, 
and a reference pose to which the other poses can be compared. For this purpose, it is needed to 
define four amino acids, one per subunit, on the top of the hERG channel, and four on the 
bottom. The centers on the top and on the bottom of the hERG channel are defined as the points 
that lie in the middle distance between the Cα of an amino acid of two opposite subunits. The 
rotational axis is the line that links these two points. The rotational angle used to rotate the ligand 
inside the binding site, in order not to change the distances and the interactions between the 
A B 
C D 
Fig. 5 Pose alignment. The green carbon colored is the reference pose. (A) a second pose is loaded in the original orientation and 
the RMSD0° calculated; (B) the pose is rotated of 90° and the RMSD90° is calculated; (C) the pose is rotated again of 90° and 
the RMSD180° is calculated; (D) the pose is rotated for the for the last time and the RMSD270° is calculated. 
A B 
C D 
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compound and the amino acids, must be 90°. The reference pose to which all the other 
conformations are compared and aligned is the first one of the database. The second pose is 
loaded in the channel and the RMSD0° is calculated using the first pose as reference. 
Subsequently the second pose is rotated three times and for each rotation the RMSD value is 
calculated (RMSD90°, RMSD180° and RMSD270°) (fig. 5). The “rotational pose”, which 
corresponds to the lowest value of RMSD, is the one that is aligned or “adjusted” with the 
reference pose. To perform the alignment was written an svl script (MOE) called ROTALI. 
5.1.1.4 RMSD matrix calculation 
The ROTALI svl script was used also to generate the RMSD matrices used to delete and to 
identify the binding modes. As for the pose alignment, the ROTALI script compares the 
reference pose with all the others in the database. The first reference pose is the first one of the 
database. The value of RMSD0° of the second pose is calculated, then the pose is rotated three 
times and for every rotation the value of RMSD (RMSD90°, RMSD180° and RMSD270°) of the 
“rotated pose” is calculated. The lowest value of RMSD is written in a RMSD matrix, because it 
corresponds to the value of the “rotational pose” that is aligned or at least is “adjusted” with the 
reference pose. When all the poses are compared to the first one, the reference pose changes to 
the second one and all the operations are repeated again. The program ends when all the poses of 
the database are taken as reference. 
5.1.1.5 Duplicate poses deletion 
Through the RMSD matrix it is possible to detect and delete the duplicate poses. 
MOE defines two poses as duplicates if they have the same hydrogen bond and hydrophobic 
interaction pattern. 
Glide defines duplicate poses as the poses with an RMSD value lower than 0.5 Å and a 
maximum atomic displacement lower than 1.3 Å. 
In order to use a definition of duplicate poses similar to the one of MOE applicable to the RMSD 
matrix, they were defined as the poses with an RMSD value lower than 0.1 Å. The poses 
obtained from the Glide docking program were deleted using their definition of duplicate poses. 
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5.1.1.6 Identification of the common binding modes 
The poses obtained with the MOE docking program were analyzed in two manners and the 
results were then compared with the results obtained with Glide. For the poses generated with 
MOE, we decided to analyze those within 10 kcal from the pose with the best London dG 
scoring function value (personal communication from Dr. Wolfram Altenhofen, Chemical 
Computing Group), from now it will be called database of poses A. With the aim to see if some 
common binding modes are lost considering only the poses within the 10 kcal from the best 
ranked pose according to the London dG scoring function, a second analysis was performed 
using a number of poses slightly higher than the maximum number of poses within the 10 kcal 
(195 in the compound propafenone). In order not to be too far from the ideal selection of poses 
suggested by Dr. Wolfram Altenhofen, we decided to consider only fiftheen more poses than the 
maximum number previously mentioned. If some possible binding modes are missed considering 
only the poses within 10 kcal, this would be immediately clear even considering only a few more 
poses in the analysis. Hence, for every ligand the first 210 poses ranked according to the London 
dG scoring function (from now database of poses B) were selected. All molecules docked are 
charcterized by a common scaffold (fig. 7). The common scaffold was extracted using the 
function abstract_commonscaffold of the previously loaded script FORMELPOOL.SVL, in 
which the string of the scaffold was specified. All the ligands docked are characterized by the 
presence of two aromatic rings connected by a ketone linker, and by a protonated nitrogen linked 
to one of the two phenyl rings by an ether linker with a hydroxyl group in position 3 (fig. 7). The 
rationale for using the common scaffold to analyze the poses, is due to the fact that it is 
reasonable to assume that compounds with the same scaffold have a common binding mode in 
the binding site. In both analyses, the non-duplicate poses were merged in a database and an 
RMSD matrix calculation based on the common scaffold (fig. 7) was performed using the 
ROTALI svl script. A hierarchical clustering of the RMSD matrix, using the Ward´s 
agglomerative method, was performed with the XLSTAT[130] added in MS Excel. The Ward´s 
method uses the variance to measure the distance between two objects. At the beginning the 
Ward´s method considers each object (in this case the poses) as single cluster. In each step the 
two clusters whose merging increases least the intracluster variance are merged. The 
agglomerative cluster analysis was performed until all the poses of the clusters were within a 
RMSD value of 2.5 Å from the centroid to obtain a good intracluster homogeneity. 
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With the aim to indentify the most energetically favourable clusters, we performed a consensus 
scoring on the two databases of MOE using the scoring functions ASE, Affinity dG, Alpha HB 
and London dG developed in MOE. The analysis of the ligand interactions with the hERG 
channel in the closed state was performed using the centroid of those clusters containing all the 
ligands and whose poses where ranked within the first 10 positions in at least three scoring 
functions out of four. The clusters were also validated using the mutagenesis data. Witchel et 
al.[11] demonstrated that only the Phe656 have a small influence on the trapping of propafenone, 
while mutation of the other residues in the central cavity did not show any influence on the 
recovery from block. The fact that the influence of Phe656 on drug trapping is small might 
indicate that the interaction between the channel in the closed state and the molecule is weak. 
5.1.1.7 Analysis of ligand interactions 
The interactions between the ligands and the hERG channel were analyzed with the 
MOE2007.09 software package. 
5.1.2 Results 
5.1.2.1 Alignment and deletion of duplicate poses 
In the hERG channel, each side of the binding site is identical to both adjacent sides, and this 
renders it difficult to analyze the poses generated. This problem can be solved if we fix 5 points, 
one in the center of the channel and one in every subunit, so we can define four directions from 
the center. With the purpose to define the direction of the pose, we can select a point in the 
ligand, and the direction of the line that links the point in the center of the channel with the point 
on the molecule can be assumed as the direction of the pose. In this work, the point selected in 
the ligand is the charged nitrogen. 
The docking programs produce for every ligand several poses which are spread in all four 
directions (fig. 6 A and B). In another docking study in the hERG channel, in order to facilitate 
the visualization of the complex, the poses were aligned by a rigid body rotation of the ligand-
hERG channel complex.[99] In ROTALI the coordinates of the hERG channel are fixed and the 
alignment is performed through the rotation of the poses and the comparison with a reference 
pose. The result of our script is that the poses that are similar to the reference pose are aligned 
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with it (fig. 6C), while the poses that are not similar to the reference one are “adjusted” with it 
(fig. 6D). It means that the poses aligned have the same direction of the reference one, while the 
poses adjusted can have also different directions. 
The fourfold symmetry of the hERG channel allows the placement of the same pose in every 
side of the channel (fig. 6 A and B). If we consider this in terms of duplicate poses, it would 
mean that almost 75% of them could be duplicates. This can happen only if there is a 
homogeneous distribution of the poses in the four directions of the hERG channel, and almost all 
the poses should have more than one similar pose. In order to investigate the similar poses, their 
distribution in the hERG channel was analyzed. The similar poses were defined as the poses that 
have a value in the RMSD matrix lower than 0.5 Å. 
In MOE (table 3) similar poses almost never lay in all four directions. Indeed the highest number 
of similar poses with four directions is obtained for compound GPV0180, and they are only 10% 
of the total number of conformations. For propafenone 53% of the total number of poses is 
Fig. 6 (A) Docking results of propafenone docked with MOE Dock program; (B) 10 poses of the compound propafenone before 
the alignment; (C) 10 poses aligned with the reference pose (green); (D) poses adjusted with the reference pose. 
A B 
C D 
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Table 3. Distribution of similar poses in MOE in the first 100 poses selected according to the scoring function. Dir.= number of 
directions in which the similar poses can be founded; N. poses = number of poses; % of poses = percentage of poses regard to the 
total number of the poses in the database. 
Table 4. Distribution of similar poses in Glide. Dir. = number of directions in which the similar poses can be founded; N. poses = 
number of poses; % of poses= percentage of poses regard to the total number of the poses in the database; N.D = no docking pose 
obtained. 
similar and 52 of them are present in two or three directions, while for other compounds this 
percentage varies between 27% for GPV0180 and 43% for GPV0929 and GPV0005. In the case 
of GPV0005 57% of the poses have one or more similar poses and only 7 of them lie in all four 
directions. 
The compounds were docked also with Gide. The poses were considered duplicates if the RMSD 
value was lower than 0.5 Å and the maximum atomic displacement was lower than 0.001 Å. The 
results (table 4) show that only for propafenone similar poses lie in the four directions and it 
happens only two times, while in the GPV0180 they are at most in three directions, and in the 
compounds GPV0005 and GPV0009 they have only one or two directions. Also in the poses 
from the Glide docking program, as in MOE, the majority of the similar poses have two or three
 Propafenone GPV0005 GPV0009 GPV0180 GPV0929 
Dir. N. poses % of poses N. poses % of poses N. poses % of poses N. poses % of poses N. poses % of poses 
1 1 1.00% 7 7.00% 2 2.00% 3 3.00% 1 1.00% 
2 24 24.00% 27 27.00% 25 25.00% 18 18.00% 30 30.00% 
3 28 28.00% 16 16.00% 3 3.00% 9 9.00% 13 13.00% 
4 0 0.00% 7 7.00% 0 0.00% 10 10.00% 8 8.00% 
Total 53 53.00% 57 57.00% 30 30.00% 40 40.00% 52 52.00% 
 Propafenone GPV0005 GPV0009 GPV0180 GPV0929 
Dir. N. poses % of poses N. poses % of poses N. poses % of poses N. poses % of poses N. poses % of poses 
1 3 3.03% 0 0.00% 1 12.50% 0 0.00% N.D N.D 
2 25 25.25% 11 39.29% 2 25.00% 3 17.65% N.D N.D 
3 14 14.14% 0 0.00% 0 0.00% 3 17.65% N.D N.D 
4 2 2.02% 0 0.00% 0 0.00% 0 0.00% N.D N.D 
Total 44 44.44% 11 39.29% 3 37.50% 6 35.29% N.D N.D 
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Table 5. Number of similar poses in MOE in the first 100 poses selected according to the scoring function. N. poses = Number of 
similar poses; N. simil.= Number of poses similar to the reference pose; % of poses = percentage of N. simil poses regard to the 
total number of the poses in the database. 
Table 6. Number of similar poses in Glide. N. poses = Number of similar poses; N.simil.= Number of poses similar to the 
reference pose; % of poses = percentage of N.simil poses regard to the total number of the poses in the database; N.D = no 
docking pose obtained. 
directions. 
The number of similar poses for every pose was investigated with the intent to understand the 
reason why so few of them lie in all four directions (table 5 and table 6). Finding a pose in all 
four directions can happen only if the pose has three or more similar poses. In MOE the 
percentage of poses which have at least 3 similar conformations varies between 0% for 
GPV0009 and 12% for GPV0005. In Glide this percentage varies between 0% for GPV0005 and 
GPV0009, and 11.76% for GPV0180. These low percentages explain the low number of similar 
poses in all four directions. 
These results might indicate that both docking programs do not explore efficiently the 
conformational space of the ligands in all four directions of the symmetric binding site, 
otherwise the number of conformations with 3 or more similar poses and the number of similar 
 Propafenone GPV0005 GPV0009 GPV0180 GPV0929 
N. poses N. simil. % of poses N. simil. % of poses N. simil. % of poses N. simil. % of poses N. simil. % of poses 
1 pose 24 24.00% 30 30.00% 20 20.00% 18 18.00% 27 27.00% 
2 poses 20 20.00% 15 15.00% 10 10.00% 12 12.00% 16 16.00% 
3 poses 4 4.00% 12 12.00% 0 0.00% 0 0.00% 5 5.00% 
4 poses 3 3.00% 0 0.00% 0 0.00% 0 0.00% 4 4.00% 
 > 4 poses 2 2.00% 0 0.00% 0 0.00% 10 10.0% 0 0.00% 
  Propafenone GPV0005 GPV0009 GPV0180 GPV0929 
N. poses N. simil. % of poses N. simil. % of poses N. simil. % of poses N. simil. % of poses N. simil. 
% of 
poses 
1 pose 29 29.29% 8 28.57% 2 25.00% 2 11.76% N.D N.D 
2 poses 5 5.05% 3 10.71% 1 12.50% 2 11.76% N.D N.D 
3 poses 5 5.05% 0 0.00% 0 0.00% 2 11.76% N.D N.D 
4 poses 3 3.03% 0 0.00% 0 0.00% 0 0.00% N.D N.D 
> 4 poses 2 2.02% 0 0.00% 0 0.00% 0 0.00% N.D N.D 
Andrea Schiesaro Results 2011 
75 
    
Table 7. Deletion of the poses from MOE docking in the first 100 poses selected according to the London dg scoring function. 
Table 8. Deletion of the poses from Glide docking. 
poses with 3 and 4 directions would be higher. However, the fact that we were able to identify 
similar poses with different directions means that the ROTALI svl script works, and that it is a 
useful tool to facilitate visual inspection of the poses. 
As mentioned before MOE defines the duplicate poses based on the hydrophobic and hydrogen 
bonds interaction pattern. It means that the RMSD value for the duplicate poses has to be low; 
hence we decided to consider as duplicates the poses that have a value of RMSD lower than 0.1 
Å. The highest number of duplicate poses deleted is obtained with the ligand GPV0005, where 
23 poses out of 100 were duplicates. Table 7 clearly shows that the method to recognise the 
duplicate poses based on the interaction pattern fails in the symmetric binding site of hERG if 
the duplicates poses have different directions, because we detected a percentage of duplicates 
between 12-23%. On the other hand these percentages show that our approach to detect the 
duplicate poses works even if they are not originally aligned. 
We docked the trapped compounds with Glide using the default parameter, in order to 
investigate the ability of the program to detect duplicates poses in the hERG binding site and to 
identify possible binding modes. We were not able to dock the compound GPV0929. Also the 
Ligand Poses start Poses end Poses deleted % deletion 
Propafenone 100 79 21 21% 
GPV0005 100 77 23 23% 
GPV0009 100 88 12 12% 
GPV0180 100 84 16 16% 
GPV0929 100 78 22 22% 
Ligand Poses start Poses end Poses deleted % deletion 
Propafenone 99 81 18 18.18% 
GPV0005 27 22 5 18.52% 
GPV0009 8 8 0 0% 
GPV0180 16 14 2 12.5% 
GPV0929 No poses No poses No poses No poses 
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protocol of Glide to detect duplicate poses based on the RMSD value and the maximum atomic 
displacement fails, as demonstrated by the detection of duplicates with our approach. This was 
foreseeable, because the poses that have different directions have a high value of RMSD, even if 
they are duplicates after the alignment (table 8). 
Table 7 and table 8 clearly show that the inability to recognise duplicates in a symmetric binding 
site is independent on the method, while they demonstrate that the alignment of the poses 
performed through the ROTALI svl script and our approach to detect duplicate poses work for 
both docking programs even if the poses have different directions. 
5.1.2.2 Pose analysis 
The binding site of the hERG channel blockers is placed in the inner cavity.[6, 9, 12, 22, 131] At 
the base of the hERG channel there are two concentric rings formed by the symmetric 
arrangement of the four Phe656 and the four Tyr652. The ring composed by the four Phe656 is 
located at the cytoplasmatic side of the channel. The second ring is formed by four Tyr652. 
Phe656 and Tyr652 are facing the inner cavity, but they have different orientations. Furthermore, 
Phe656 and Tyr652 are perpendicular to the channel axis, but in the case of Tyr652 they are 
slightly bent outwards. The distance between the Cα of Phe656 of opposite subunits in the closed 
channel is 9.4 Å and this spatial constriction of the ring of the four Phe656 leads to the 
impossibility for the ligand to interact through π-stacking interactions with the Phe656, which is 
important to block the channel when it is in the open state.[11] The hERG blockers bind the 
hERG channel in the open conformation from the intracellular side. In the open state the volume 
of the binding site of the hERG channel is 1642.2 Å
3
.[102] In the closed conformation the 
volume of the binding site is reduced more than 30% to 1048.2 Å
3
, and it implies that only small 
and flexible compounds can be trapped in the closed state.[102] 
The compounds propafenone, GPV0005, GPV0009 and GPV0180 were docked into the closed 
state homology model of the hERG channel. The compound GPV0929 was not analyzed, 
because the different scaffold and the visual inspection of the first ranked poses suggest that it 
might have a different binding mode respect to the four ligands above cited, and because it was 
not possible to dock it in Glide. Due to the distribution of the poses in all four directions, the 
symmetry operation with ROTALI was applied to delete the duplicate poses. The RMSD matrix 
obtained from the ROTALI script, calculated based on the common scaffold of the non-duplicate 
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poses (fig. 7), was used to identify the common binding modes through 
agglomerative hierarchical cluster analysis. In the cluster analysis of 
the RMSD matrix of the database of poses A, 33 clusters were 
obtained with a cut off of the RMSD value of 2.5 Å from the centroid. 
In six of these clusters at least one pose of all the ligands was present. 
In the agglomerative cluster analysis of the RMSD matrix of the 
database of poses B, the clusters containing all the trapped ligands 
were 11 (out of a total number of 45). A further selection of the 
clusters was performed based on consensus scoring, in which the 
scoring functions ASE, Affinity dG, Alpha HB and London dG of MOE were used. Considering 
the consensus scoring for the database of poses A and B, it was possible to select 4 clusters in 
both cases. The interaction analysis of the centroids shows that some poses with a similar 
interaction pattern have the scaffold oriented with opposite directions (fig. 8 A, C and D). If the 
orientation of the scaffold is considered, we can distinguish four different binding modes, which 
can be reduced to two considering the interaction pattern. 
In the first binding mode (fig. 9) the two phenyl rings forms parallel-displaced π-π and/or T-
stacking interactions with Tyr652 of opposite subunits, and hydrophobic interactions with 
Phe656. The hydroxyl group and the charged nitrogen don´t interact with the hERG channel. The 
substituent R1 is placed near the the Tyr652 with which it forms hydrophobic interactions. 
In the second binding mode (fig. 10) the two phenyl rings of the ligand interact with two Tyr652 
of adjacent subunits through parallel-displaced π-π and/or T-stacking interactions, and with 
Phe656 through hydrophobic interactions. The hydroxyl group and the charged nitrogen don´t 
interact with the amino acids in the central cavity of the channel. As found in the first binding 
mode, the substituent R1 makes hydrophobic interactions with Tyr652. 
The alanine scanning performed by Witchel et al.[11] shows that only Phe656 has a small 
influence on the propafenone recovery, while Ser624, Val625 and Tyr652 don´t have any effect 
in that way. This suggests that propafenone interacts weakly with the Phe656, making T-
stacking, parallel-displaced π-π, or hydrophobic interactions when the hERG channel is in the 
closed conformation. In agreement with these results, our poses cannot make π-stacking 
interaction with Phe656, due to the spatial size reduction of the ring of the four Phe656. 
The compounds were also docked with Glide. Of 13 clusters obtained with the agglomerative 
O
OH
N
O
Fig. 7 Common scaffold used 
to calculate the RMSD matrix. 
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hierarchical cluster analysis of the RMSD matrix, only 1 cluster contains poses of all trapped 
ligands. As shown in fig. 9D, the phenyl rings and the charged nitrogen of the first binding mode 
obtained in MOE and the centroid of Glide are placed in the same positions, while the position of 
the hydroxyl group is slightly different and in the centroid of Glide forms a hydrogen-bond with 
the Ser624 (fig. 11). The fact that similar poses were found with MOE and with Glide might 
indicate that this binding mode could be the most reasonable to describe the interactions of 
trapped ligands with the hERG channel in the closed state. 
As found by Witchel et al.[11] and Thai et al.[102] in the closed state conformation of hERG 
channel the molecules docked interact also with the amino acid Tyr652 and not exclusively with 
Phe656. In agreement with the mutagenesis data, the selected poses do not form strong 
interactions with Phe656. 
Fig. 8 Centroids of the four selected clusters. (A) Centroids of database of poses A. The centroid green colored and the yellow 
colored have the phenyl groups and the charged nitrogen placed in the same position, while in the centroid element colored the 
position of the two phenyl rings is inverted and the charged nitrogen is in the same position of the first two centroids. (B) The 
centroid of the database of poses A (green colored) is superposed with the centroid of database of poses B. (C) Centroids of the 
database of poses B with the scaffold inverted. (D) Superposition of two selected centroids of the database of poses B (pink 
colored and element colored) with a centroid of the database of poses A (azure colored). The pink colored centroid has the 
direction of the scaffold inverted with respect to the other two centroids. Only the scaffolds of the centroids are visualized. 
A B 
C D 
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In the first binding mode (fig. 9) the two phenyl groups of the scaffold are placed near the 
Tyr652 of opposite subunits with which they can interact through parallel-displaced π-π and/or 
T-stacking interactions. The hydroxyl groups are placed between Ser624 of the adjacent subunits 
and the charged nitrogens lie between two Ser624 of adjacent subunits. 
In the second binding mode (fig. 10) the two phenyl rings interact with Tyr652 of adjacent 
subunits through parallel-displaced π-π and/or T-stacking interactions. In two of the three poses 
of the second binding mode, the hydroxyl groups are downward and placed under the Ser624, 
while in the third pose the hydroxyl group is upward and placed near the hydroxyl group of the 
Fig. 9 First binding mode. Top view (A); lateral view (B); interaction pattern of the first binding mode (C); (D) superposition of 
the centroid of the validated clusters of database of poses A (green), database of poses B (yellow), and Glide (dark violet). Only 
the amino acids Thr623 (violet), Ser624 (orange), Tyr652 (cyan) and Phe656 (brown) of the four subunits are visualized.  The 
yellow arrows indicates the two Tyr652 interacting with the trapped compounds through parrallel π-π displaced and/or T-stacking 
interactions. 
A B 
C 
D 
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previously published pose.[102] In both binding modes, the charged nitrogens are grouped under 
the Ser624, as found by Thai et al.[102] 
In the pose published by our group[102] the phenyl ring of propafenone is positioned in an 
optimal position to make π-stacking interaction with Tyr652, the hydroxyl group is placed under 
Thr623 with which it forms a hydrogen bond and the charged nitrogen, located close to the 
position of the first binding mode, makes hydrogen bonds with Thr623 and Ser624. In contrast to 
this result, in the poses obtained in this study the two aromatic rings of the selected binding 
Fig. 10 Second binding mode. (A)Top view, (B) lateral view, and (C) interaction pattern of the second binding mode. (D) 
Superposition of the centroid of the validated clusters of database of poses A (green), and database of poses B (yellow). Only the 
amino acids Thr623 (violet), Ser624 (orange), Tyr652 (cyan) and Phe656 (brown) of the four subunits are visualized. The yellow 
arrows indicate the Tyr652 of adjacent subunits interacting with the trapped compounds through parallel-displaced π-π and/or T-
stacking interactions. 
A B 
C 
D 
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Fig. 11 Glide result. (A) Propafenone binding mode docked with Glide. (B) Propafenone interaction pattern. Only the amino 
acids Thr623 (violet), Ser624 (orange), Ser649 (dark cyan), Tyr652 (cyan) and Phe656 (brown) are represented. 
A 
B 
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modes form parallel-displaced π-π and/or T-stacking interactions with Tyr652 of opposite or 
adjacent subunits, while the protonated nitrogen doesn’t make any hydrogen bond interaction. In 
addition, Glide suggests a possible hydrogen bond in the first binding mode between the 
hydroxyl group and Ser624. 
As indicated in our previous work,[102] the size of the substituent attached to the charged 
nitrogen might be the first hint to discriminate between trapped/non-trapped compounds. A 
recent study[126] shows that the rigidy of the substituent R1 (table 2), the pKa of the basic 
nitrogen and the presence of a hydrogen bond acceptor in the substituent attached to it might 
play a role in the drug trapping. In this study, the poses show that the charged nitrogen is placed 
near the Ty652 and Ser649, in a zone where it is not possible to place a large and rigid 
substituent due to the lack of space between the two amino acids above-cited (fig. 12), and 
between the two amino acids and the protonated nitrogen. A bulky and rigid substituent attached 
to the charged nitrogen would push back the entire molecule, forcing it to assume an 
unfavourable high-energy conformation, while the hydrogen bond acceptor might form a 
hydrogen bond with the hERG during the channel closure, hindering the gating mechanism and 
forcing the dissociation. Small and flexible substituents can bend in the small space between the 
basic nitrogen and the amino acids Ser649 and Tyr652, without destabilizing the conformation of 
trapped propafenones in the closed hERG channel. The drug trapping phenomena is a multistep 
mechanism that starts in the open state and finish in the closed state, in which many intermediate 
Fig. 12 First and second binding modes. Top view (A) and lateral view (B) of the first (green) and the second (yellow) binding 
mode. Only the amino acids Thr623 (violet), Ser624 (orange), Ser649 (dark cyan), Tyr652 (cyan) and Phe656 (brown) are 
reppresented. Due to the lack of space between the amino acids Ser649 and Tyr652, and between them and the protonated 
nitrogen, it is not possible for a trapped compound to have a bulky and rigid substituent attached to the basic nitrogen. 
A B 
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conformations of the channel might play an important role. Probably the dissociation of non-
trapped compounds occurs in one of the intermediate conformations that might be formed during 
the hERG closure.  
5.1.3 Conclusions 
A series of trapped propafenone derivatives with a different size of the substituent attached to the 
charged nitrogen were docked into a homology model of the hERG channel in the closed state. 
The fourfold symmetry of the hERG channel renders it possible to find similar poses with four 
different directions, hence it is also possible to find duplicate poses with four different directions. 
In a symmetric protein like the hERG channel it is thus necessary to align and delete the 
duplicates that have originally different directions. This can be done easily through the RMSD 
matrix calculated with the svl script ROTALI. Through cluster analysis of the RMSD matrix 
based on the common scaffold, consensus scoring and mutagenesis data evaluation two possible 
binding modes were selected, which might explain the trapping/non trapping behaviour. One of 
these two possible binding modes was also found with Glide and it might indicate that this pose 
could better explain the trapping behaviour. Interestingly, in both binding hypothesis the R1 
group is located in a zone were it is not possible to place bulky and rigid substituents. 
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5.2 Docking studies into a homology model of the hERG channel in the open 
state 
5.2.1 Material and methods 
5.2.1.1 Docking protocol 
The homology model of the hERG channel in the open state was obtained using the crystal 
structure of KvAP as previously described by Tseng et al.[96] The hydrogen atoms were added 
to the pdb file kindly provided by Prof. Dr. R. H. Guy and minimized using the Amber99 force 
field with the MOE2008.10 tool Energy Minimize. The partial charges of the amino acids were 
recalculated during the minimization. The molecules propafenone, GPV0005, GPV0009, 
GPV0031, GPV0180 and GPV0576 were built and the most 100 diverse conformations were 
selected as described in the subchapter 5.1.1.1 using the programs implemented in MOE2008.10. 
The aniline nitrogen of the compounds GPV0031 and GPV0576 was assigned as sp
2
 
hybridization state. In the systematic search, for the compound GPV0576, due to the huge 
number of conformations generated using the default conditions (10.480.616 conformations) 
which made the size of the database too big to calculate E and RMSD, the step of the phenyl-
carbonyl carbon bond rotation was modified to 180 in order to reduce the number of 
conformations generated. The MOE2008.10 docking tool Dock was used to dock the 100 most 
diverse conformations into the hERG channel in the open state, retaining 20 poses per run. The 
binding site was defined by the atoms of the amino acids Ser624, Ser649, Tyr652 and Phe656 of 
each subunit. We decided to use the Alpha PMI placement method and the minimization of the 
poses according to the MMFF94x force field to obtain a better performance of the docking 
program (personal communication from Dr. Wolfram Altenhofen, Chemical Computing Group). 
All the other parameters were left in their default values. In contrast to the protocol applied in the 
closed state, the Glide docking program was not used due to the fact that MOE showed a better 
performance to explore the conformational space of the trapped compounds in all 4 directions of 
the central cavity, and that the pose obtained with Glide was similar to the first binding mode 
hypothesized with MOE, indicating that Glide finds the same pose of MOE, and that with the 
latter more possible binding modes are taken into account. Moreover, it was possible to prioritize 
one of the 3 possible binding modes through consensus scoring and mutagenesis data. 
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5.2.1.2 Alignment 
The methodology used to align the poses has been described in detail in subchapters 5.1.1.2 and 
5.1.1.3. 
5.2.1.3 RMSD matrix calculation and duplicate poses deletion 
These processes are described in the subchapters 5.1.1.3, 5.1.1.4 and 5.1.1.5. 
5.2.1.4 Identification of the common binding modes 
For each docked ligand were selected the first 210 poses ranked according to the London dG 
scoring function. It was not possible to use the poses within 10 kcal due to the fact that only a 
maximum of 8 poses per ligand were considered and it was not possible to select a common 
binding mode through the agglomerative hierarchical clustering. Moreover, the docking study in 
the closed state channel demonstrates that we achieve the same results using the poses within the 
10 kcal from the best pose or the first 210 poses ranked according to the London dG scoring 
function, and that with Glide one of the possible binding modes selected with MOE is 
reproduced. 
A RMSD matrix based on the common scaffold was generated using the non-duplicate poses 
(see the subchapter 5.1.1.6). The MS Excel Add-In XLSTAT[130] was used for hierarchical 
clustering of the RMSD matrix above-mentioned using the Single Linkage method. Bottegoni et 
al.[132] demonstrated that the Single Linkage rule is more aggregative than the Ward’s method, 
hence the number of clusters obtained in the first case is lower. The use of the Single Linkage 
instead of the Ward’s method, used to analyze the poses of trapped propafenones docked into the 
closed conformation of the hERG channel, comes from the idea that a lower number of clusters 
facilitates the analysis of the docking poses, and that similar poses are less dispersed in different 
clusters. In the Single Linkage clustering method the similarity between two clusters is 
determined by the distance between the two closest pair of objects belonging to the two clusters 
considered. In the first step, all objects are considered as a single cluster. At each step, the 
distance between the clusters is computed. To calculate the distances between the clusters all 
objects of all clusters are considered. The distance between two clusters is the shortest distance 
from any object of one cluster with any object in the second one. The clusters with the shortest 
distance are merged into a new cluster. With the aim to obtain a good intracluster homogeneity, 
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only when all the poses in all clusters were within 2.5 Å from the centroid the hierarchical 
clustering procedure was completed. Subsequently, the poses of the clusters containing at least 
one pose of all compounds and the amino acids within 5 Å from the ligand were minimized 
using the MMFF94x force field. After the minimization, the conformations with distorted 
aromatic groups were deleted after a visual comparison with some distorted crystallized aromatic 
rings obtained from the Cambridge Crystallographic Data Centre.[133] To analyze the remaining 
poses, the RMSD_MATRIX.SVL was written to calculate a second RMSD matrix based on the 
common scaffold. The Single Linkage agglomerative hierarchical clustering method was then 
applied to identify the common binding modes. The clusters containing one or more poses of all 
ligands were selected. The RMSD_MATRIX.SVL generates an RMSD matrix without 
performing the rotation of the poses as in ROTALI. Only the heavy atoms of the scaffold are 
considered to calculate the RMSD values. At the beginning it takes the first pose of the database 
as the reference pose against which the RMSD value of the other poses are calculated, then the 
second pose is taken as the reference one. The operations are repeated until all the poses of the 
database are taken as reference. To refine the selection of the binding modes, an appropriate svl 
script called RECEPTOR_RMSD.SVL was written to calculate the RMSD matrix of the 
complexes generated merging the RMSD matrices of the minimized models and poses of each 
selected clusters, taking into account the common scaffold of the ligands (fig. 7) and the amino 
acids that have at least one atom within 4.5 Å in 90% of the poses. The 
RECEPTOR_RMSD.SVL calculates the RMSD matrix of the common scaffold (through the 
function RMSD_MATRIX.SVL) and of the amino acids selected in each subunits. To find the 
amino acids within 4.5 Å from the ligand the script COUNT_SIDECHAIN.SVL was written. 
The script detects which amino acids are within the cut off distance from the ligand, and it 
creates columns headed with the subunit number and the name of the amino acids detected. 
Every time that an amino acid of a certain subunit is within the distance of 4.5 Å from the pose, 
the script writes the number 1 under the respective column. Subsequently, manually ranking the 
coloums it is possible to determine whether the amino acid considered is within 4.5 Å in 90% of 
the poses or not. On the RMSD matrix of the complexes was performed a cluster analysis using 
the Single Linkage clustering method to identify the common binding modes. The clusters 
containing poses of all ligands were validated through consensus scoring analysis using the 
London dG, ASE, Affinity dG and Alpha HB scoring functions as described in the subchapter 
5.1.1.6, and through mutagenesis data.[11, 126] Both Witchel et al.[11] and Windisch et al.[126] 
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demonstrated toward the mutagenesis data that only the amino acid Phe656 is essential in the 
hERG inhibition mediated by propafenone and derivatives, while it is less sensible or insensible 
to the mutations of the amino acids Thr623, Ser624, Val625, Ser631, Gly648, Tyr652 and 
Val659. 
In order to discriminate between the trapped and non-trapped compounds, potential energies 
considering the heavy atoms of the scaffold, poses, and substituents R1 (table 2) were calculated 
with the software pakage MOE2008.10 using MMFF94x force field, and finally these values 
were ranked in ascending order. In order to get a size independent parameter potential energy 
values were divided by the total number of heavy atoms. To extract the heavy atoms of the 
common scaffold, poses and R1 substituents, the smile string of the function 
abstract_commonscaffold in the script FORMELPOOL.SVL (subchapter 5.1.1.6) was from time 
to time modified specifying the smile strings regarding the molecules and each moieties of the 
compounds considered in the calculation of the potential energy. For each ligand a database was 
created considering only the heavy atoms of the poses, common scaffold and R1 substituents. 
Subsequently the databases were merged and the potential energy values calculated. 
5.2.1.5 Analysis of ligand interactions 
The interactions between the ligands and the hERG channel were analyzed with the 
MOE2008.10 software package. 
5.2.2 Results 
5.2.2.1 Poses analysis 
Many studies demonstrate that the hERG blockers inhibit the channel in the open state. Several 
lines of evidences indicate that the binding site is located in the central cavity.[6, 9, 12, 22, 131]. 
At the level of the inner pore there are two concentric rings. The ring formed by four Tyr652 
faces to the inner cavity. During the transition from the closed state to the open state the distance 
between the Cα of Tyr652 of opposite subunits increases from 14.3 Å to 19.3 Å. Four Phe656 
form the ring at the cytoplasmic side of the hERG channel. When the hERG channel is in the 
closed conformation, the space between the Cα of Phe656 of opposite subunits is too tight to 
allow the molecules to interact with Phe656.[102] During the channel opening the distance 
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between the Cα increases from 9.4 Å to 15.6 Å, allowing the compounds to enter into the central 
cavity and to block the channel.[102] In the open conformation of the hERG channel, the four 
Phe656 can form hydrophobic, π-cation or π-stacking interactions with hERG blockers, making 
the channel polyspecific in ligand recognition. The increase in the size of the two concentric 
rings from the closed to the open state corresponds also to an increase of the volume from 1048.2 
Å
3
 to 1642.2 Å
3
. The reduction of more than 30% of the volume during the channel gating might 
explain why only small and flexible compounds are trapped into the closed state.[102] 
In this study, we docked the compounds propafenone, GPV0005, GPV0009, GPV0180, 
GPV0031 and GPV0576 (table 2) into the homology model of hERG channel in the open state, 
in order to investigate the interactions that determine the inhibition of the channel and to shed 
light on the drug trapping phenomena. Due to the symmetry of the homology model of the hERG 
channel in the open state, the poses were distributed in all four directions (see also the subchapter 
5.1.1.2). The symmetry operation was applied to align the poses and to delete the duplicates. The 
non-duplicate poses were used to generate a RMSD matrix based on the common scaffold. 
Through hierarchical cluster analysis, we identified 3 clusters containing one or more poses of all 
compounds. A visual inspection of the clusters highlighted that some poses had a distorted 
aromatic group. For this reason, the poses of the selected clusters and the amino acids that were 
within 5 Å from the ligand were minimized. After the minimization, the poses that still had a 
distorted aromatic group were deleted. The remaining poses were analyzed through the Single 
Linkage clustering method performed on the RMSD matrix based on the common scaffold (fig. 
7), and the clusters containing poses of all ligands were selected. The poses of the selected 
clusters and the amino acids defined as part of the binding site were used to calculate the RMSD 
matrix of the complexes. Through the Single Linkage clustering method of the RMSD matrix 3 
clusters were selected. 
In the first cluster, the analysis of the centroid interactions shows that it forms three hydrogen-
bonds with two amino acids of the same subunit: two hydrogen-bonds are between the hydroxyl 
group of the propafenone scaffold and the amino acids Thr623 and Ser624, and one involves the 
charged nitrogen atom and the Ser624 (fig. 13). The two aromatic groups make T-stacking and 
hydrophobic interactions with three Phe656 of the subunits B-D. The poses in the first cluster 
show that the two aromatic groups of the ligands form π-stacking, and/or T-stacking, and/or 
parallel-displaced π-π interactions with two or three Phe656 of the subunits B-D. Due to the 
small distance between the four subunits near the selectivity filter, the hydroxyl group of the 
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Fig. 13 Centroid of the first cluster. 3D (A) and 2D (B) interaction pattern of the centroid of the first cluster. Only the amino 
acids Thr623 (violet), Ser624 (orange), Ser649 (dark cyan), Tyr652 (cyan) and Phe656 (brown) are reppresented. The subunits A, 
B, C and D are colored in green, yellow, grey and pink respectively. The yellow arrows indicate the amino acids Phe656 
inteacting with the centroid through T-stacking and hydrophobic interactions. 
A 
B 
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Fig. 14 Centroid of the second cluster. 3D (A) and 2D (B) interaction pattern of the centroid of the second cluster. The amino 
acids Thr623 (violet), Ser624 (orange), Ser649 (dark cyan), Tyr652 (cyan) and Phe656 (brown) are reppresented. The subunits A, 
B, C and D are colored in green, yellow, grey and pink respectively. The violet and yellow arrows indicate respectively the 
Phe656 forming π-cation and T-stacking/parrelell displaced π-π interactions with the centroid. 
A 
B 
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Fig. 15 Centroid of the third cluster. 3D (A) and 2D (B) interaction pattern of the centroid. Only the amino acids Thr623 (violet), 
Ser624 (orange), Ser649 (dark cyan), Tyr652 (cyan) and Phe656 (brown) are reppresented. The subunits A, B, C and D are green, 
yellow, grey and pink colored respectively. The green and the violet arrows indicate respectively the Phe656 making π-π and π-
cation interactions with the centroid. 
A 
B 
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ligands can form hydrogen bonds with the amino acid Ser624 of the subunits A-B and D, and/or 
with the Thr623 of the subunit B. The charged nitrogen can make hydrogen-bond interactions 
with Ser624 and/or with Thr623 of the subunits A-C and A-B, respectively. 
In the second cluster, the charged nitrogen atom of the centroid forms π-cation interaction with 
Phe656, while the phenyl rings make T-stacking and parallel-displaced π-π interactions with the 
other three Phe656 (fig. 14). The analysis of the poses in the second cluster reveals that the two 
aromatic rings of the ligands interact with two or three Phe656 of subunits A-C through π-
stacking, and/or T-stacking, and/or parallel-displaced π-π interactions, while the charged 
nitrogen atom forms π-cation interactions with one or two Phe656 of subunits A and D. In this 
cluster there is at least one pose per ligand that makes π-cation, and/or π-stacking, and/or 
parallel-displaced π-π, and/or T-stacking interactions with Phe656, but not with other amino 
acids, in agreement with the mutagenesis data.[11, 126] 
In the third cluster, the centroid interacts with the hERG channel through π-stacking and π-cation 
interactions with two Phe656 of adjacent subunits (fig. 15). The two aromatic rings of the poses 
in the third cluster interact with the hERG channel through π-stacking, and/or T-stacking, and/or 
parallel diplaced interactions of one or two Phe656 of the subunits B-D. The protonated nitrogen 
forms π-cation interactions with one or two Phe656 of the subunits A and D. In these cluster not 
all ligands show π-cation, and/or π-stacking, and/or T-stacking, and/or parallel-displaced π-π 
interactions with the amino acid Phe656 in contrast to the mutagenesis data.  
With the aim to further select the clusters, we performed a consensus scoring based on the first 
ten poses ranked according to the Affinity dG, Alpha HB, ASE and Londong dG scoring 
functions of MOE. The first and the second clusters have one or more poses ranked within the 
first ten in all four scoring functions, while in the third cluster the first ten poses of the London 
dG scoring function are missing. In an interesting study Witchel et al.[11] performed a detailed 
alanine scanning to determine the binding site of propafenone. Noteworthy they found that only 
the Phe656Ala mutation affects the block of the hERG channel by propafenone, while it is 
insensitive or less sensitive to the mutations of Thr623, Ser624, Val625, Gly628, Ser631, 
Gly648, Tyr652 and Val659. Similar results were obtained by Windisch et al.[126] Considering 
the consensus scoring and the mutagenesis data we can prioritize the second cluster, because it 
has one or more conformations within the top ten in all four scoring functions, and only this 
cluster has at least one pose per ligand in agreement with the mutagenesis data. 
Even if it is possible to prioritize the second binding mode, to not neglect any possible trapping 
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mechanisms, the positions of the substituent attached to protonated nitrogen in all three selected 
clusters will be discussed. 
The poses of the first cluster show that the substituent attached to the charged nitrogen is placed 
near the amino acids Ser649 and Tyr652 of the same subunit (fig. 16). The presence of the 
backbone (fig. 16C) renders it impossible for the non-trapped propafenones to place the 
protonated nitrogen near the two amino acids above-mentioned due to the bulkiness and the 
rigidity of the R1 substituents, in contrast with the position of the charged nitrogen of trapped 
compounds. This leads to a push back of the charged nitrogen in the non-trapped compounds 
(fig. 16A), and forces their R1 substituent to bend upward (fig. 16B and 16C). In contrast to the 
results of Windisch et al.,[126] through these poses it is not possible to explain the “foot in the 
door” mechanism. This suggests that these conformations might be not as reliable as the poses in 
Fig. 16 Position of R1 in the poses of cluster1. Upper (A), lateral (B) and frontal view (C) of the substituent R1 in poses of 
cluster1. Only the amino acids Thr623 (violet), Ser624 (orange), Ser649 (dark cyan), Tyr652 (cyan) and Phe656 (brown) are 
reppresented. The subunits A, B, C and D are colored in green, yellow, grey and pink respectively. The carbon atoms of the 
substituent R1 of the non-trapped compounds are colored in black. The charged nitrogen is colored in blue and in violet in the 
trapped and non-trapped molecules respectively. The non-protonated nitrogen of the non-trapped compounds is colored in 
yellow. 
B 
A 
C 
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the second and third clusters. 
The poses of the second cluster place the R1 substituent in a zone of the channel delimited by the 
amino acids Ser649-Tyr652 of the same subunit and Tyr652 of an adjacent subunit (fig. 17A and 
B). As in the first cluster the protonated nitrogen of non-trapped propafenones is pushed away by 
the R1 substituent from the three amino acids above-mentioned. In contrast to the first cluster, 
the charged nitrogen of the poses in the second cluster is located lower, near the ring formed by 
the four Phe656. This forces the piperidin group present in some R1 substituents to bend upward 
to avoid clashes with the Phe656. The space between the position of the piperidin group in the 
trapped compounds and the top of the hERG channel is not big enough to accommodate the 
Fig. 17 Position of R1 substituents in the poses of cluster2. Upper (A), lateral (B) and frontal view (C) of the substituent R1 in 
poses of cluster2. Only the amino acids Thr623 (violet), Ser624 (orange), Ser649 (dark cyan), Tyr652 (cyan) and Phe656 (brown) 
are reppresented. The subunits A, B, C and D are colored in green, yellow, grey and pink respectively. The carbon atoms of the 
substituent R1 of the non-trapped compounds are colored in black. The charged nitrogen is colored in blue and in violet for the 
trapped and non-trapped molecules respectively. The noncharged nitrogen of the substituent of the non-trapped compounds is 
colored in yellow. 
B 
A 
C 
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substituted phenyl rings in the R1 substituents of non-trapped propafenones. This determines the 
placement of the charged nitrogen in the piperazine group of non-trapped molecules within the 
four Phe656, while in the trapped compounds the protonated nitrogen is above these four amino 
acids (fig. 17B and C). During the channel gating the protonated nitrogen of the trapped 
propafenones moves near the amino acids Ser649 and Tyr652, as seen in the subchapter of 
closed hERG channel conformation. In non-trapped propafenones the rigidity and the bulkiness 
of the substituents R1 prevent this movement. Hence, due to the position of the charged nitrogen 
within the ring formed by the four Phe656, the substituents R1 of the non-trapped compounds 
hinder the channel gating with the “foot in the door” mechanism.  
In the poses of the third cluster the substituent R1 is placed in the zone delimited by two Tyr652 
and one Ser649 (fig. 18A, B and C). The charged nitrogen atoms of the poses in the second and 
Fig. 18 Position of R1 in the poses of cluster3. Upper (A), lateral (B) and frontal view (C) of the substituent R1 in poses of 
cluster3. Only the amino acids Thr623 (violet), Ser624 (orange), Ser649 (dark cyan), Tyr652 (cyan) and Phe656 (brown) are 
reppresented. The subunits A, B, C and D are colored in green, yellow, grey and pink respectively. The carbon atoms of the 
substituent R1 of the non-trapped compounds are colored in black. The charged nitrogen is colored in blue and in violet for the 
trapped and non-trapped molecules respectively. The noncharged nitrogen of the substituent of the non-trapped compounds is 
colored in yellow. 
B 
A 
C 
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third clusters are located at the same level. Generally in the non-trapped propafenones the bulky 
and rigid substituent push the protonated nitrogen lower than to its position in the trapped 
compounds. The piperidine ring present in some R1 substituents is bent upward to avoid possible 
clashes with the four Phe656. Due to the lack of space between the piperidine ring of the 
compounds GPV0005 and GPV0180 and the top of the central cavity, the phenyl rings present in 
the R1 substituents of the non-trapped molecules force the piperazine moieties to be placed in a 
lower position. Hence, the protonated nitrogen of the non-trapped compounds is within the ring 
formed by the four Phe656, while in the trapped propafenones it is above it (fig. 18B and C). As 
previously described, in the non-trapped molecules the position of the charged nitrogen within 
this ring hinders the hERG channel gating with the “foot in the door” mechanism due to the 
rigidity and the bulkyness of the R1 substituent. 
The poses of cluster1 are similar to the conformations of propafenone, GPV0005 and GPV0576 
published by Thai et al.[102] (RMSD value from the centroid lower than 2.5 Å). The two phenyl 
rings of the centroid and of the published poses are near each other, with the aromatic rings of 
the previously published poses placed orthogonal to the cannel axis, while in the centroid of 
cluster1 they are bent to form T-stacking and hydrophobic interactions with three Phe656 of 
adjacent subunits. The chain that connects the two rings is upward in the published poses, and 
downward in the centroid, explaining why it looses the hydrogen bond between the carbonyl 
group and the Ser624 predicted by Thai et al.[102] Another difference regards the position of the 
protonated nitrogen and the substituents attached. In the centroid of cluster1 the charged nitrogen 
forms a hydrogen bond with Ser624, placing the substituent in a zone delimited by Ser649 and 
Tyr652 of the same subunit. In the previously published poses, the protonated nitrogen is placed 
near the ring formed by the four Phe656, at the same level where the second and third clusters 
place the non-protonated nitrogen of the non-trapped compounds. Despite the fact that the 
centroid is similar to the poses published by Thai et al.,[102] the mutagenesis data, the consensus 
scoring analysis and the agreement with the “foot in the door” mechanism suggest that it is 
reasonable to prioritize the second binding mode. 
The position of the protonated nitrogen of the non-trapped compounds within the ring on the 
cytoplasmic side of the hERG, as it happens in the second and third clusters, might hinder the 
closure of the activation gate. This is in agreement with the “foot in the door” mechanism,[101, 
134] and explains why the molecules with a R1 substituent bulky and rigid are not trapped in the
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Table 9. Poses of cluster1. E scaffold: potential energy calculated considering the heavy atoms of the scaffold (table 2). E pose: 
potential energy calculated considering only the heavy atoms of the pose. N1: number of heavy atoms of the pose. E R1: potential 
energy calculated considering only the heavy atoms of the substituent R1. N2: number of heavy atoms of the substituent R1. The 
values of E are in kcal/mol. 
Poses E scaffold E pose N1 E pose / N1 E R1 N2 E R1 / N2 Trapped? 
Propafenone 60.58 88.07 25 3.52 0.72 4 0.18 Yes 
Propafenone 77.94 111.62 25 4.46 0.80 4 0.20 Yes 
Propafenone 76.79 100.86 25 4.03 0.80 4 0.20 Yes 
Propafenone 71.19 90.32 25 3.61 0.83 4 0.21 Yes 
Propafenone 73.70 114.09 25 4.56 0.90 4 0.22 Yes 
Propafenone 74.69 93.40 25 3.74 2.45 4 0.61 Yes 
Propafenone 83.22 114.61 25 4.58 2.79 4 0.70 Yes 
Propafenone 73.88 118.95 25 4.76 4.48 4 1.12 Yes 
GPV0009 73.39 102.49 28 3.66 10.66 7 1.52 Yes 
GPV0180 66.24 109.49 31 3.53 12.38 6 2.06 Yes 
GPV0005 70.65 90.18 27 3.34 13.10 6 2.18 Yes 
Propafenone 64.45 99.49 25 3.98 9.03 4 2.26 Yes 
GPV0005 63.96 86.46 27 3.20 13.62 6 2.27 Yes 
GPV0005 70.82 95.07 27 3.52 13.76 6 2.29 Yes 
GPV0005 75.54 96.77 27 3.58 13.76 6 2.29 Yes 
GPV0180 67.75 112.49 31 3.63 16.21 6 2.70 Yes 
GPV0005 65.19 91.42 27 3.38 17.39 6 2.90 Yes 
GPV0031 77.48 170.26 34 5.01 77.35 13 5.95 No 
GPV0576 61.29 160.88 35 4.60 88.66 14 6.33 No 
hERG channel. It is interesting to note that the propafenones docked into the hERG channel in 
the closed state as well as in the open state place the R1 substituent near the amino acids Ser649 
and Tyr652 of the same and/or adjacent subunits. 
To discriminate between trapped and non-trapped propafenone derivatives the potential energy 
values of the poses, scaffold and R1 substituents (table 2), were calculated. Obviously in all three 
clusters it is not possible to separate the poses of the trapped compounds from the non-trapped 
ones considering the potential energy values of the scaffold (table 9, 10 and 11). In all three 
clusters the potential energy values of the non-trapped poses, and of their substituent R1, are 
always higher than the values obtained for the trapped compounds. This is due to the greater 
number of atoms in the non-trapped compounds, and to the less favorable conformation with 
which the non-trapped propafenone derivatives interact with the hERG channel in the open state. 
In the first and in the second cluster, ranking the compounds according to the values obtained 
dividing the potential energy by the total number of heavy atoms, it is not possible to 
discriminate between the trapped and non-trapped compounds, due to the presence of one outlier 
(one pose of propafenone and GPV0005 for cluster1 and cluster2 respectively) in the poses of 
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Table 10. Poses of cluster2. E scaffold: potential energy calculated considering the heavy atoms of the scaffold (table 2). E pose: 
potential energy calculated considering only the heavy atoms of the pose. N1: number of heavy atoms of the pose. E R1: potential 
energy calculated considering only the heavy atoms of the substituent R1. N2: number of heavy atoms of the substituent R1. The 
values of E are in kcal/mol. 
non-trapped propafenone derivatives. For the first cluster, it is not clear why this pose is an 
outlier (table 9). Regarding the second cluster (table 10), the ether linkage between the phenyl 
ring and the piperidine group of the outlier goes deep into the ring formed by the four Phe656 of 
the hERG channel, in the same position found in non-trapped propafenones, assuming an 
unfavourable conformation that explains the high value of potential energy. In contrast to the 
first two clusters, in the third one it is possible to discriminate between the trapped and non-
trapped propafenone derivatives ranking the compounds according to the values obtained 
dividing the potential energy of the pose by the total number of heavy atoms (table 11). The high 
values of potential energy of non-trapped molecules are due to the phenyl-R1 linker that is 
placed deeply into the inner pore, assuming a U conformation, and to the rigidity and bulkiness 
of the R1 substituents. Only one pose of the trapped compounds have the phenyl-R1 linker that
Poses E scaffold E pose N1 E pose / N1 E R1 N2 E R1 / N2 Trapped? 
Propafenone 84.91 113.63 25 4.54 1.01 4 0.25 Yes 
Propafenone 80.37 100.56 25 4.02 2.49 4 0.62 Yes 
GPV0009 75.29 100.24 28 3.58 8.61 7 1.23 Yes 
GPV0009 80.98 101.94 28 3.64 8.85 7 1.26 Yes 
GPV0009 81.32 102.48 28 3.66 9.12 7 1.30 Yes 
GPV0009 66.24 91.45 28 3.27 9.20 7 1.31 Yes 
GPV0009 65.86 90.80 28 3.24 9.91 7 1.42 Yes 
GPV0009 64.50 90.03 28 3.21 10.28 7 1.47 Yes 
GPV0009 71.53 97.32 28 3.48 11.12 7 1.59 Yes 
GPV0009 68.11 93.03 28 3.32 11.12 7 1.59 Yes 
GPV0009 66.02 94.24 28 3.37 11.83 7 1.69 Yes 
GPV0180 62.29 105.30 31 3.40 12.68 6 2.11 Yes 
GPV0005 89.73 128.59 27 4.76 13.25 6 2.21 Yes 
GPV0005 80.12 105.34 27 3.90 13.57 6 2.26 Yes 
GPV0180 64.41 120.40 31 3.88 13.58 6 2.26 Yes 
GPV0180 64.47 118.68 31 3.83 13.66 6 2.28 Yes 
GPV0005 62.00 101.57 27 3.76 13.85 6 2.31 Yes 
GPV0005 63.05 103.27 27 3.82 13.96 6 2.33 Yes 
GPV0180 68.75 118.72 31 3.83 16.31 6 2.72 Yes 
GPV0576 77.59 170.33 35 4.87 76.16 14 5.44 No 
GPV0576 74.81 169.48 35 4.84 77.10 14 5.51 No 
GPV0031 76.44 165.55 34 4.87 71.67 13 5.51 No 
GPV0031 75.08 160.75 34 4.73 71.71 13 5.52 No 
GPV0031 76.43 164.80 34 4.85 71.83 13 5.52 No 
GPV0031 77.59 169.55 34 4.99 76.21 13 5.86 No 
GPV0031 73.94 178.14 34 5.24 90.02 13 6.92 No 
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Table 11. Poses of cluster3. E scaffold: potential energy calculated considering the heavy atoms of the scaffold (table 2). E pose: 
potential energy calculated considering only the heavy atoms of the pose. N1: number of heavy atoms of the pose. E R1: potential 
energy calculated considering only the heavy atoms of the substituent R1. N2: number of heavy atoms of the substituent R1. The 
values of E are in kcal/mol. 
goes deeply into the inner pore as in the non-trapped compounds, but it has a lower value of 
potential energy probably due to the smaller size and to the flexibility of the molecule. 
In all three clusters the values of potential energy of the R1 substituents is much higher in the 
non-trapped propafenones than in the trapped ones. The discrimination between trapped and non-
trapped compounds is still clear even when the value of potential energy is divided by the total 
number of heavy atoms of R1. This is due to the size and to the rigidity of the substituent in the 
non-trapped propafenone derivatives. This result allow to hypothesize that during the channel 
closure, the rigidity and the bulkiness of the substituent R1 of non-trapped compounds 
destabilize the ligand-hERG complex, forcing the dissociation through the “foot in the door” 
mechanism. 
5.2.3 Conclusions 
In this work, we docked a series of six propafenone derivatives into the homology model of the 
hERG channel in the open state. Hierarchical cluster analysis of the RMSD matrix based on the 
common scaffold and considering the amino acids interacting with the poses reveals three 
possible binding modes. The comparison of the selected clusters with the results obtained in the 
closed state shows that the substituent attached to the charged nitrogen is situated near the zone 
Tyr652-Ser649-Tyr652 in both cases. In the second and in the third cluster the bulky and rigid 
R1 substituents of non-trapped compounds force the protonated nitrogen to be placed within the 
Poses E scaffold E pose N1 E pose / N1 E R1 N2 E R1/ N2 Trapped? 
GPV0009 65,67 89,13 28 3,18 8,87 7 1,27 Yes 
Propafenone 56,58 90,04 25 3,60 7,61 4 1,90 Yes 
GPV0180 79,49 124,37 31 4,01 12,13 6 2,02 Yes 
GPV0005 71,04 101,04 27 3,74 12,90 6 2,15 Yes 
GPV0005 75,82 100,13 27 3,71 15,91 6 2,65 Yes 
GPV0005 55,82 87,74 27 3,25 16,68 6 2,78 Yes 
GPV0005 74,33 109,08 27 4,04 17,32 6 2,89 Yes 
GPV0005 71,04 106,82 27 3,96 17,53 6 2,92 Yes 
GPV0005 60,63 89,65 27 3,32 17,75 6 2,96 Yes 
GPV0576 78,17 178,60 35 5,10 88,14 14 6,30 No 
GPV0031 58,85 152,94 34 4,50 85,21 13 6,55 No 
GPV0031 82,91 189,38 34 5,57 90,94 13 6,99 No 
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ring formed by the four Phe656. This might hinder the closure of the channel activation gate, 
leading to the dissociation of the ligand with the “foot in the door” mechanism. Hence, these 
clusters can explain why the propafenone derivatives with a rigid and bulky R1 substituent are 
not trapped. Interestingly, the values of potential energy of R1, and this value divided by the 
number of heavy atoms, allow us to discriminate between trapped and non-trapped propafenone 
and derivatives. This might indicate that the bulkiness and the rigidity of the R1 substituent play 
an important role in the propafenone derivatives-hERG complex dissociation during the channel 
gating. 
In this study only a small set of propafenones were used, hence these results cannot be 
generalized for other classes of hERG blockers. It is also important to note that drug trapping is a 
multistep mechanism in which different intermediate states of the hERG channel gating might 
have a strong influence. 
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5.3 Docking studies into models of hERG channel in the open state obtained 
from molecular dynamics simulations 
5.3.1 Material and methods 
5.3.1.1 Docking protocol 
With the aim to take into account the flexibility of the amino acid sidechains facing the central 
cavity of the hERG channel, nine propafenone derivatives were docked into several models of 
hERG channel in the open state obtained from snapshots of molecular dynamics simulations 
kindly provided by Anna Weinzinger.[135] To the pdb file of the eleven models the hydrogen 
atoms were added. The models were minimized by soft minimization operation performed with 
the MOE2008.10 tool Energy Minimize[127] in the Amber 99 force field, constraining the 
chirality, applying a root mean square gradient value of 0.5 and a value of 10 to the Thether 
Atoms option for heavy atoms. The partial charges of the atoms were recalculated during the 
minimization. The models in which the amino acids of the central cavity or of the inner pore 
violated the Ramachandran Plot were discarded. The remaining eight models were then 
superposed according to the Cα of the amino acids with the MOE2008.10 tool Protein Superpose 
using the default conditions. 
Recently Windisch et al.[126] synthesized and tested the new propafenone derivatives GPV0019, 
GPV0062 and STC-AS03. These molecules have only small differences in the R1 substituents, 
but they show a different recovery from the hERG block. In the non-trapped compound 
GPV0019 the substituent at the nitrogen atom is a piperazine group, while in the trapped 
molecules GPV0062 and STC-AS03 this moiety is replaced with a piperidine. To investigate in 
more detail the trapping phenomena these compounds were included in this study. The ligands 
GPV0019, GPV0062 and SCT-AS03 were built and minimized as described in the subchapter 
5.1.1.1 using the tools implemented in MOE2008.10. The sp
2
 hybridization was assigned to the 
aniline nitrogen of the compound GPV0019. The 100 most diverse conformations of the 
compounds GPV0019, GPV0062 and SCT-AS03 were selected through a systematic search and 
the tool Diverse Subset implemented in MOE2008.10 applying the protocol described in the 
subchapter 5.1.1.1. The selection of the 100 most diverse conformations of propafenone, 
GPV0005, GPV0009, GPV0031, GPV0180 and GPV0576 was already done in the previous 
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study (see the subchapter 5.2.1.1). The databases of the 100 most diverse conformations were 
then docked into the eight selected models. The binding site was defined by the atoms of the 
amino acids within a sphere of 6.5 Å from the amino acids Thr623, Ser624, Tyr652 and Phe656 
of each subunit. This allows the selection of all the amino acids of the central cavity. In the 
previous study (chapter 5.2) this was not possible, due to the high number of poses docked 
outside the hERG channel applying this definition of the binding site. The placement method, the 
minimization and the other conditions used to dock the compounds are described in the 
subchapter 5.2.1.1. 
5.3.1.2 Identification of the common binding modes 
Due to the asymmetric binding site it was not necessary to apply the alignment of the poses and 
delete the duplicates with the processes described in subchapters 5.1.1.2, 5.1.1.3, 5.1.1.4 and 
5.1.1.5. 
For each database of poses, the first 210 poses ranked according to the London dG scoring 
function were selected. To reduce the amount of poses considered, and to take into account only 
the most different ones to cover as much conformational space as possible, of the 210 poses only 
the 20 most diverse conformations based on the RMSD and E were selected with the Diverse 
Subset tool of MOE2008.10. 
The common binding modes were selected and validated, and the potential energy values of the 
poses, common scaffold and R1 substituents calculated as described in the subchapter 5.2.1.4. 
5.3.1.3 Analysis of ligand interactions 
See the subchapter 5.2.1.5. 
5.3.2 Results 
5.3.2.1 Pose analysis 
A series of nine propafenone derivatives were docked into eight homology models of hERG 
channel in the open state derived from molecular dynamics simulations. Table 12 clearly shows 
that the cytoplasmic side of the inner cavity exhibits significant movements, while the 
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movements of the four amino acids Ser624 are smaller. This is in agreement with the fact that 
the movement of the amino acids in the inner pore determines the closure of the hERG channel. 
The volume of the hERG channel varies from a minimum of 1322.0 Å
3
 to a maximum of 2246.1 
Å
3
. 
Table 12. Structural information on the eight hERG models. Distance 1: distance between the Cα of Ser624 of opposite subunits. 
Distance 2: distance between the Cα of Phe656 of opposite subunits. 
Models Distance 1 (Å)  Distance 2 (Å) Volume (Å
3
) 
Model 1 8.28 - 8.97 18.30 – 18.63 1670.8 
Model 2 8.32 – 8.80 17.19 – 19.44 1681.5 
Model 3 9.17 – 9.36 16.59 – 16.92 2097.3 
Model 5 9.52 – 9.77 16.83 – 17.28 1647.1 
Model 6 8.42 – 10.07 17.27 – 19.72 2246.1 
Model 8 9.82 – 10.00 15.30 – 16.07 1623.8 
Model 9 10.04 – 11.09 13.68 – 16.39 1370.3 
Model 11 9.79 – 10.13 13.86 – 17.97 1322.0 
In this study, we docked propafenone, GPV0005, GPV0009, GPV0019, GPV0031, GPV0062, 
GPV0180, GPV0576 and SCT-AS03 (table 2) into eight models of the hERG channel in the 
open state. Two clusters, from now on called cluster four and five, were selected through Single 
Linkage cluster analysis of the RMSD matrix based on the common scaffold and the successive 
refinements. 
In cluster four, one phenyl ring of the centroid forms a parallel-displaced π-π interaction with 
Phe656 (fig. 19). The second phenyl ring is located under the four Phe656. The analysis of the 
poses of this cluster show that the aromatic ring form π-stacking, and/or parallel-displaced π-π 
interactions with Phe656 of the subunit D, π-cation interaction with Phe656 of subunit B, and 
parallel-displaced π-π interaction with the Tyr652 of subunit C. 
The centroid of cluster five makes π-stacking interaction with the Phe656 of the subunit D (fig. 
20). The protonated nitrogen is placed under the ring formed by the four Phe656 directly in 
contact with the cytoplasm (fig. 20A). In this position, the charged nitrogen cannot interact with 
the hERG channel. One phenyl ring of the scaffold is placed between the two concentric rings of 
the inner pore, while the second one is placed under the selectivity filter. The poses of the fifth 
cluster show that the phenyl ring form π-stacking or parallel-displaced π-π interactions with the 
Phe656 of the subunit D, and T-stacking, or parallel-displaced π-π interactions with Tyr652 of 
the subunit C. This binding mode seems to be not reliable, because it cannot explain the role of 
the protonated nitrogen in the hERG inhibition. 
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Fig. 19 Centroid of cluster four. 3D (A) and 2D (B) interaction pattern of the centroid of cluster four. Only the amino acids 
Thr623 (violet), Ser624 (orange), Ser649 (dark cyan), Tyr652 (cyan) and Phe656 (brown) are reppresented. The subunits A, B, C 
and D are colored in green, yellow, grey and pink respectively. The yellow arrow indicates the Phe656 that interacts with the  
centroid through parallel-displaced π-π interaction. 
B 
A 
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Fig. 20 Centroid of cluster five. 3D (A) and 2D (B) interaction pattern of the centroid of cluster five. Only the amino acids 
Thr623 (violet), Ser624 (orange), Ser649 (dark cyan), Tyr652 (cyan) and Phe656 (brown) are reppresented. The subunits A, B, C 
and D are colored in green, yellow, grey and pink respectively. The green arrow indicates the Phe656 that makes π-stacking 
interaction with the phenyl ring of the centroid. 
B 
A 
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Neither through consensus scoring nor through mutagenesis data it was possible to prioritize one 
of the two clusters. In both clusters one or more poses are present which are ranked within the 
first ten positions in the four scoring functions used in the consensus scoring, and not all ligands 
have at least one pose in agreement with mutagenesis data,[11, 126] due to the lack of π-
stacking, or π-cation, or T-stacking, or parallel diplaced π-π interactions with the amino acid 
Phe656. 
Both centroids show a different binding mode regarding the interactions and the scaffold 
orientations. In contrast to the three clusters obtained previously (subchapter 5.2), in cluster four 
the placement of the substituent R1 is “messy” (fig. 21A). This is probably due to the fact that in 
the first case the docking was performed in a symmetric model of the hERG channel, while the 
binding site of the eight selected models are snapshots of molecular dynamics simulations, hence 
the hERG channel is asymmetric. In cluster four some poses place the R1 substituent between 
the Ser649 of subunit A and the Tyr652 of subunit B (fig. 21B), while in other conformations the 
substituent is located between the Ser649 of subunit A and Ty652 of subunit D (fig. 21C), and in 
two poses of trapped compounds it is oriented towards the selectivity filter (fig. 21D). In contrast 
to clusters one, two and three, there are no clear differences in the charged nitrogen position of 
trapped and non-trapped propafenone derivatives (fig. 21E). 
In the fifth cluster, the substituents R1 are situated under the ring formed by the four Phe656. As 
in cluster four, the substituents have different directions and it is not possible to distinguish 
between trapped and non-trapped compounds based on the protonated nitrogen position (fig. 22). 
Both clusters are in agreement with the “foot in the door” mechanism. In the fourth cluster the 
second phenyl ring, as previously mentioned, lies under the ring formed by the four Phe656. 
During the channel gating the aromatic group has to move into the central cavity, forcing the 
protonated nitrogen to get closer to the amino acids Ser649 and Tyr652, as seen in the subchapter 
5.1. In the non-trapped compounds this movement is prevented by the rigid and bulky R1 
substituents. Hence, the tail of the scaffold placed in the middle of the ring formed by the four 
Phe656 hinders the hERG channel closure facilitating the drug dissociation. In cluster five, the 
charged nitrogen is located under the ring formed by the four Phe656. During hERG channel 
gating the trapped compounds move into the central cavity. In the non-trapped propafenones this 
movement is impeded by the bulkiness and rigidity of R1 substituents, which in turn hinders the 
channel gating with the “foot in the door” mechanism and thereby facilitates the ligand 
Andrea Schiesaro Results 2011 
107 
 
 
Fig. 21 Position of the substituents in the poses of cluster four. (A) top view of the substituent R1. (B) Propafenone (element) 
and GPV0009 (dark green) placing the substituent between Ser649 and Tyr652 of the subunits A and B. (C) Pose placing the 
substituent between Ser649 and Tyr652 of the subunits A and D. (D) Poses with the substituent R1 oriented toward the selectivity 
filter. (E) Lateral view of substiuents R1. The protonated nitrogen of trapped, non-trapped ligands and GPV0062 is colored in 
blue, violet and orange respectively. The aniline nitrogen of the non-trapped compounds is colored in yellow. The carbon atoms 
of the non-trapped ligands and of the GPV0062 are colore in black and green respectively. The amino acids Thr623 (violet), 
Ser624 (orange), Ser649 (dark cyan), Tyr652 (cyan) and Phe656 (brown) are reppresented. The subunits A, B, C and D are 
colored in green, yellow, grey and pink respectively. 
A B 
C D 
E 
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dissociation.  
As already seen in the previous subchapter, the potential energy of the scaffold, pose and 
substituent R1 (table2) considering only the heavy atoms was calculated in order to discriminate 
between trapped and non-trapped propafenones. Taking into account the potential energy values 
of the scaffold, obviously, in both clusters it is not possible to distinguish between the poses of 
trapped and non-trapped compounds. As in clusters one, two and three, the conformations of 
trapped molecules have a lower value of potential energy than the one of non-trapped ligands. In 
cluster four, ranking the conformations according to the value obtained dividing the potential 
energy values of the poses by the total number of heavy atoms, it is still possible to discriminate 
between trapped and non-trapped molecules (table 13). The propafenone derivative GPV0062, 
which does not show a clear behavior with a recovery value between the trapped and non-
trapped molecules, is ranked as a trapped compound.[126] The difference in the potential energy 
values of trapped and non-trapped compounds is due to the rigidity and bulkiness of R1 
susbtituents. In contrast to cluster four, in the fifth one it is not possible to discern between 
trapped and non-trapped propafenones by ranking the values calculated dividing the potential 
energy of the pose by the number of heavy atoms, due to the incorrect classification of two 
propafenone poses (table 14). The reasons why these two conformations are outliers are not 
Fig. 22 Lateral view of the substituents R1 position in cluster five. The protonated nitrogen of trapped, non-trapped and 
GPV0062 compounds is colored in blue, violet and orange respectively. The non-protonated nitrogen of non-trapped molecules 
is colored in yellow. The carbon atoms of the non-trapped compounds and of the GPV0062 are colored in black and green 
respectively. The subunits A, B, C and D are colored in green, yellow, grey and pink respectively. 
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Table 13. Poses of cluster4. E scaffold: potential energy calculated considering the heavy atoms of the scaffold (table 2). E pose: 
potential energy calculated considering only the heavy atoms of the pose. N1: number of heavy atoms of the pose. E R1: potential 
energy calculated considering only the heavy atoms of the substituent R1. N2: number of heavy atoms of the substituent R1. The 
values of E are in kcal/mol. 
Poses E scaffold E pose N1 E pose / N1 E R1 N2 E R1/ N2 Trapped? 
GPV0009 68.26 97.64 28 3.49 10.17 7 1.45 Yes 
GPV0009 70.43 95.10 28 3.40 11.06 7 1.58 Yes 
GPV0009 81.11 108.68 28 3.88 12.30 7 1.76 Yes 
Propafenone 66.79 104.50 25 4.18 7.35 4 1.84 Yes 
GPV0180 71.59 112.88 31 3.64 13.10 6 2.18 Yes 
GPV0062 60.53 107.47 34 3.16 31.72 13 2.44 Yes 
GPV0005 77.28 109.81 27 4.07 15.08 6 2.51 Yes 
SCT-AS03 75.15 129.23 33 3.92 36.00 12 3.00 Yes 
GPV0005 71.82 103.52 27 3.83 20.12 6 3.35 Yes 
GPV0031 61.74 156.56 34 4.60 83.54 13 6.42 No 
GPV0019 84.21 196.07 33 5.94 81.41 12 6.78 No 
GPV0031 91.20 185.00 34 5.44 90.09 13 6.93 No 
GPV0576 89.82 193.77 35 5.54 97.88 14 6.99 No 
clear. 
As seen for the first, second and third clusters, also for the fourth and fifth ones it is possible to 
discriminate between trapped and non-trapped compounds ranking the ligands according to the 
potential energy values of the R1 substituents. The difference in the potential energy values is 
clear also when it is divided by the number of heavy atoms. Interestingly, the only difference 
between the compounds SCT-AS03 and GPV0019 is the substitution of the aniline-nitrogen with 
a carbon atom. The aniline nitrogen hybridized sp
2
 renders the phenylpiperazine ring less flexible 
than the phenylpiperidine. Considering cluster four, during the channel gating the rigidity of the 
phenylpiperazine moiety prevents the protonated nitrogen of GPV0019 to get closer to the amino 
acids Ser649-Tyr652 and to adopt one of the two conformations hypothesized for the closed 
state. In cluster five, the rigidity of the phenylpiperazine ring and the bulkiness of the phenyl 
groups attached might impede to the protonated nitrogen to enter into the central cavity. 
Interestingly, as previously mentioned, in all five clusters the substituent R1 in the non-trapped 
compounds have always a value much higher than in the trapped propafenones. Furthermore, in 
cluster five the substituent is placed under the ring formed by the four Phe656, hence the values 
of potential energy calculated do not depend on possible conformations influenced by the 
binding site. This result seems to indicate that for propafenones the trapping phenomena depends 
on intrinsic properties of the R1 susbstituents, such as the bulkiness and the rigidity, rather than 
the binding mode in the open or closed conformations of the hERG channel. This means that for
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Table 14. Poses of cluster5. E scaffold: potential energy calculated considering the heavy atoms of the scaffold (table 2). E pose: 
potential energy calculated considering only the heavy atoms of the pose. N1: number of heavy atoms of the pose. E R1: potential 
energy calculated considering only the heavy atoms of the substituent R1. N2: number of heavy atoms of the substituent R1. The 
values of E are in kcal/mol. 
Poses E scaffold E pose N1 E pose / N1 E R1 N2 E R1/ N2 Trapped? 
Propafenone 68.89 96.42 25 3.86 0.33 4 0.08 Yes 
Propafenone 75.84 101.80 25 4.07 0.55 4 0.14 Yes 
Propafenone 64.05 87.78 25 3.51 0.85 4 0.21 Yes 
Propafenone 88.00 116.36 25 4.65 1.55 4 0.39 Yes 
Propafenone 86.77 124.98 25 5.00 2.21 4 0.55 Yes 
GPV0009 76.76 102.41 28 3.66 8.65 7 1.23 Yes 
GPV0009 63.27 93.81 28 3.35 8.93 7 1.28 Yes 
GPV0009 68.90 99.39 28 3.55 8.95 7 1.28 Yes 
GPV0009 75.35 97.37 28 3.48 9.55 7 1.36 Yes 
GPV0009 80.94 106.34 28 3.80 9.64 7 1.38 Yes 
GPV0009 86.08 118.17 28 4.22 10.11 7 1.44 Yes 
GPV0009 85.00 107.47 28 3.84 10.52 7 1.50 Yes 
GPV0009 80.53 104.43 28 3.73 10.79 7 1.54 Yes 
GPV0009 84.17 108.59 28 3.88 11.17 7 1.60 Yes 
SCT-AS03 69.49 108.12 33 3.28 22.82 12 1.90 Yes 
SCT-AS03 78.81 125.25 33 3.80 23.08 12 1.92 Yes 
GPV0062 91.16 141.46 34 4.16 25.56 13 1.97 Yes 
GPV0062 89.71 138.69 34 4.08 25.61 13 1.97 Yes 
GPV0062 84.42 129.58 34 3.81 26.16 13 2.01 Yes 
GPV0005 77.04 113.99 27 4.22 14.98 6 2.50 Yes 
GPV0180 65.70 117.50 31 3.79 17.59 6 2.93 Yes 
GPV0031 90.67 172.46 34 5.07 67.16 13 5.17 No 
GPV0031 63.88 147.47 34 4.34 70.94 13 5.46 No 
GPV0031 62.71 146.94 34 4.32 73.62 13 5.66 No 
GPV0576 64.92 163.19 35 4.66 86.71 14 6.19 No 
GPV0019 85.27 189.06 33 5.73 80.46 12 6.70 No 
propafenone and derivatives it might be not necessary to perform a docking study to discriminate 
between the trapped and non-trapped compounds, but it might be enough to calculate the 
potential energies of the R1 substituents after a simple systematic search. However, in the last 
case it would be impossible to investigate and understand the drug trapping and drug dissociation 
mechanisms. Windisch et al.[126] hypothesized that the pKa of the molecule, the possibility to 
form hydrogen-bonds, the bulkiness and the rigidity of the compound, play a role in the drug 
trapping. Hence, by modulating these properties of the substituent it might be possible to avoid 
drug trapping. It has to be noted that we docked only propafenones and derivatives, hence this 
hypothesis cannot be generalized to other types of molecules. 
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5.3.3 Conclusions 
In this study, we docked nine propafenone and derivatives into eight models of the hERG 
channel in the open state. Two binding modes were selected through Single Linkage cluster 
analysis of the RMSD matrix of the ligand-hERG complexes. In cluster four, the charged 
nitrogen is located near the amino acids Ser649 and Tyr652, as previously found in the poses 
obtained docking the molecules into the open and closed hERG channel conformations, while 
one of the two aromatic rings is placed under the four Phe656. During the channel gating the 
phenyl ring of the trapped propafenones has to move into the central cavity forcing the 
protonated nitrogen to be close to the amino acids Ser649 and Tyr652. For the non-trapped 
propafenones these movements are prevented by the R1 substituent: the phenyl ring placed under 
the ring formed by the four Phe656 cannot move into the central cavity hindering the channel 
gating with the “foot in the door” mechanism. In cluster five the protonated nitrogen is placed 
under the four Phe656. This renders the conformations of cluster five not as reliable as the poses 
in cluster four, because it cannot explain why the charged nitrogen is an important feature for 
hERG inhibition. The R1 substituents of the poses in cluster five during the channel gating have 
to move into the central cavity. In non-trapped propafenones this movement is prevented by 
bulky and rigid substituents, hindering the gating through the “foot in the door” mechanism. 
In both clusters it is possible to discern between the trapped and non-trapped molecules ranking 
them according to the potential energy values of the R1 substituents, and according to this value 
divided by the total number of heavy atoms. The fact that also in cluster five the potential energy 
values of R1 substituents of the trapped compounds is lower than in the non-trapped ones, it 
might indicate that the trapping phenomena of propafenone derivatives is determined by intrinsic 
properties of R1 moieties. 
In this study, we docked only propafenone derivatives, hence these considerations cannot be 
generalized to non-propafenone type molecules. 
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